0000950170-25-068549.txt : 20250512 0000950170-25-068549.hdr.sgml : 20250512 20250512071032 ACCESSION NUMBER: 0000950170-25-068549 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250512 DATE AS OF CHANGE: 20250512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tango Therapeutics, Inc. CENTRAL INDEX KEY: 0001819133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39485 FILM NUMBER: 25932563 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (857) 320-4900 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 FORMER COMPANY: FORMER CONFORMED NAME: BCTG Acquisition Corp. DATE OF NAME CHANGE: 20200723 10-Q 1 tngx-20250331.htm 10-Q 10-Q
Q10001819133false--12-31http://www.tangotx.com/20250331#MarketableDebtSecuritiesMemberhttp://www.tangotx.com/20250331#MarketableDebtSecuritiesMemberhttp://fasb.org/us-gaap/2024#MarketableSecuritiesCurrenthttp://fasb.org/us-gaap/2024#MarketableSecuritiesCurrenthttp://fasb.org/srt/2024#ChiefExecutiveOfficerMember0001819133tngx:TNG462DirectProgramExpenses-RDMember2024-01-012024-03-310001819133tngx:SecurityDepositsMember2024-03-310001819133us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-12-3100018191332025-03-310001819133us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001819133tngx:TNG456DirectProgramExpenses-RDMember2025-01-012025-03-310001819133us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001819133us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-03-310001819133us-gaap:CommonStockMember2025-03-310001819133us-gaap:ConstructionInProgressMember2024-12-310001819133tngx:FacilitiesAndOtherRelatedExpenses-RDMember2025-01-012025-03-310001819133tngx:MedivirAgreementMembertngx:SpecifiedRegulatoryApprovalAndSalesMilestonesMember2020-03-310001819133tngx:ComputerSoftwareMember2024-12-310001819133tngx:TwoThousandAndEighteenGileadAgreementMember2018-10-012018-10-310001819133tngx:AmendedGileadAgreementMember2025-01-012025-03-310001819133us-gaap:RetainedEarningsMember2025-01-012025-03-310001819133srt:MaximumMember2024-01-012024-03-310001819133tngx:FacilitiesAndOtherRelatedExpenses-RDMember2024-01-012024-03-310001819133us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001819133tngx:AmendedGileadAgreementMember2021-09-300001819133us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001819133tngx:TwoThousandAndTwentyOnePlanMember2025-03-3100018191332024-03-310001819133us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001819133tngx:Personnel-RelatedExpenses-RDMember2024-01-012024-03-310001819133tngx:PreFundedWarrantsMember2023-08-110001819133us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001819133us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001819133tngx:SecurityDepositsMember2025-03-310001819133tngx:AmendedGileadAgreementMember2020-12-310001819133tngx:TNG348DirectProgramExpenses-RDMember2024-01-012024-03-310001819133tngx:TNG260DirectProgramExpenses-RDMember2024-01-012024-03-310001819133tngx:TwoThousandAndEighteenGileadAgreementMember2025-01-012025-03-310001819133us-gaap:RetainedEarningsMember2023-12-310001819133tngx:MedivirAgreementMembertngx:SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember2020-03-310001819133tngx:CollaborationRevenueMembertngx:GileadAgreementMember2025-01-012025-03-310001819133tngx:TNG908DirectProgramExpenses-RDMember2025-01-012025-03-310001819133tngx:StockOptionsMember2025-03-310001819133tngx:AmendedGileadAgreementMember2020-08-310001819133tngx:SesameAgreementMember2024-06-300001819133tngx:TNG908DirectProgramExpenses-RDMember2024-01-012024-03-310001819133tngx:CollaborationRevenueMember2024-01-012024-03-310001819133us-gaap:CommonStockMember2024-01-012024-03-310001819133tngx:AmendedGileadAgreementMember2020-08-012020-08-3100018191332025-01-012025-03-3100018191332024-12-310001819133us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001819133us-gaap:RetainedEarningsMember2024-01-012024-03-310001819133us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001819133us-gaap:ComputerEquipmentMember2024-12-310001819133us-gaap:AdditionalPaidInCapitalMember2024-03-310001819133tngx:CollaborationRevenueMembertngx:GileadAgreementMember2024-01-012024-03-310001819133us-gaap:RetainedEarningsMember2024-03-310001819133us-gaap:RetainedEarningsMember2024-12-310001819133tngx:MarketableDebtSecuritiesMember2025-01-012025-03-310001819133us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001819133us-gaap:USTreasurySecuritiesMember2024-12-3100018191332025-05-050001819133us-gaap:AdditionalPaidInCapitalMember2024-12-310001819133us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001819133us-gaap:RestrictedStockMember2025-01-012025-03-310001819133us-gaap:LeaseholdImprovementsMember2024-12-310001819133us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001819133us-gaap:CommonStockMember2025-01-012025-03-310001819133tngx:GileadAgreementMember2025-03-310001819133us-gaap:EquipmentMember2024-12-310001819133us-gaap:RestrictedStockUnitsRSUMember2024-12-310001819133us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001819133us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001819133us-gaap:AdditionalPaidInCapitalMember2023-12-310001819133us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001819133tngx:ComputerSoftwareMember2025-03-310001819133tngx:TNG348DirectProgramExpenses-RDMember2025-01-012025-03-310001819133us-gaap:EquipmentMember2025-03-310001819133us-gaap:RetainedEarningsMember2025-03-310001819133tngx:ForecastingTaxableLossPositionDeferredTaxAssetsMember2025-01-012025-03-310001819133us-gaap:FurnitureAndFixturesMember2025-03-310001819133tngx:GileadAgreementMember2024-12-310001819133us-gaap:RestrictedStockMember2024-01-012024-12-310001819133us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001819133us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001819133tngx:TNG961DirectProgramExpenses-RDMember2025-01-012025-03-310001819133tngx:StockOptionsMember2025-01-012025-03-310001819133tngx:DiscoveryDirectProgramExpenses-RDMember2025-01-012025-03-310001819133us-gaap:CommonStockMember2024-03-310001819133us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001819133us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001819133tngx:MedivirAgreementMember2020-03-310001819133us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001819133tngx:TNG462DirectProgramExpenses-RDMember2025-01-012025-03-310001819133tngx:MarketableDebtSecuritiesMember2025-03-310001819133tngx:TNG961DirectProgramExpenses-RDMember2024-01-012024-03-310001819133tngx:MedivirAgreementMembertngx:SpecifiedClinicalMilestonesMember2020-03-310001819133us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001819133us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001819133tngx:DiscoveryDirectProgramExpenses-RDMember2024-01-012024-03-310001819133us-gaap:ComputerEquipmentMember2025-03-310001819133us-gaap:USTreasurySecuritiesMember2025-03-310001819133us-gaap:ConstructionInProgressMember2025-03-310001819133srt:MaximumMember2025-01-012025-03-310001819133us-gaap:RestrictedStockUnitsRSUMember2025-03-310001819133us-gaap:LeaseholdImprovementsMember2025-03-310001819133us-gaap:FairValueMeasurementsRecurringMember2024-12-310001819133us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001819133tngx:TNG260DirectProgramExpenses-RDMember2025-01-012025-03-3100018191332023-12-310001819133tngx:Personnel-RelatedExpenses-RDMember2025-01-012025-03-310001819133tngx:TwoThousandTwentyThreeInducementPlanMember2025-03-3100018191332025-04-012025-03-310001819133us-gaap:FairValueMeasurementsRecurringMember2025-03-3100018191332024-01-012024-03-3100018191332024-01-012024-12-310001819133us-gaap:AdditionalPaidInCapitalMember2025-03-310001819133us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001819133us-gaap:PrivatePlacementMember2023-08-112023-08-110001819133us-gaap:CommonStockMember2024-12-310001819133tngx:AmendedGileadAgreementMembertngx:SeriesBOnePreferredStockMember2020-08-310001819133us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001819133tngx:TNG456DirectProgramExpenses-RDMember2024-01-012024-03-310001819133tngx:MarketableDebtSecuritiesMember2024-01-012024-12-310001819133tngx:CollaborationRevenueMember2025-01-012025-03-310001819133tngx:TwoThousandAndEighteenGileadAgreementMember2018-01-012018-12-310001819133us-gaap:FurnitureAndFixturesMember2024-12-310001819133us-gaap:CommonStockMember2023-12-310001819133tngx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember2025-01-012025-03-310001819133us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001819133us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31tngx:Programxbrli:purexbrli:sharestngx:Segmentiso4217:USDxbrli:sharesiso4217:USD

 

i113.ROC

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2025

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File Number: 001-39485

 

TANGO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

85-1195036

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

201 Brookline Ave., Suite 901

Boston, MA

02215

(Address of principal executive offices)

(Zip Code)

(857) 320-4900

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.001 per share

 

TNGX

 

Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

As of May 5, 2025, the registrant had 108,394,190 shares of common stock, $0.001 par value per share, outstanding.

 

 

 

 


 

Table of Contents

 

 

 

Page

 

 

 

PART I.

FINANCIAL INFORMATION

 

 

 

Item 1.

Financial Statements (Unaudited)

1

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

2

 

Condensed Consolidated Statements of Stockholders' Equity

3

 

Condensed Consolidated Statements of Cash Flows

4

 

Notes to Unaudited Condensed Consolidated Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

16

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

25

Item 4.

Controls and Procedures

26

 

 

 

PART II.

OTHER INFORMATION

27

 

 

 

Item 1.

Legal Proceedings

27

Item 1A.

Risk Factors

28

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

30

Item 3.

Defaults Upon Senior Securities

30

Item 4.

Mine Safety Disclosures

30

Item 5.

Other Information

30

Item 6.

Exhibits

30

Signatures

31

 

i


 

 

Summary of Material Risks Associated with Our Business

Our business is subject to numerous material and other risks that you should be aware of before making an investment decision with respect to our securities. These risks are described more fully in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 and this Quarterly Report on Form 10-Q. These risks include, among others, the following (which is not an exhaustive list of all such risks):

 

 

We are a precision oncology company with a limited operating history. We have no products approved for commercial sale, have not generated any revenue from product sales and may never become profitable. Further, we face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.

 

 

 

We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We expect our operating results to fluctuate significantly in the future as our business advances.

 

 

 

We will need to raise substantial additional funding. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.

 

 

 

We have never successfully completed any clinical trials and we may be unable to do so for any product candidates we develop. Certain of our programs are still in preclinical development and may never advance to clinical development.

 

 

 

Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products.

 

 

 

If we are unable to successfully validate, develop and obtain regulatory approval for screening tests and companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates. We will also rely on third-parties for screening for biomarkers that enable patient selection for clinical trials and target engagement.

 

 

 

Clinical product development involves a lengthy and expensive process, with an uncertain outcome. Further, our current and potential future collaborations may not realize the anticipated benefits.

 

 

 

Initial, interim and top-line data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data.

 

 

 

Results from earlier preclinical studies of our programs and product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our programs and product candidates. If we cannot replicate the results from our earlier preclinical studies of our programs and product candidates in our later preclinical studies and clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.

 

 

 

If we experience delays or difficulties in the initiation, enrollment or dosing of patients in clinical trials, the announcement of clinical trial results and our receipt of necessary regulatory approvals (if any) could be delayed or prevented.

 

 

 

Our clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.

 

 

 

Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, and utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.

 

ii


 

 

 

If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.

 

 

 

Public health crises may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates and the initiation and completion of clinical trials.

 

 

 

We currently rely and expect to continue to rely on third parties to conduct our clinical trials, as well as investigator-sponsored clinical trials of our product candidates (if any). If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.

 

 

 

We contract with a limited number of third parties for the manufacture of our product candidates for preclinical development and clinical trials and expect to continue to do so for future clinical testing and commercialization (if approved). This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

 

 

 

We rely on a very limited number of third parties for the supply of the active pharmaceutical ingredients, or API, and drug product to be used in our product candidates (for example, an affiliate of WuXi AppTec is the sole source of API for all of our clinical-stage product candidates), and WuXi AppTec has been the subject of proposed Congressional legislation that, if enacted, could materially restrict our ability to conduct business with, and obtain API from, WuXi AppTec. The loss of any of these suppliers, including WuXi AppTec, could significantly harm our business.

 

 

 

If we cannot obtain new patents, maintain our existing patents and protect the confidentiality and proprietary nature of our trade secrets and other intellectual property, our business and competitive position may be harmed.

 

 

 

If we are found to be infringing third party patents, we may be forced to pay damages to the patent owner and/or obtain a license to continue the manufacture, sale or development of our products. If we cannot obtain a license, we may be prevented from the manufacture, sale or development of our products or product candidates, which may adversely affect our business.

 

 

 

Development of combination therapies may present more or different challenges than development of single agent therapies.

 

 

 

 

Inadequate funding for government agencies in or outside the United States, including from government shutdowns or other disruptions to these agencies' staffing and operations, could prevent new products and services being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

 

Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Words such as "anticipates," "continue," "could," "may," "forecasts," "expects," "intends," "plans," "potentially," "believes," "seeks," "estimates," "predict," "target," and variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict; therefore, actual results may differ materially from those expressed or forecasted in any such statements. Such forward-looking statements are based on current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by our management, and may include, but are not limited to, statements regarding:

 

 

the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials and combination clinical trials, including statements regarding the timing of IND filings and acceptance, active enrollment and dosing in clinical trials (including combination clinical trials), future plans for dose expansions and dose escalations, and initiation and completion of studies or clinical trials (including combination

iii


 

 

 

 

trials), plans for filing a registrational trial and initiating a combination clinical trial in TNG462, and related preparatory work for each, plans for the TNG456 clinical trial, and the period during which the results of the clinical trials (including initial and final trial results) will become available (such as the clinical data update from the ongoing TNG462 clinical trial and the data from the ongoing TNG260 clinical trial, both expected in the second half of 2025);

 

 

our ability to discover and develop product candidates efficiently (including the advancement of development candidates on the timelines identified and the ability to identify and contract with clinical trial sites and investigators to use our product candidates in trials);

 

 

our ability and potential (or those of third parties) to manufacture our drug product, drug substance and product candidates successfully for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;

 

 

the ability and willingness of our third-party strategic collaborators to license and to continue research and development activities relating to our development candidates and product candidates;

 

 

our ability to obtain funding for our operations necessary to complete further research, development and commercialization of our product candidates (and that existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2027);

 

 

our ability to obtain and, if approved, maintain regulatory approval of our product candidates (as well as approval or clearance of screening tests and companion diagnostic tests for our product candidates) and the potential paths to approval for TNG462 in MTAP-deleted pancreatic and lung cancer;

 

 

our ability to commercialize our products, if approved;

 

 

the pricing and reimbursement of our product candidates, if approved;

 

 

the implementation of our business model, and strategic plans for our business and product candidates;

 

 

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to enforce our intellectual property rights;

 

 

estimates of our future expenses, capital requirements, and our need for additional financing;

 

 

the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;

 

 

future agreements with third parties in connection with the commercialization of product candidates (if approved) and any other approved products;

 

 

the size and growth potential of the markets for our product candidates, and our ability to serve those markets;

 

 

our financial performance, including the expectation that we will continue to incur operating losses and negative cash flow;

 

 

the rate and degree of market acceptance of our product candidates, if approved;

 

 

regulatory developments in the United States and foreign countries, including product approval requirements and pricing regulations by U.S. regulatory authorities (such as the Centers for Medicare & Medicaid Services) and foreign regulatory authorities;

 

 

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

 

 

 

our ability (or the ability of third parties with whom we contract) to produce our products or product candidates with advantages in turnaround times or manufacturing cost;

iv


 

 

 

our ability to deliver the deep, sustained target inhibition necessary to optimize tumor response and clinical benefit as a result of the unique ability of synthetic lethal targeting to spare normal cells, as well as the success of competing therapies that are or may become available;

 

 

our ability to attract and retain key scientific or management personnel;

 

 

the impact of laws and regulations;

 

 

 

 

developments relating to our competitors and industry;

 

the impact of trade restrictions (such as sanctions or tariffs); regulatory requirements, legal actions, or enforcement; inflation rates; and inadequate funding for government agencies on our business, financial condition, and results of operations;

 

 

the effect of public health crises on our business operations, including but not limited to our preclinical studies and clinical trials and any future studies or trials;

 

 

 

the expected benefits of the use of our drugs in patients as single agents and/or in combination, including our beliefs that: TNG462 has the potential to be a best-in-class molecule; and preclinical studies in TNG456 demonstrate sufficient brain penetrance for meaningful efficacy in GBM; and

 

 

 

other risks and uncertainties, including those identified in Part II, Item 1A of this Quarterly Report on Form 10-Q and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. In both cases, see section titled “Risk Factors.”

 

The forward-looking statements contained in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 and Part II, Item 1A of this Quarterly Report on Form 10-Q are based on current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that we currently consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

USE OF DEFINED TERMS IN THIS QUARTERLY REPORT ON FORM 10-Q

Unless the context otherwise requires in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, we use the following defined terms:

i.
“the Company”, “we”, “our” and “us” mean Tango Therapeutics, Inc. and its wholly-owned subsidiaries;
ii.
“Business Combination” means the merger of BCTG Merger Sub Inc. with and into Tango Therapeutics, Inc. (now known as Tango Therapeutics Sub, Inc.) on August 10, 2021, with Tango Therapeutics, Inc. as the surviving company in the merger as a wholly-owned subsidiary of BCTG Acquisition Corp. (now known as Tango Therapeutics, Inc.);
iii.
“CNS” means central nervous system;
iv.
“CoREST” means Co-repressor of Repressor Element-1 Silencing Transcription;
v.
“FDA” means U.S. Food and Drug Administration;
vi.
“Gilead” means Gilead Sciences, Inc.;
vii.
“GBM” means glioblastoma;
viii.
“IND” means Investigational New Drug Application;

v


 

ix.
“MTA” means methylthioadenosine;
x.
“MTAP” means methylthioadenosine phosphorylase;
xi.
“NSCLC” means non-small cell lung cancer;
xii.
“PRMT5” means protein arginine methyltransferase 5;
xiii.
“Quarterly Report” means this Quarterly Report on Form 10-Q for the quarter ended March 31, 2025;
xiv.
“STK11” means serine-threonine kinase 11; and
xv.
“USP1” means ubiquitin-specific protease 1.

 

Corporate Information

We were formerly known as BCTG Acquisition Corp., or BCTG, and were incorporated in Delaware in May 2020 as a special purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination. On August 10, 2021, we consummated the merger pursuant to the Agreement and Plan of Merger, dated as of April 13, 2021, by and among BCTG, BCTG Merger Sub Inc. and Tango Therapeutics Sub, Inc. Upon the consummation of the merger, we changed our name to Tango Therapeutics, Inc.

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the “Investors” portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or SEC. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. Accordingly, investors should monitor such portions of the Company’s website, in addition to following the Company’s press releases, SEC filings and public conference calls and webcasts (if any). Information on our website is not to be deemed to be incorporated by reference in, and is not part of, this Quarterly Report on Form 10-Q or any of our other securities filings, unless specifically incorporated herein by reference, and should not be relied upon in making a decision as to whether or not to purchase our common stock. Our filings with the SEC may be accessed through the SEC’s Interactive Data Electronic Applications system at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.

Further, the Company intends to use its website at http://www.tangotx.com as a means of disclosing material non-public information and for complying with its disclosure obligations under the SEC Regulation FD. Such disclosures will be included on the Company’s website under the heading “Investors.” Accordingly, investors should monitor such portions of the Company’s website, in addition to following the Company’s press releases, SEC filings and public conference calls and webcasts (if any). The information contained on, or that may be accessed through, the website is not part of, and is not incorporated into, this Quarterly Report on Form 10-Q.

Our principal executive office is located at 201 Brookline Avenue, Suite 901, Boston, Massachusetts 02215.

vi


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

TANGO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

 

March 31,

 

 

December 31,

 

 

2025

 

 

2024

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

58,432

 

 

$

69,530

 

Marketable securities

 

 

158,292

 

 

 

188,387

 

Restricted cash

 

 

428

 

 

 

 

Prepaid expenses and other current assets

 

 

7,778

 

 

 

8,426

 

Total current assets

 

 

224,930

 

 

 

266,343

 

Property and equipment, net

 

 

7,539

 

 

 

8,102

 

Operating lease right-of-use assets

 

 

39,697

 

 

 

39,476

 

Restricted cash, net of current portion

 

 

2,139

 

 

 

2,567

 

Other assets

 

 

1

 

 

 

4

 

Total assets

 

$

274,306

 

 

$

316,492

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,239

 

 

$

1,601

 

Accrued expenses and other current liabilities

 

 

10,374

 

 

 

16,497

 

Operating lease liabilities

 

 

2,824

 

 

 

2,454

 

Deferred revenue

 

 

19,480

 

 

 

17,618

 

Total current liabilities

 

 

35,917

 

 

 

38,170

 

Operating lease liabilities, net of current portion

 

 

34,122

 

 

 

34,039

 

Deferred revenue, net of current portion

 

 

37,511

 

 

 

44,766

 

Total liabilities

 

 

107,550

 

 

 

116,975

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

Preferred stock, $0.001 par value; 10,000,000 shares
   authorized;
no shares issued and outstanding as of March 31, 2025
   and December 31, 2024, respectively

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares
   authorized at March 31, 2025 and December 31, 2024, respectively;
   
108,107,890 and 107,729,343 shares issued and outstanding as of
   March 31, 2025 and December 31, 2024, respectively

 

 

108

 

 

 

108

 

Additional paid-in capital

 

 

707,888

 

 

 

700,631

 

Accumulated other comprehensive income

 

 

194

 

 

 

336

 

Accumulated deficit

 

 

(541,434

)

 

 

(501,558

)

Total stockholders’ equity

 

 

166,756

 

 

 

199,517

 

Total liabilities and stockholders’ equity

 

$

274,306

 

 

$

316,492

 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

1


 

TANGO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share amounts)

(Unaudited)

 

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

Collaboration revenue

 

$

5,392

 

 

$

6,471

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

36,442

 

 

 

38,065

 

General and administrative

 

 

11,480

 

 

 

10,661

 

Total operating expenses

 

 

47,922

 

 

 

48,726

 

Loss from operations

 

 

(42,530

)

 

 

(42,255

)

Other income:

 

 

 

 

 

 

Interest income

 

 

1,614

 

 

 

2,197

 

Other income, net

 

 

1,074

 

 

 

2,184

 

Total other income, net

 

 

2,688

 

 

 

4,381

 

Loss before income taxes

 

 

(39,842

)

 

 

(37,874

)

Provision for income taxes

 

 

(34

)

 

 

(40

)

Net loss

 

$

(39,876

)

 

$

(37,914

)

 

 

 

 

 

 

Net loss per common share – basic and diluted

 

$

(0.36

)

 

$

(0.35

)

Weighted average number of common shares outstanding – basic and diluted

 

 

110,301,256

 

 

 

108,171,463

 

 

 

 

 

 

 

 

Net loss

 

$

(39,876

)

 

$

(37,914

)

Other comprehensive income (loss):

 

 

 

 

 

 

Unrealized loss on marketable securities

 

 

(142

)

 

 

(443

)

Comprehensive loss

 

$

(40,018

)

 

$

(38,357

)

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

2


 

TANGO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

Additional

 

 

Accumulated
Other

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2024

 

 

107,729,343

 

 

$

108

 

 

$

700,631

 

 

$

336

 

 

$

(501,558

)

 

$

199,517

 

Issuance of common stock under stock plans

 

 

378,547

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

2

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

7,255

 

 

 

 

 

 

 

 

 

7,255

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(142

)

 

 

 

 

 

(142

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(39,876

)

 

 

(39,876

)

Balance at March 31, 2025

 

 

108,107,890

 

 

$

108

 

 

$

707,888

 

 

$

194

 

 

$

(541,434

)

 

$

166,756

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Accumulated
Other

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2023

 

 

102,202,759

 

 

$

102

 

 

$

624,076

 

 

$

186

 

 

$

(371,256

)

 

$

253,108

 

Issuance of common stock under stock plans

 

 

526,826

 

 

 

1

 

 

 

1,258

 

 

 

 

 

 

 

 

 

1,259

 

At-the-market offerings, net of issuance costs

 

 

4,001,200

 

 

 

4

 

 

 

41,719

 

 

 

 

 

 

 

 

 

41,723

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

6,719

 

 

 

 

 

 

 

 

 

6,719

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(443

)

 

 

 

 

 

(443

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(37,914

)

 

 

(37,914

)

Balance at March 31, 2024

 

 

106,730,785

 

 

$

107

 

 

$

673,772

 

 

$

(257

)

 

$

(409,170

)

 

$

264,452

 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

3


 

TANGO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

 

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$

(39,876

)

 

$

(37,914

)

Adjustments to reconcile net loss to net cash from
   operating activities:

 

 

 

 

 

 

Depreciation

 

 

622

 

 

 

625

 

Noncash operating lease expense

 

 

1,012

 

 

 

925

 

Stock-based compensation

 

 

7,255

 

 

 

6,719

 

Accretion on marketable securities

 

 

(638

)

 

 

(1,371

)

Other, net

 

 

(56

)

 

 

(10

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

649

 

 

 

360

 

Other long-term assets

 

 

1

 

 

 

35

 

Accounts payable

 

 

1,630

 

 

 

1,042

 

Accrued expenses and other liabilities

 

 

(6,124

)

 

 

(1,609

)

Operating lease liabilities

 

 

(780

)

 

 

(188

)

Deferred revenue

 

 

(5,392

)

 

 

(6,471

)

Net cash used in operating activities

 

 

(41,697

)

 

 

(37,857

)

Cash flows from investing activities

 

 

 

 

 

 

Purchase of property and equipment

 

 

(51

)

 

 

(195

)

Sales and maturities of marketable securities

 

 

77,812

 

 

 

109,255

 

Purchases of marketable securities

 

 

(47,164

)

 

 

(120,263

)

Net cash provided by (used in) investing activities

 

 

30,597

 

 

 

(11,203

)

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from issuance of common stock and pre-funded warrants

 

 

 

 

 

41,723

 

Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under ESPP

 

 

2

 

 

 

1,259

 

Net cash provided by financing activities

 

 

2

 

 

 

42,982

 

Net change in cash, cash equivalents and restricted cash

 

 

(11,098

)

 

 

(6,078

)

Cash, cash equivalents and restricted cash, beginning of period

 

 

72,097

 

 

 

69,808

 

Cash, cash equivalents and restricted cash, end of period

 

$

60,999

 

 

$

63,730

 

Supplemental cash flow information:

 

 

 

 

 

 

Cash paid for leases

 

$

1,935

 

 

$

1,351

 

Supplemental disclosure of noncash investing and financing activity:

 

 

 

 

 

 

Purchases of property and equipment included in accounts payable and accrued expenses

 

$

8

 

 

$

71

 

Operating lease liabilities from obtaining right-of-use assets

 

$

1,308

 

 

$

 

Revaluation of right-of-use asset and lease liability upon lease remeasurement

 

$

75

 

 

$

497

 

 

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

4


 

TANGO THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.
Nature of the Business and Basis of Presentation

Tango Therapeutics, Inc. is a precision oncology company committed to the discovery and development of novel drugs in defined patient populations with high unmet medical need.

Tango Therapeutics, Inc. (together with its consolidated subsidiaries, Tango or the Company), formerly known as BCTG Acquisition Corp. (BCTG), was incorporated in Delaware on May 21, 2020. BCTG was a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements reflect the operations of Tango and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.

In the opinion of management, all adjustments necessary for a fair statement of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three months ended March 31, 2025 and 2024 are not necessarily indicative of the results for the year ending December 31, 2025, any other interim periods, or any future year or period. The unaudited condensed consolidated financial statements for the three months ended March 31, 2025 and 2024 have been prepared on the same basis as and should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on February 27, 2025.

Liquidity and Capital Resources

The Company expects that its existing cash, cash equivalents and marketable securities as of March 31, 2025 of $216.7 million will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of these financial statements with an expected cash runway into the first quarter of 2027.

Since inception, the Company has incurred significant operating losses and expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future. The Company will need to finance its operations through public or private securities offerings, debt financings or other sources, which may include licensing, collaborations or other strategic transactions or arrangements. If the Company is unable to obtain funding, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.

2.
Summary of Significant Accounting Policies

There have been no significant changes from the significant accounting policies disclosed in Note 2, Summary of Significant Accounting Policies, of the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

Use of Estimates

The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated

5


 

financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Recently Adopted Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its consolidated financial statements and disclosures.

Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The standard is intended to enhance the existing income tax disclosures to provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The standard is effective for annual periods beginning after December 15, 2024. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, "Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

3.
Collaboration Agreements

In October 2018, the Company entered into a Research Collaboration and License Agreement (the 2018 Gilead Agreement) with Gilead Sciences, Inc. (Gilead). Pursuant to the terms of the 2018 Gilead Agreement, the Company received an initial upfront payment of $50.0 million. Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to five validated programs (Gilead Program License).

In August 2020, the Company and Gilead entered into an Amended Research Collaboration and License Agreement (the Gilead Agreement), which superseded and replaced the 2018 Gilead Agreement. The Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the 2018 Gilead Agreement. Under the Gilead Agreement:

The Company received upfront, non-refundable consideration of $125.0 million from Gilead upon execution of the Gilead Agreement in 2020;
The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement has a research term of seven years;
Gilead expanded its option to license up to 15 programs for which Gilead may obtain exclusive, worldwide licenses to develop and commercialize therapies, subject to applicable license fees;
Prior to exercising its option to license a program, Gilead may “extend” such program, in which case Gilead will pay research option-extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development;
Gilead has the option to “reserve” a target during which Gilead may: (i) license the target, (ii) “extend” the target, or (iii) decline the target, during the designated reserve target period. If, during the reserve target period Tango elects to work on the reserved target, Tango will retain full rights to the target program and Gilead receives a right of first negotiation in connection with any future partnering or licensing of such target by Tango, if any; and

6


 

For up to five programs licensed by Gilead, the Company has the option to co-develop and co-promote the lead product in the U.S., subject to certain exceptions, and is eligible to receive tiered royalties in the first decile on ex-U.S. sales.

The Company is eligible to receive up to $410.0 million per program in license, research option-extension, and clinical, regulatory, and commercial milestones and royalties on future sales of commercialized products, if any.

In August 2020, Gilead also made an equity investment of $20.0 million into the Company as a participant in the Company’s Series B-1 preferred stock offering. At the time of the original investment, as of the March 31, 2025 balance sheet date, and based on current ownership of common stock, Gilead is not considered to be a related party to the Company.

Accounting for the Gilead Collaboration

The Gilead Agreement is accounted for under ASC 606. The Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering committee during the research term. For research option-extension fees, the Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the on-going research plan. Consideration pertaining to each of the research option-extensions is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. The research option-extension consideration are added to the transaction price under the Gilead Agreement. License fees are recognized as revenue immediately as the Company has no continued involvement in the advancement of the program, Gilead can benefit from the license on its own, and the license is separately identifiable from the research services.

Gilead Revenue Recognized

The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $199.0 million at March 31, 2025. The total transaction price was comprised of the $50.0 million upfront payment pursuant to the 2018 Gilead Agreement, the $125.0 million upfront payment pursuant to the Gilead Agreement, and $24.0 million payment pursuant to the research option-extension fee in December 2020 and in September 2021. During the three months ended March 31, 2025 and 2024, the Company recognized $5.4 million and $6.5 million, respectively, of collaboration revenue associated with the Gilead agreements based on performance completed during each period.

The Company reevaluates the transaction price and the total estimated costs expected to be incurred to satisfy the performance obligations at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the Company is responsible for, are resolved or other changes in circumstances occur. As of March 31, 2025 and December 31, 2024, the Company had short-term deferred revenue of $19.5 million and $17.6 million, respectively, and long-term deferred revenue of $37.5 million and $44.8 million, respectively, related to the Gilead collaboration. The remaining long-term deferred revenue is expected to be recognized proportionally to the completed obligations over an expected remaining contractual term of approximately 2.4 years.

Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company’s condensed consolidated balance sheets.

Costs incurred pursuant to the Gilead Agreement and the 2018 Gilead Agreement are recorded as research and development expense.

7


 

4.
Fair Value Measurements

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis:

 

 

Fair Market Value Measurements
as of March 31, 2025

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

(in thousands)

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

14,801

 

 

$

 

 

$

 

 

$

14,801

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

 

 

 

 

147,386

 

 

 

 

 

 

147,386

 

U.S. government agency bonds

 

 

 

 

 

10,906

 

 

 

 

 

 

10,906

 

Total assets

 

$

14,801

 

 

$

158,292

 

 

$

 

 

$

173,093

 

 

 

Fair Market Value Measurements
as of December 31, 2024

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

(in thousands)

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

14,915

 

 

$

 

 

$

 

 

$

14,915

 

U.S. Treasury bills

 

 

 

 

 

10,112

 

 

 

 

 

 

10,112

 

Marketable debt securities

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

 

 

 

 

176,374

 

 

 

 

 

 

176,374

 

U.S. government agency bonds

 

 

 

 

 

12,013

 

 

 

 

 

 

12,013

 

Total assets

 

$

14,915

 

 

$

198,499

 

 

$

 

 

$

213,414

 

 

There were no transfers between fair value levels during the three months ended March 31, 2025.

5.
Marketable Securities

The Company values its marketable securities using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources.

The following table summarizes the Company’s marketable debt securities, classified as available-for-sale:

 

Fair Value Measurements
as of March 31, 2025

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gains

 

 

Gross
Unrealized
Loss

 

 

Fair
Value

 

 

(in thousands)

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

$

147,194

 

 

$

218

 

 

$

(26

)

 

$

147,386

 

U.S. government agency bonds

 

 

10,904

 

 

 

3

 

 

 

(1

)

 

 

10,906

 

 

$

158,098

 

 

$

221

 

 

$

(27

)

 

$

158,292

 

 

 

Fair Value Measurements
as of December 31, 2024

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gains

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

 

(in thousands)

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

$

176,049

 

 

$

364

 

 

$

(39

)

 

$

176,374

 

U.S. government agency bonds

 

 

12,002

 

 

 

11

 

 

 

 

 

 

12,013

 

 

$

188,051

 

 

$

375

 

 

$

(39

)

 

$

188,387

 

 

8


 

The aggregate fair value of marketable debt securities with a contractual maturity date of greater than one year was $7.2 million as of March 31, 2025.

The following table summarizes the fair value and gross unrealized losses aggregated by category and the length of time that individual securities have been in an unrealized loss position:

 

March 31, 2025

 

 

Less than twelve months

 

 

Greater than twelve months

 

 

Total

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

(in thousands)

 

U.S. Treasury bills

$

53,897

 

 

$

(26

)

 

$

-

 

 

$

-

 

 

$

53,897

 

 

$

(26

)

U.S. government agency bonds

 

2,957

 

 

 

(1

)

 

 

-

 

 

 

-

 

 

 

2,957

 

 

 

(1

)

 

$

56,854

 

 

$

(27

)

 

$

-

 

 

$

-

 

 

$

56,854

 

 

$

(27

)

 

 

December 31, 2024

 

 

Less than twelve months

 

 

Greater than twelve months

 

 

Total

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

(in thousands)

 

U.S. Treasury bills

$

46,016

 

 

$

(39

)

 

$

-

 

 

$

-

 

 

$

46,016

 

 

$

(39

)

 

$

46,016

 

 

$

(39

)

 

$

-

 

 

$

-

 

 

$

46,016

 

 

$

(39

)

The Company holds investment grade marketable securities considered to be in an unrealized loss position. Although these marketable securities are held at an unrealized loss position at March 31, 2025, the Company does not intend to sell the marketable securities prior to the value of the securities being recovered and the Company has concluded that it is more likely than not that the marketable securities cost basis values will be recovered prior to sale of the securities and that there are no conditions or events that might require the Company to sell the securities before recovery of the cost basis occurs. Further, the Company did not record any impairments to marketable securities or reserves for credit losses related to its marketable debt securities during the periods then ended. Marketable securities include $0.9 million and $1.4 million in accrued interest at March 31, 2025 and December 31, 2024, respectively.

6.
Supplemental Balance Sheet Information

Property and Equipment

Property and equipment, net consists of the following:

 

March 31,

 

 

December 31,

 

 

2025

 

 

2024

 

 

(in thousands)

 

Laboratory equipment

 

$

8,936

 

 

$

8,936

 

Computer equipment

 

 

2,437

 

 

 

2,437

 

Computer software

 

 

125

 

 

 

125

 

Furniture and fixtures

 

 

1,945

 

 

 

1,945

 

Leasehold improvements

 

 

2,870

 

 

 

2,870

 

Construction in progress

 

 

211

 

 

 

152

 

 

 

16,524

 

 

 

16,465

 

Less: Accumulated depreciation

 

 

(8,985

)

 

 

(8,363

)

Property and equipment, net

 

$

7,539

 

 

$

8,102

 

 

9


 

Depreciation expense was $0.6 million and $0.6 million for the three months ended March 31, 2025 and 2024, respectively.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities include the following:

 

March 31,

 

 

December 31,

 

 

2025

 

 

2024

 

 

(in thousands)

 

Payroll and employee-related costs

 

$

3,180

 

 

$

8,951

 

Research and development costs

 

 

5,216

 

 

 

5,811

 

Other

 

 

1,978

 

 

 

1,735

 

Total accrued expenses and other current liabilities

 

$

10,374

 

 

$

16,497

 

Restricted Cash

As of March 31, 2025 and 2024, the Company maintained a restricted cash balance of $2.6 million and $2.6 million, respectively, all of which was related to a security deposit associated with the Company’s facility lease. The cash will remain restricted in accordance with the lease agreement absent the event of a lease termination or modification. The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the condensed consolidated statements of cash flows are as follows:

 

 

March 31,
2025

 

 

March 31,
2024

 

 

 

(in thousands)

 

Cash and cash equivalents

 

$

58,432

 

 

$

61,163

 

Restricted cash

 

 

2,567

 

 

 

2,567

 

Cash, cash equivalents and restricted cash

 

$

60,999

 

 

$

63,730

 

 

7.
Commitments and Contingencies

License Agreements

Sesame Therapeutics, Inc.

In June 2024, the Company and Sesame Therapeutics, Inc. (Sesame) entered into a license agreement pursuant to which the Company granted Sesame a non-exclusive license to certain know-how associated with preclinical research (the Sesame Agreement). Pursuant to the Sesame Agreement, the Company received a $0.1 million upfront, non-refundable payment in June 2024. Under the terms of the Sesame Agreement, the Company is eligible to receive up to $25.9 million in potential future clinical, regulatory, and commercial milestone event payments. The Company is also eligible to receive low single-digit tiered royalties on net sales of any product covered by a licensed patent.

The Company evaluated the Sesame Agreement under ASC 606. The Company identified the following promises under the agreement: (1) the non-exclusive license and (2) the initial know-how transfer, and determined that the promises were immaterial as the upfront license payment at contract inception was an inconsequential payment amount. The initial upfront license payment was recorded as license revenue on the consolidated statements of operations and comprehensive loss during the period ended June 30, 2024.

All potential future milestone payments are considered to be variable consideration and have been excluded from the transaction price. Revenue for all potential clinical and regulatory milestone achievements will be recognized when the related milestones are achieved or when it becomes probable that a significant reversal in the amount of revenue recognized relating to the milestone event will not occur. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Additionally, revenue related to potential sales milestones and royalties from the sales of the licensed products will be recognized when the related sales occur.

Due to common relationships amongst members of management and the boards of directors, the transaction above with Sesame is a related party transaction.

10


 

Medivir AB

In March 2020, the Company entered into a license agreement (the Medivir Agreement) with Medivir AB (Medivir), pursuant to which the Company obtained an exclusive license to all patents, know-how and other intellectual property associated with certain USP1 assets. Pursuant to the Medivir Agreement, the Company made an upfront payment of $0.4 million.

Under the terms of the Medivir Agreement, the Company is obligated to pay Medivir in connection with development, regulatory and commercial activities. The Company has agreed to make certain milestone payments of $1.4 million in the aggregate for the first licensed product that achieves specified clinical milestones, plus $25.0 million for the first licensed product that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and $0.7 million in the aggregate if that first licensed product achieves specified clinical milestones, plus $5.0 million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development, regulatory and sales milestones in either of the first two specified genetic contexts. The Company has the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir’s patents or if payments are due to a third party for a license under such third party’s intellectual property rights. The Company is also obligated to pay Medivir a low single-digit royalty on net sales of any product covered by a licensed patent. The Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party.

Upfront fees and subsequent milestone amounts paid pursuant to the Medivir Agreement were recorded to research and development expense.

In May 2024, the Company made the decision to discontinue further development of TNG348, the basis of the USP1 program, due to liver toxicity experienced by patients in the dose escalation portion of the Phase1/2 clinical trial. As a result, the Company does not expect any on-going material obligations under the Medivir Agreement.

Clinical Trial Collaboration and Supply Agreement

In November 2024, the Company and Revolution Medicines, Inc. (RevMed) entered into a Clinical Trial Collaboration and Supply Agreement. The agreement provides that RevMed will supply daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, at no cost to the Company for use in trials that will include TNG462 and each of these RAS(ON) inhibitors. The Company will be the sponsor of any combination trials and bear associated costs. Each company will retain commercial rights to its respective compounds, and the agreement is mutually non-exclusive. Due to common relationships amongst members of management and the boards of directors, this transaction is a related party transaction.

Other Funding Commitments

As of March 31, 2025, the Company had ongoing preclinical and clinical studies. The Company enters into contracts in the normal course of business with contract research organizations in connection with the preparation and operation of clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other preclinical and clinical services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.

Guarantees

The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, construction companies, contract research organizations, clinical trial sites, and other parties. Under these provisions, the Company generally indemnifies, defends and holds harmless the indemnified party for losses suffered or incurred by the indemnified party under the terms of the contract, including as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.

11


 

Litigation

The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of March 31, 2025, and no material legal proceedings are currently pending or threatened. Because of uncertainties related to claims, proceedings and litigation, assessments of potential liabilities are based on the Company's best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse effect on the operating results of the Company. Costs associated with involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were to be unable to prevail in any such proceedings, the consolidated financial position, results of operations, and future cash flows of the Company may be materially impacted.

8.
Preferred Stock

The Company’s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of preferred stock with a par value of $0.001 per share. The number of shares of preferred stock authorized to be issued is 10,000,000 shares as of March 31, 2025 and December 31, 2024. The shares of preferred stock are currently undesignated and no shares are issued or outstanding.

9.
Stock-Based Compensation

Stock Incentive Plan

In March 2017, the Company’s stockholders approved the 2017 Stock Option and Grant Plan (the 2017 Plan), under which stock options and restricted stock awards were granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances under the 2017 Plan were subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors at the time of issuance.

Upon effectiveness of the 2021 Stock Option and Incentive Plan (the 2021 Plan) in August 2021, the remaining shares available under the 2017 Plan ceased to be available for issuance and no future issuances will be made under the 2017 Plan. The shares of common stock underlying outstanding awards under the 2017 Plan that are forfeited, cancelled, reacquired by the Company prior to vesting, expire or are otherwise terminated (other than by exercise) will be added to the shares of common stock available for issuance under the 2021 Plan.

In August 2021, the Company's board of directors and stockholders approved the 2021 Plan, under which stock options, restricted stock units (RSUs) and other equity-based awards or any combination of these may be granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances are subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors at the time of issuance. As of March 31, 2025, the Company had 7,471,496 shares available for future issuance under the 2021 Plan.

In February 2023, the Company's board of directors approved the 2023 Inducement Plan (the Inducement Plan), under which the Company reserved shares of common stock, to be used exclusively for grants of non-qualified stock options, restricted stock units and other equity-based awards, or any combination of these to individuals who were not previously employees or directors of the Company. As of March 31, 2025, the Company had 2,041,015 shares available for future issuance under the Inducement Plan.

The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations:

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Research and development

 

$

3,986

 

 

$

3,806

 

General and administrative

 

 

3,269

 

 

 

2,913

 

Total

 

$

7,255

 

 

$

6,719

 

 

12


 

Stock Option Activity

The following table summarizes the stock option activity for the three months ended March 31, 2025:

 

Number of
shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Contractual
Term

 

 

Aggregate
Intrinsic
Value

 

 

 

 

 

 

 

 

(in years)

 

 

 

 

Options outstanding as of December 31, 2024

 

 

19,615,023

 

 

$

7.41

 

 

 

7.43

 

 

$

2,157,177

 

Granted

 

 

4,467,208

 

 

$

2.89

 

 

 

 

 

 

 

Exercised

 

 

(1,062

)

 

$

1.65

 

 

 

 

 

 

 

Cancelled

 

 

(269,912

)

 

$

6.35

 

 

 

 

 

 

 

Options outstanding as of March 31, 2025

 

 

23,811,257

 

 

$

6.57

 

 

 

7.61

 

 

$

 

Options exercisable as of March 31, 2025

 

 

12,934,117

 

 

$

6.72

 

 

 

6.58

 

 

$

 

As of March 31, 2025, total unrecognized compensation expense related to stock options was $45.1 million, which the Company expects to recognize over a remaining weighted-average period of 2.7 years.

Restricted Stock Unit Activity

The following table summarizes the RSU activity for the three months ended March 31, 2025:

 

 

Number of
Stock Units

 

 

Weighted Average
Grant Date Fair Value Per Share

 

Unvested and outstanding as of December 31, 2024

 

 

1,209,333

 

 

$

8.92

 

Granted

 

 

732,830

 

 

 

2.89

 

Vested

 

 

(377,485

)

 

 

8.86

 

Forfeited

 

 

(27,523

)

 

 

6.22

 

Unvested and outstanding as of March 31, 2025

 

 

1,537,155

 

 

$

6.11

 

As of March 31, 2025, total unrecognized compensation expense related to RSUs was $8.3 million, which the Company expects to recognize over a remaining weighted-average period of 2.2 years.

2021 Employee Stock Purchase Plan

The 2021 Employee Stock Purchase Plan (the 2021 ESPP) was adopted and approved by the Company’s board of directors and by the Company’s stockholders and became effective in August 2021. No shares of common stock were issued under the 2021 ESPP during the three months ended March 31, 2025.

10.
Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

 

Three Months Ended March 31,

 

 

(in thousands, except share and per
share data)

 

 

2025

 

 

2024

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(39,876

)

 

$

(37,914

)

Denominator:

 

 

 

 

 

 

Weighted-average common stock outstanding – basic and diluted

 

$

110,301,256

 

 

$

108,171,463

 

Net loss per common share – basic and diluted

 

$

(0.36

)

 

$

(0.35

)

In August 2023, the Company completed a private placement, in which 13,196,671 shares of common stock were sold together with pre-funded warrants to purchase 2,340,579 shares of common stock with an exercise price of $0.0001 per share. The pre-funded warrants were classified as a component of permanent equity in the Company's condensed consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the

13


 

shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate basic and diluted net loss per common share because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.

The Company’s potential dilutive securities, which include common stock options and unvested restricted common stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

Stock options to purchase common stock

 

 

23,811,257

 

 

 

20,589,225

 

Unvested restricted common stock

 

 

1,537,155

 

 

 

1,254,456

 

Total

 

 

25,348,412

 

 

 

21,843,681

 

 

11.
Income Taxes

The Company’s effective income tax rate was -0.1% and -0.1% for the three months ended March 31, 2025 and 2024, respectively. The income tax provision was less than $0.1 million for both the three months ended March 31, 2025 and 2024, respectively. Consistent with the prior year, for 2025 the Company assessed the requirement to capitalize and amortize research and experimentation expenditures for US tax purposes, which remains effective as of March 31, 2025. The Company is forecasting a taxable loss position in 2025 for which no tax benefit is recorded due to the valuation allowance maintained against the Company’s deferred tax assets.

The effective income tax rate for the three months ended March 31, 2025 and 2024 differed from the 21.0% federal statutory rate primarily due to the valuation allowance maintained against the Company’s deferred tax assets.

12.
Segment Information

The Company operates in the U.S. and has one operating segment that is managed on a consolidated basis. The Company’s revenues are primarily generated through its license and collaboration agreement with Gilead. The accounting policies, as described in the summary of significant accounting policies, is applicable across all Company operations. The Company’s chief executive officer (CEO), as the chief operating decision maker (CODM), manages and allocates resources to the operations of our company on a consolidated basis. Managing and allocating resources on a total company basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across departments and research and development programs that are in-line with our long-term company-wide strategic goals. Consistent with this decision-making process, the Company’s CODM uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results and allocating resources.

The CODM assesses performance and decides how to allocate resources based on segment net income (loss). This measure is used to monitor budget versus actual results to assess performance of the segment.

The following table presents the Company’s segment expense for the three months ended March 31, 2025 and 2024:

14


 

 

Oncology Segment

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Revenue

 

$

5,392

 

 

$

6,471

 

Less R&D expenses:

 

 

 

 

 

 

       TNG462 direct program expenses

 

 

5,461

 

 

 

5,086

 

       TNG456 direct program expenses

 

 

1,324

 

 

 

-

 

       TNG260 direct program expenses

 

 

1,730

 

 

 

2,236

 

       TNG961 direct program expenses

 

 

2,221

 

 

 

-

 

       TNG908 direct program expenses*

 

 

1,712

 

 

 

4,258

 

       TNG348 direct program expenses**

 

 

-

 

 

 

3,300

 

       Discovery direct program expenses

 

 

4,679

 

 

 

5,511

 

       Personnel-related expenses

 

 

13,850

 

 

 

12,798

 

       Facilities and other related expenses

 

 

5,465

 

 

 

4,876

 

Less G&A and other expenses:

 

 

 

 

 

 

       Other segment expenses (a)

 

 

8,826

 

 

 

6,320

 

Segment net loss

 

$

(39,876

)

 

$

(37,914

)

*In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.

**In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.

(a) Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.

The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. The CODM reviews cash, cash equivalents and marketable securities as a measure of segment assets. As of March 31, 2025, the Company’s cash, cash equivalents and marketable securities were $216.7 million. All long-lived assets of the Company reside in the U.S.

15


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and related notes for the year ended December 31, 2024 included in our Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.

Overview

Tango Therapeutics was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. Tumor suppressor gene loss remains a largely unaddressed target space specifically because these genetic events cannot be directly targeted. Our novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. We also are extending this target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss to include the discovery of novel targets that reverse tumor suppressor gene mediated immune evasion which prevents the immune system from recognizing and killing cancer cells. We believe our approach will provide the ability to deliver deep, durable target inhibition with favorable tolerability and safety profiles, thus potentially maximizing clinical benefit.

We are currently developing two MTA-cooperative PRMT5 inhibitors: TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, our next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM.

In November 2024, we reported positive early data from the ongoing Phase 1/2 clinical trial of TNG462, demonstrating durable clinical activity across multiple cancer types with a good safety and tolerability profile. We are currently enrolling patients in the ongoing TNG462 Phase 1/2 monotherapy clinical trial and plan to provide a clinical data update on TNG462 in the second half of 2025.

Based on promising preclinical data, we plan to initiate a combination trial with TNG462, including RAS(ON) multi-selective inhibitor, daraxonrasib, and RAS(ON) G12D-selective inhibitor, zoldonrasib (Revolution Medicines). This trial is expected to begin enrolling in the second quarter of 2025.

Based on preclinical data showing favorable potency and MTAP selectivity and sufficient brain penetrance, TNG456 will move into clinical development and focus on GBM. The FDA cleared the TNG456 IND in January 2025 and we plan to begin enrolling patients in a Phase 1/2 clinical trial in the second quarter of 2025.

TNG260 is a first-in-class CoREST inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations. TNG260 has a favorable safety, tolerability and pharmacokinetic profile in dose escalation, and clinical proof-of-mechanism has now been established based on pharmacodynamic data from on-treatment patient biopsies. We are enrolling patients in the dose expansion portion of the Phase 1/2 trial and we plan to provide clinical data for TNG260 in the second half of 2025.

TNG961 is a development candidate targeting HBS1L in FOCAD-deleted solid tumors. FOCAD deletion occurs in 20-40% of all MTAP-deleted cancers. FOCAD deletion is common in NSCLC, occurring in ~7% of these patients. 20-40% of cancers with MTAP deletion have a coincident FOCAD deletion on chromosome 9, and cancers with FOCAD deletion are dependent on HBS1L for mRNA processing, thus protein synthesis. By degrading HBS1L and disrupting the HBS1L/PELO complex, TNG961 causes tumor regression in FOCAD-deleted preclinical models of multiple histologies.

 

Financial Overview

Since the Company's inception, we have focused primarily on organizing and staffing our company, business planning, raising capital, discovering product candidates, securing related intellectual property, and conducting research and development activities for our programs. To date, we have funded our operations primarily through equity financings and from the proceeds received from our collaboration agreement with Gilead. Since inception, we have raised an aggregate of $166.9 million of gross

16


 

proceeds from the sale of our preferred shares, $342.1 million in gross proceeds through the closing of the Business Combination and simultaneous financing transactions, $237.1 million through our collaboration with Gilead and $123.0 million of gross proceeds through (i) $80.0 million from the private placement of common shares and pre-funded warrants to purchase common shares in August 2023 and (ii) $43.0 million from our "at-the-market" stock offering program in January 2024.

We expect that our existing cash, cash equivalents and marketable securities on hand as of March 31, 2025 of $216.7 million will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2027. Since inception, we have incurred significant operating losses. For the three months ended March 31, 2025 and 2024, our net losses were $39.9 million and $37.9 million, respectively. We had an accumulated deficit of $541.4 million as of March 31, 2025. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our product candidates through preclinical and clinical development and seek regulatory approvals, manufacture drug product and drug supply, and maintain and expand our intellectual property portfolio. We also expect to hire additional personnel, pay for accounting, audit, legal, regulatory and consulting services, and pay costs associated with maintaining compliance with Nasdaq listing rules and the requirements of the U.S. Securities and Exchange Commission, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our preclinical studies, our clinical trials, and our expenditures on other research and development activities.

We do not have any product candidates approved for sale and have not generated any revenue from product sales. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates, if ever. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed, could have a negative effect on our business, results of operations and financial condition.

Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our therapies, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.

At-the-Market Stock Offering

In September 2022, we entered into a sales agreement (the Sales Agreement) with Jefferies LLC (Jefferies), which permits us to sell from time to time, at our option, up to an aggregate of $100.0 million of shares of our common stock through Jefferies, as sales agent. Sales of the common stock, if any, will be made by methods deemed to be "at-the-market" stock offerings. The Sales Agreement will terminate upon the earliest of: (a) the sale of $100.0 million of shares of our common stock or (b) the termination of the Sales Agreement by us or Jefferies. To date, the Company has sold 4,001,200 shares of common stock under this program for gross proceeds of $43.0 million.

Revenue

To date, we have not recognized any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the next several years. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.

Collaboration Agreements with Gilead Sciences

In October 2018, we entered into a collaboration agreement (the 2018 Gilead Agreement) with Gilead Sciences, Inc. (Gilead). Pursuant to the terms of the 2018 Gilead Agreement, we received an initial upfront payment of $50.0 million. The upfront payment was initially recorded as deferred revenue on our balance sheet and is recognized as revenue as or when the performance obligation under the contract is satisfied. In August 2020, the 2018 Gilead Agreement was expanded into a broader collaboration via an amended and restated research collaboration and license agreement (the Gilead Agreement). Pursuant to the

17


 

terms of the Gilead Agreement, we received an upfront payment of $125.0 million. Consistent with the treatment of the previously received upfront payment, this upfront payment was recorded as deferred revenue on our balance sheet and is recognized as revenue as or when the performance obligation under the contract is satisfied. In 2020 and 2021, Gilead elected to extend two programs for research extension fees totaling $24.0 million, which was added to our estimate of the transaction price to total $199.0 million. In June 2024, Gilead licensed a program for a $12.0 million fee, which was recognized as license revenue in the second quarter of 2024.

As of March 31, 2025, $142.0 million has been recognized as collaboration revenue related to the upfront and research option-extension payments from the Gilead Agreements.

During the three months ended March 31, 2025 and 2024, we recognized $5.4 million and $6.5 million, respectively, of collaboration revenue associated with the Gilead agreements based on performance completed during each period.

Refer to Note 2 and Note 3 to our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes for the year ended December 31, 2024 included in our Annual Report on Form 10-K for additional information regarding our revenue recognition accounting policy and our collaboration agreement with Gilead.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:

employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, other related costs for those employees involved in research and development efforts;
external research and development expenses incurred under agreements with contract research organizations, or CROs, as well as consultants that conduct our preclinical studies and development services;
costs related to manufacturing material for our preclinical and clinical studies;
laboratory supplies and research materials;
costs to fulfill our obligations under the collaboration with Gilead;
costs related to compliance with regulatory requirements; and
facilities, information technology systems, depreciation and other allocated expenses, which include direct and allocated expenses for rent, utilities and insurance.

Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period.

Our direct external research and development expenses consist primarily of fees paid to CROs and outside consultants in connection with our preclinical and clinical development and manufacturing activities. Our direct external research and development expenses also include fees incurred under license agreements. We track these external research and development costs on a program-by-program basis once we have identified a product candidate.

We do not allocate employee costs or costs associated with our target discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We characterize research and development costs incurred prior to the identification of a product candidate as discovery costs. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical, development and manufacturing activities.

18


 

The following table summarizes our research and development expenses:

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

 

(in thousands)

 

TNG462 direct program expenses

 

$

5,461

 

 

$

5,086

 

TNG456 direct program expenses

 

 

1,324

 

 

 

 

TNG260 direct program expenses

 

 

1,730

 

 

 

2,236

 

TNG961 direct program expenses

 

 

2,221

 

 

 

 

TNG908 direct program expenses*

 

 

1,712

 

 

 

4,258

 

TNG348 direct program expenses**

 

 

 

 

 

3,300

 

Discovery direct program expenses

 

 

4,679

 

 

 

5,511

 

Unallocated research and development expenses:

 

 

 

 

 

 

       Personnel-related expenses

 

 

13,850

 

 

 

12,798

 

       Facilities and other related expenses

 

 

5,465

 

 

 

4,876

 

Total research and development expenses

 

$

36,442

 

 

$

38,065

 

*In November 2024, we announced we stopped enrollment in the TNG908 Phase 1/2 trial due to insufficient brain exposure for GBM clinical activity and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.

**In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.

The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our preclinical programs. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates or the timing of regulatory filings in connection with clinical trials or regulatory approval, due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate’s commercial potential. Our clinical development costs have, and are expected to continue to increase significantly with the commencement and continuation of our current and planned clinical trials, including our planned combination clinical trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:

the scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies, clinical trials and other research and development activities;
establishing an appropriate safety profile with IND-enabling studies;
successful enrollment in and completion of our clinical trials, including our combination clinical trials;
whether our product candidates show safety and efficacy in our clinical trials;
the receipt of marketing approvals from applicable regulatory authorities;
the progress of our collaboration with Gilead;
establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;
obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;
commercializing product candidates, if and when approved, whether alone or in collaboration with others; and
continued acceptable safety profile of products following any regulatory approval.

Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates.

19


 

General and Administrative Expenses

General and administrative expenses consist primarily of employee related costs, including salaries, bonuses, benefits, stock-based compensation and other related costs. General and administrative expense also includes professional services, including legal, accounting and audit services and other consulting fees as well as facility costs not otherwise included in research and development expenses, insurance and other general administrative expenses.

We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.

Other Income, Net

Interest Income

Interest income consists of income earned and losses incurred in connection with our investments in money market funds, U.S. Treasury bills and U.S. government agency bonds.

Other Income, Net

Other income, net consists of miscellaneous income and expense unrelated to our core operations.

Provision for Income Taxes

Our provision for income tax consists of an estimate for U.S. federal and state income taxes based on enacted rates, as adjusted for allowable credits, deductions, uncertain tax positions, changes in deferred tax assets and liabilities and changes in tax law. We recorded an insignificant provision for income taxes for each of the three months ended March 31, 2025 and 2024.

20


 

Results of Operations

Comparison of the three months ended March 31, 2025 and 2024

The following table summarizes our results of operations for the three months ended March 31, 2025 and 2024:

 

Three Months Ended March 31,

 

 

 

 

 

2025

 

 

2024

 

 

Change

 

 

(in thousands)

 

Collaboration revenue

 

$

5,392

 

 

$

6,471

 

 

$

(1,079

)

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

36,442

 

 

 

38,065

 

 

 

(1,623

)

General and administrative

 

 

11,480

 

 

 

10,661

 

 

 

819

 

Total operating expenses

 

 

47,922

 

 

 

48,726

 

 

 

(804

)

Loss from operations

 

 

(42,530

)

 

 

(42,255

)

 

 

(275

)

Other income:

 

 

 

 

 

 

 

 

 

Interest income

 

 

1,614

 

 

 

2,197

 

 

 

(583

)

Other income, net

 

 

1,074

 

 

 

2,184

 

 

 

(1,110

)

Total other income, net

 

 

2,688

 

 

 

4,381

 

 

 

(1,693

)

Loss before income taxes

 

 

(39,842

)

 

 

(37,874

)

 

 

(1,968

)

Provision for income taxes

 

 

(34

)

 

 

(40

)

 

 

6

 

Net loss

 

$

(39,876

)

 

$

(37,914

)

 

$

(1,962

)

Collaboration Revenue

Collaboration revenue of $5.4 million and $6.5 million for the three months ended March 31, 2025 and 2024, respectively, was derived from the Gilead collaboration. Research costs incurred under the collaboration were lower during the three months ended March 31, 2025, which resulted in lower collaboration revenue amounts recognized.

Research and Development Expenses

Research and development expense was $36.4 million for the three months ended March 31, 2025 compared to $38.1 million for the three months ended March 31, 2024. The decrease of $1.6 million was primarily driven by a $5.8 million decrease due to the discontinuation of the TNG908 and TNG348 clinical programs. This decrease was partially offset by a $3.5 million increase related to TNG961 and TNG456 and a $1.1 million increase in personnel-related costs, including share-based compensation expense and additional headcount to support our research and development activities.

General and Administrative Expenses

General and administrative expense was $11.5 million for the three months ended March 31, 2025 compared to $10.7 million for the three months ended March 31, 2024. The increase of $0.8 million was primarily due to $0.7 million in personnel-related costs, including share-based compensation expense and additional headcount.

Interest Income

Interest income was $1.6 million for the three months ended March 31, 2025 compared to $2.2 million for the three months ended March 31, 2024, with the decrease attributed to a decrease in our marketable securities balance in 2025 as compared to 2024.

Other Income, Net

Other income, net was $1.1 million for the three months ended March 31, 2025 compared to other income, net of $2.2 million for the three months ended March 31, 2024, with the decrease attributed to lower accretion from investments purchased at a discount.

21


 

Provision for Income Taxes

Provision for income taxes was less than $0.1 million for the three months ended March 31, 2025 and less than $0.1 million for the three months ended March 31, 2024. The income tax provision amount for both periods is primarily attributable to state taxes on interest income earned on marketable securities.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception, we have generated recurring net losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any products for several years, if at all. To date, we have funded our operations primarily through equity financings and from the proceeds received from our collaboration agreement with Gilead. Since inception, we have raised an aggregate of $166.9 million of gross proceeds from the sale of our preferred shares, $342.1 million in gross proceeds from the Business Combination and simultaneous financing transactions, $123.0 million of gross proceeds through (i) the $80.0 million private placement of common shares and pre-funded warrants to purchase common shares in August 2023, and (ii) the $43.0 million from our "at-the-market" stock offering program in January 2024, and another $237.1 million through our collaboration with Gilead. As of March 31, 2025, we had cash and cash equivalents and marketable securities of $216.7 million.

Funding Requirements

We expect that our existing cash, cash equivalents and marketable securities on hand as of March 31, 2025 of $216.7 million will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2027. Extension of cash runway was primarily due to reduction of preclinical pipeline, target discovery efforts and the associated research headcount. We have based this estimate on assumptions that may prove to be wrong, and we could expend our capital resources sooner than we expect.

Cash Flows

Comparison of the three months ended March 31, 2025 and 2024

The following table summarizes our cash flows for each of the three month periods presented:

 

Three Months Ended March 31,

 

 

 

 

 

2025

 

 

2024

 

 

Change

 

 

(in thousands)

 

 

 

 

Net cash used in operating activities

 

$

(41,697

)

 

$

(37,857

)

 

$

(3,840

)

Net cash provided by (used in) investing activities

 

 

30,597

 

 

 

(11,203

)

 

 

41,800

 

Net cash provided by financing activities

 

 

2

 

 

 

42,982

 

 

 

(42,980

)

Net change in cash, cash equivalents and restricted cash

 

$

(11,098

)

 

$

(6,078

)

 

$

(5,020

)

Operating Activities

Net cash used in operating activities was $41.7 million for the three months ended March 31, 2025 compared to net cash used in operating activities of $37.9 million for the three months ended March 31, 2024. The increase in net cash used in operating activities for the three months ended March 31, 2025 was primarily due to an increase in net loss and an increase to accrued expenses related to the advancement of our programs and personnel-related costs.

Investing Activities

Net cash provided by investing activities was $30.6 million for the three months ended March 31, 2025 compared to net cash used in investing activities of $11.2 million for the three months ended March 31, 2024. The change was primarily due to a decrease in purchases of marketable securities as compared to the three months ended March 31, 2024, which was partially offset by a decrease in sales and maturities of marketable securities as compared to the three months ended March 31, 2024.

Financing Activities

Net cash provided by financing activities was less than $0.1 million for the three months ended March 31, 2025 compared to net cash provided by financing activities of $43.0 million for the three months ended March 31, 2024. The cash provided by

22


 

financing activities for the three months ended March 31, 2025 consisted of less than $0.1 million in net proceeds received from the exercises of stock options. The cash provided by financing activities for the three months ended March 31, 2024 consisted of the $41.7 million in net proceeds received from our "at-the-market" stock offering program in January 2024, as well as the cash provided from the exercises of stock options and ESPP purchases.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations at March 31, 2025 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods:

 

Payments Due by Period

 

 

Total

 

 

Less than
1 Year

 

 

1 – 3 Years

 

 

3 – 5 Years

 

 

More than
5 Years

 

 

(in thousands)

 

Operating lease commitments

 

$

50,440

 

 

$

6,127

 

 

$

12,724

 

 

$

12,532

 

 

$

19,057

 

Total

 

$

50,440

 

 

$

6,127

 

 

$

12,724

 

 

$

12,532

 

 

$

19,057

 

The commitment amounts in the table above primarily reflect the minimum payments due under our amended operating lease for office and laboratory space at our 201 Brookline Avenue, Boston, Massachusetts location. These commitments are also recognized as operating lease liabilities in our balance sheet at March 31, 2025. Refer to Note 7 to our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2024 for additional discussion of the lease.

Purchase Obligations

In the normal course of business, we enter into contracts with third parties for preclinical studies, clinical operations, manufacturing and research and development supplies. These contracts generally do not contain minimum purchase commitments and generally provide for termination with limited notice, and therefore are cancellable contracts. These payments are not included in the table above as the amount and timing of such payments are not known as of March 31, 2025.

License Agreement Obligations

We have also entered into a license agreement under which we may be obligated to make milestone and royalty payments. We have not included future milestone or royalty payments under the agreement in the table above since the payment obligations are contingent upon future events, such as achieving certain development, regulatory, and commercial milestones or generating product sales. As of March 31, 2025 and December 31, 2024, we were unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. Refer to Note 8 of our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2024 for a description of our license agreement.

Critical Accounting Policies and Significant Judgments and Estimates

Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances and at the time these estimates are made, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Some of the judgments and estimates we make can be subjective and complex. Our actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates.

While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2024, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.

23


 

Revenue Recognition

The terms of our collaboration agreements may include consideration such as non-refundable up-front payments, license fees, research extension fees, and clinical, regulatory and sales-based milestones and royalties on product sales.

We recognize revenue under ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of the revenue standard, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) determine whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations; and (v) recognize revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when collectability of the consideration to which we are entitled in exchange for the goods or services we transfer to the customer is determined to be likely. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. We then allocate the transaction price (the amount of consideration we expect to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognize the associated revenue when (or as) each performance obligation is satisfied. Our estimate of the transaction price for each contract includes all variable consideration to which we expect to be entitled.

We recognize the transaction price allocated to license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. If the license is considered to not be distinct from other performance obligations, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied (i) at a point in time, but only for licenses determined to be distinct from other performance obligations in the contract, or (ii) over time; and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from license payments. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

We evaluate whether it is probable that the consideration associated with each milestone payment will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are considered constrained and excluded from the transaction price until they meet this threshold. Milestones tied to regulatory approval, and therefore not within our control, are considered constrained until such approval is received. Upfront and ongoing development milestones under our collaboration agreements are not subject to refund if the development activities are not successful. At the end of each subsequent reporting period, we re-evaluate the probability of a significant reversal of the cumulative revenue recognized for the milestones, and, if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues from collaborators in the period of adjustment. We exclude sales-based milestone payments and royalties from the transaction price until the sale occurs (or, if later, until the underlying performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied), because the license to our intellectual property is deemed to be the predominant item to which the royalties relate as it is the primary driver of value.

ASC 606 requires us to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in ASC 606 as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which we have sold the same performance obligation separately are not available, we are required to estimate the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.

Whenever we determine that multiple promises to a customer are not distinct and comprise a combined performance obligation that includes services, we recognize revenue over time using the cost-to-cost input method, based on the total estimated cost to fulfill the obligation. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement.

24


 

Consideration that does not meet the requirements to satisfy the above revenue recognition criteria is a contract liability and is recorded as deferred revenue in the consolidated balance sheets. We have recorded short-term and long-term deferred revenue on our consolidated balance sheets based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that we expect will not be recognized within the next 12 months are classified as long-term deferred revenue.

In certain instances, the timing of and total costs of satisfying these obligations under our collaboration agreement can be difficult to estimate. Accordingly, our estimates may change in the future. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount of revenue that we will recognize and record in future periods.

Under ASC 606, we will recognize revenue when we fulfill our performance obligations under the agreements with customers. As the required performance obligation is satisfied, we will recognize revenue for the portion satisfied and record a receivable for any fees that have not been received. Amounts are recorded as short-term collaboration receivables when our right to consideration is unconditional. A contract liability is recognized when a customer prepays consideration or owes payment to an entity in advance of our performance according to a contract. We do not assess whether a contract has a significant financing component if the expectation at contract inception is that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.

Accrued Research and Development Expenses

As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments, which would be recorded as a prepaid expense in other assets, or if there is the right of offset, offset against our liability balance with the counterparty. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary.

We record the expense and accrual related to research and development activities performed by our vendors based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research and development activities; invoicing to date under the contracts; communication from the vendors of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the contracts and purchase orders. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.

Recently Adopted Accounting Pronouncements

A description of recently issued and adopted accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed within Note 2 of our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and also in Note 2 to our audited consolidated financial statements and related notes in our Annual Report on Form 10-K for the year ended December 31, 2024.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

There were no material changes to our market risks from those described in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," in our Annual Report on Form 10-K for the year ended December 31, 2024.

25


 

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2025.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rules 13a-15 and 15d-15(d) under the Exchange Act that occurred during the quarter ended March 31, 2025 that materially affected, or were reasonably likely to materially affect, the Company’s internal control over financial reporting.

26


 

PART II—OTHER INFORMATION

From time to time, we may become involved in litigation or other legal proceedings. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.

We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business.

27


 

Item 1A. Risk Factors.

Investing in our securities involves a high degree of risk. In addition to the other information set forth in this Quarterly Report on Form 10-Q, careful consideration should be given to the risk factors discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, which could materially affect our business, financial condition, and/or future results. The risks described in our Annual Report on Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. Other than as set forth below, there have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on February 27, 2025.

Inadequate funding for the FDA, the SEC and other U.S. government agencies or the EMA or comparable foreign regulatory authorities, including from government shut downs, or other disruptions to these agencies’ staffing and operations, including significant leadership, personnel, and policy changes, could prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA, the EMA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government priorities and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and enact statutory, regulatory and policy changes. Average review times at the FDA or other regulatory authorities have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.

In addition, government funding of the SEC and other government agencies on which our operations may rely, and those that fund research and development activities that is required by third parties we enter into agreements with, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other federal agencies, including substantial leadership departures, personnel cuts, and policy changes, may also slow the time necessary for new drugs to be reviewed and/or approved, which would harm our business. Changes and cuts in FDA staffing also could result in delays in the FDA’s responsiveness or in its ability to review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all.

Currently, federal agencies in the U.S. are operating under a continuing resolution that is set to expire on September 30, 2025. For example, in prior years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. A prolonged government shutdown, significant leadership, personnel, and/or policy changes, or other substantial modification in agency activities (including due to global health concerns, the aims of the Trump administration, or geopolitical factors) could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

With the change in the U.S. presidential administration in 2025, there is substantial uncertainty as to whether and how the Trump administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates and any products for which we obtain approval. This uncertainty could present new challenges and/or opportunities as we navigate development and approval of our product candidates. Additionally, the new administration could issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic candidates.

Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.

Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the United States and other countries recently experienced increased inflation and interest

28


 

rates increased in response to this inflation. These conditions in the U.S. and global economy have caused significant volatility and uncertainty in U.S. and international markets. A severe or prolonged economic downturn, a marked increase in interest rates and inflation could result in a variety of risks to our business, including, weakened demand for our product candidates (if and when approved by regulatory authorities) and our inability to raise additional capital when needed on acceptable terms, if at all. Changes in U.S. government and other nations’ administrations and their associated shifts in policy and priorities could also impact our operations and market conditions. Our business is sensitive to geopolitical issues, including foreign policy actions taken by governments such as tariffs, sanctions, embargoes, export and import controls, and other trade restrictions, which can affect our operations, cause disruptions to our supply chain, and, ultimately, could adversely affect our business. For example, the Trump administration has initiated or is considering imposing tariffs on certain foreign goods (and we do import certain goods from foreign countries and certain services are performed for our benefit in foreign countries). In response to this action, certain foreign governments, including China’s, have instituted or are considering imposing tariffs on certain U.S. goods, which could impact inflation rate, increase the costs of goods, and adversely affect our business. It remains unclear what the Trump administration or foreign governments will or will not do with respect to tariffs or other international trade agreements and policies.

In addition, our business may be generally exposed to the impact of political or civil unrest or military action, including the current conflict between Russia and Ukraine (where a vendor that performs chemistry related work on our pre-clinical product candidates is located). Other global conflicts, including conflicts in the Middle East, and heightened tensions in the Pacific region, have significantly elevated global geopolitical tensions and security concerns. While we do not otherwise have direct exposure to Ukraine, our business and results of operations may be impacted based upon the events taking place there and economic sanctions, export controls, and other trade restrictions, for instance those that the U.S. Government and other nations implemented against Russia in light of its invasion of Ukraine or those relating to the conflict in the Middle East, could directly and indirectly result in the disruption of our business and supply chain. A weak or declining economy could also strain our suppliers and the global supply chain, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.

29


 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Insider Adoption or Termination of Trading Arrangements

During the fiscal quarter ended March 31, 2025, none of our directors or officers informed us of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408.

Item 6. Exhibits.

Exhibit

Number

Description

3.1

 

Second Amended and Restated Certificate of Incorporation of Tango Therapeutics, Inc., as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024).

3.2

 

Amended and Restated Bylaws of Tango Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 to the Registrant’s registration statement on Form S-8 filed with the SEC on October 14, 2021).

31.1*

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH*

 

Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

104*

 

Cover Page Interactive Data File (formatted in as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

 

* Filed herewith.

** The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.

 

 

30


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Tango Therapeutics, Inc.

Dated: May 12, 2025

By:

/s/ Barbara Weber

Barbara Weber, MD

President and Chief Executive Officer

 

(Principal Executive Officer)

 

 

Tango Therapeutics, Inc.

 

By:

/s/ Daniella Beckman

Daniella Beckman

Chief Financial Officer

 

(Principal Financial Officer)

 

31


EX-31.1 2 tngx-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Barbara Weber, M.D., certify that:

 

1.
I have reviewed this Quarterly Report on Form 10-Q of Tango Therapeutics, Inc.;

 

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 


 

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Dated: May 12, 2025 /s/ Barbara Weber, M.D.

Barbara Weber, M.D.

Chief Executive Officer

(Principal Executive Officer)

 

 


EX-31.2 3 tngx-ex31_2.htm EX-31.2 EX-31.2

 

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

I, Daniella Beckman, certify that:

 

1.
I have reviewed this Quarterly Report on Form 10-Q of Tango Therapeutics, Inc.;

 

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 


 

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Dated: May 12, 2025 /s/ Daniella Beckman

Daniella Beckman

Chief Financial Officer

(Principal Financial Officer)

 


EX-32.1 4 tngx-ex32_1.htm EX-32.1 EX-32.1

 

Exhibit 32.1

 

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Tango Therapeutics, Inc. (the “Company”) for the fiscal quarter ended March 31, 2025 as filed with the Securities and Exchange Commission (the “Report”), I, Barbara Weber, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

 

(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 12, 2025 /s/ Barbara Weber, M.D.

Barbara Weber, M.D.

Chief Executive Officer

(Principal Executive Officer)

 

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 


EX-32.2 5 tngx-ex32_2.htm EX-32.2 EX-32.2

 

Exhibit 32.2

 

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of Tango Therapeutics, Inc. (the “Company”) for the fiscal quarter ended March 31, 2025 as filed with the Securities and Exchange Commission (the “Report”), I, Daniella Beckman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

 

(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 12, 2025 /s/ Daniella Beckman

Daniella Beckman

Chief Financial Officer

(Principal Financial Officer)

 

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 


EX-101.SCH 6 tngx-20250331.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Redeemable Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Collaboration Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Collaboration Agreements - Additional Information (Details1) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Marketable Securities - Summary of Debt Securities, Available For Sale (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Marketable Securities - Summary of Fair Value and Gross Unrealized Losses on Securities (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Supplemental Balance Sheet Information - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Net Loss Per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Segment Information - Schedule of Segment Expense (Details) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items] Statement [Line Items] Statement [Line Items] Plan Name [Domain] Plan Name [Domain] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation Of financial statements. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Transaction price allocated to performance obligation Revenue, Remaining Performance Obligation, Amount Research Extension Fee Research Extension Fee . Research extension fee Fair Value, Recurring and Nonrecurring [Table] Marketable Security, Unrealized Gain (Loss) Marketable Securities, Unrealized Gain (Loss), Total Unrealized loss on marketable securities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income (loss): Number of operating segments Number of Operating Segments Weighted Average Exercise Price Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Shares, Outstanding Balance at the beginning (in Shares) Balance at the ending (in Shares) Other, net Other Noncash Income (Expense) Other Noncash Income (Expense), Total Fair Value Hierarchy and NAV [Axis] Redeemable convertible preferred stock, issued Temporary Equity, Shares Issued Redeemable Convertible Preferred Stock Issued Fair Value, Inputs, Level 2 [Member] Level 2 [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Segment Reporting, Other Segment Item, Amount Other segment expenses Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Product and Service [Axis] Temporary Equity, Par Value Temporary equity, par value Finite-Lived Intangible Assets by Major Class [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Sale of Stock [Domain] Cash and Cash Equivalents [Domain] Summary of Fair value and Gross Unrealized Losses on Securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Entity Central Index Key Entity Central Index Key Debt Securities, Available-for-Sale [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of shares Cancelled Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Common Stock, Shares, Issued Common Stock, Shares, Issued Common Stock, Shares, Issued, Total Common Stock Shares Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Stock issued during period shares common stock and pre funded warrants net. Stock Issued During Period Shares Common Stock And Pre Funded Warrants Net Issuance of common stock from private placement financing, net (in Shares) Income Statement [Abstract] Recently Issued Accounting Pronouncements Recently Issued Accounting Pronouncements [Policy Text Block] Disclosure of accounting policy for recently issued accounting pronouncements. Entity Address, State or Province Entity Address, State or Province Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under stock plans Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Class of Warrant or Right [Table] Contract with Customer, Liability, Revenue Recognized Contract with customer liability, revenue recognized TNG260 Direct Program Expenses - R&D [Member] TNG260 direct program expenses - R&D. TNG260 direct program expenses - R&D [Member] Securities, Total Fair value Debt Securities, Available-for-Sale, Unrealized Loss Position Debt securities considered to be an unrealized loss position Aggregate Intrinsic Value Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Cover [Abstract] Net loss per common share - basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Operating expenses: Operating Expenses [Abstract] Series B One Preferred Stock [Member] Series B One Preferred Stock. Series B-1 Preferred Stock [Member] Contract with Customer, Liability, Current Short-term deferred revenue Deferred revenue Milestone payments. Milestone Payments Milestone payments Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Investments, Debt and Equity Securities [Abstract] Commitments And Contingencies Details [Table] Commitments and Contingencies. Commitments And Contingencies Details [Table] Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash Share-based Payment Arrangement, Expense Stock-based compensation expense Accumulated deficit Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Plan Name [Axis] Plan Name [Axis] Segment Reporting [Abstract] Organization Consolidation And Presentation Of Financial Statements [Table] Organization consolidation and presentation of financial statements. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Number of shares, Options outstanding Beginning balance Number of shares, Options outstanding Ending balance Current assets: Assets, Current [Abstract] Number of shares reserved for issuance Share based payment arrangement, Shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Share-based Payment Arrangement, Disclosure [Abstract] Share-Based Payment Arrangement, Disclosure [Abstract] Investment Type [Axis] Research and development costs Accrued Research And Development Costs Current Accrued research and development costs current. Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Facilities and Other Related Expenses - R&D [Member] Facilities and other related expenses - R&D. Facilities and other related expenses - R&D [Member] Weighted Average Grant Date Fair Value Per Share, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Product and Service [Domain] Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive income Pre-funded warrants. Pre-funded Warrants [Member] Pre-funded Warrants [Member] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Contract with Customer, Liability, Noncurrent Long-term deferred revenue Deferred revenue, net of current portion Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Fair Value, Recurring [Member] Fair Value Measurements Recurring [Member] Schedule of estimated useful lives of the Company's property and equipment. Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block] Summary of estimated useful lives of property and equipment Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Stock options to purchase common stock [Member] Temporary Equity, Carrying Amount, Attributable to Parent Balance at the beginning Balance at the ending Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively Deferred Tax Asset [Domain] Taxes Payable, Current, Total Taxes Payable, Current Income tax payable Statement of Cash Flows [Abstract] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Restricted Stock [Member] Restricted Stock Awards [Member] Unvested restricted common stock [Member] Equity Components [Axis] Equity Components [Axis] Entity Address, Address Line One Entity Address, Address Line One Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted Other Commitments [Axis] Payroll and employee-related costs Employee-related Liabilities, Current Employee-related Liabilities, Current, Total Number of Stock Units, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Computer Equipment [Member] Computer equipment [Member] Computer Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Accounts payable Increase (Decrease) in Accounts Payable, Trade Nonoperating Income (Expense) Total other income, net Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Number of Stock Units, Unvested and outstanding Ending balance Number of Stock Units, Unvested and outstanding Beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Amendment Flag Amendment Flag Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Schedule Of Accrued Expenses And Other Current Liabilities Current [Table Text Block] Schedule of accrued expenses and other current liabilities current. Schedule of Accrued Expenses and Other Current Liabilities Current Personnel-related expenses - R&D [Member] Personnel-Related Expenses - R&D [Member] Personnel-related expenses - R&D. Net loss Net loss Share based payment arrangement,Options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercise of stock options, (in Shares) Number of shares Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Number of shares Options exercisable Research and Development [Member] Research and Development Expense [Member] Equity Component [Domain] Equity Component [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] General and administrative General and Administrative Expense General and Administrative Expense, Total Supplemental Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Other income, net Furniture and Fixtures [Member] Furniture and fixtures [Member] Furniture and Fixtures [Member] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Deferred Revenue, Current, Total Deferred Revenue, Current Short-term deferred revenue Amended Gilead Agreement [Member] Amended gilead agreement. Payables and Accruals [Abstract] Payables and Accruals [Abstract] Short-term restricted cash Restricted Cash, Current Restricted cash Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under stock plans, (in shares) Research Term Research term. Research term Deferred Revenue, Noncurrent, Total Deferred Revenue, Noncurrent Long-term deferred revenue Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Weighted Average Exercise Price Cancelled Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Restricted Cash, Noncurrent Restricted cash, net of current portion Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Domain] Collaborative Arrangement Disclosure [Text Block] Collaboration Agreements Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Common shares outstanding Finite-Lived Intangible Assets, Major Class Name [Domain] Revaluation of Right-of-use Asset and Lease Liability Upon Lease Modification Revaluation of right-of-use asset and lease liability upon lease modification. Revaluation of right-of-use asset and lease liability upon lease remeasurement Interest Income (Expense), Net, Total Interest Income (Expense), Operating Interest income Other Commitments [Domain] 2023 Inducement Plan [Member] Two Thousand Twenty Three Inducement Plan [Member] Two Thousand Twenty Three Inducement Plan [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accrued expenses and other liabilities Increase (Decrease) In Accrued Expenses And Other Liabilities Increase (decrease) in accrued expenses and other liabilities. Adjustments to additional paid in capital business combination and pipe financing issuance costs. Adjustments To Additional Paid In Capital Business Combination And Pipe Financing Issuance Costs Business combination and PIPE financing, issuance costs Business combination and PIPE financing, issuance costs Entity Interactive Data Current Entity Interactive Data Current Marketable Securities [Table] Accounting Standards Update [Domain] Document Quarterly Report Document Quarterly Report Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under employee stock purchase plans. Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under Employee stock purchase plans Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under ESPP Weighted Average Grant Date Fair Value Per Share, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Statistical Measurement [Axis] Statistical Measurement [Axis] Total assets Assets, Fair Value Disclosure Restricted Cash and Cash Equivalents [Axis] Fair value assets transfer from Level 1 to Level 2 Fair Value Asset Level1 To Level2 Transfer Amount Fair value asset level1 to level2 transfer amount. Summary of Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Weighted Average Grant Date Fair Value Per Share, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average amortization period Share-based compensation expense, Period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition License Revenue [Member] License Revenue Member Statement of Income Location, Balance [Axis] Total assets Assets 2021 Plan [Member] Two thousand and twenty one plan. Two Thousand And Twenty One Plan [Member] Number of Stock Units, Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Number of Stock Units, Vested Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Restricted Cash and Cash Equivalents, Noncurrent, Total Entity Address, City or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss [Member] Segments [Axis] Number of Stock Units, Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Depreciation Depreciation Depreciation, Total Depreciation expense Schedule of Segment Reporting Information, by Segment [Table] Fair value liabilities transfer from Level 2 to Level 1 Fair Value Liabilities Level2 To Level1 Transfer Amounts Fair value liabilities level2 to level1 transfer amounts. Computer Software, Intangible Asset [Member] Computer Software [Member] Medivir agreement. Medivir Agreement [Member] Medivir Agreement [Member] Private Placement [Member] Private Placement [Member] Share-based Payment Arrangement [Text Block] Stock-Based Compensation Construction in Progress [Member] Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration] Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Fair Value Disclosures [Abstract] Stock Issued During Period, Value, New Issues At-the-market offerings, net of issuance costs ASU 2023-09 [Member] Accounting Standards Update 2023-09 [Member] Current liabilities: Liabilities, Current [Abstract] Document Type Document Type Accounting Standards Update [Axis] US Government Agencies Debt Securities [Member] U.S. Government Agency Bonds [Member] Title of 12(b) Security Title of 12(b) Security Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Impairments to marketable securities or reserves for credit losses Debt and Equity Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Research and development Research and Development Expense Research and Development Expense, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Number of shares Granted Fair value liabilities transfer from Level 1 to Level 2 Fair Value Liabilities Level1 To Level2 Transfer Amounts Fair value liabilities level1 to level2 transfer amounts. Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Accretion on marketable securities 1. Accretion On Marketable Securities 1 Accretion on marketable securities Cash cash equivalents and marketable securities Cash Cash Equivalents and Marketable Securities Cash Cash Equivalents and Marketable Securities Securities Greater than twelve months, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price Financial Instruments [Domain] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue remaining performance obligations expected remaining contractual term Class of Warrant or Right [Line Items] Sale of Stock [Axis] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investments [Domain] Money Market Funds, at Carrying Value Cash equivalents, Money market funds Marketable securities Marketable Securities, Current Marketable Securities, Current, Total Income Taxes Income Tax Disclosure [Text Block] Cash paid for leases Cash Paid For Leases Cash paid for leases. Debt Securities, Available-for-Sale [Table] Gilead Agreement [Member] Gilead Agreement . Other current liabilities Other Accrued Liabilities, Current Entity Address, Address Line Two Entity Address, Address Line Two Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effective income tax rate Effective tax rate Effective Income Tax Rate Reconciliation, Percent Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Provision for income taxes Tax provision or benefit Provision for income taxes Trading Symbol Trading Symbol Balance at the beginning Balance at the ending Equity, Attributable to Parent Total stockholders' equity Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] US Government Securities, at Carrying Value Cash equivalents, U.S. Treasury bills Restricted Stock Units (RSUs) [Member] RSU [Member] Sale of Stock, Number of Shares Issued in Transaction Number of shares sold Number of units issued in transaction Deferred revenue Increase (Decrease) in Deferred Revenue Redeemable convertible preferred stock shares authorized Temporary Equity, Shares Authorized Temporary Equity, Shares Authorized Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Change in accounting principle accounting standards update adopted [true or false] Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Unrecognized compensation cost Schedule of Stock-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Gross Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Equipment [Member] Equipment [Member] Laboratory Equipment [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Marketable Debt Securities [Member] Marketable Debt Securities . Marketable Debt Securities [Member] Stock based compensation expense APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurements Operating lease liabilities Increase (Decrease) In Operating Lease Liabilities Increase (decrease) in operating lease liabilities. Security Exchange Name Security Exchange Name 2021 Employee Stock Purchase Plan [Member] Two Thousand and Twenty One Employee Stock Purchase Plan [Member] Two thousand and twenty one employee stock purchase plan. Commitments and Contingencies. Commitments And Contingencies Details [Line Items] Commitments and Contingencies (Details) [Line Items] TNG348 direct program expenses - R&D [Member] TNG348 Direct Program Expenses- R&D [Member] TNG348 direct program expenses- R&D. Total operating expenses Operating Expenses Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Axis] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Maximum [Member] Liabilities and Equity Total liabilities and stockholders' equity Operating lease right-of-use asset Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] TNG462 Direct Program Expenses - R&D [Member] TNG462 direct program expenses - R&D. TNG462 direct program expenses - R&D [Member] Net loss per common share - diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Leasehold Improvements [Member] Leasehold improvements [Member] Leasehold Improvements [Member] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities. Total accrued expenses and other current liabilities Entity Ex Transition Period Entity Ex Transition Period Impairments to marketable securities or reserves for credit losses Other Than Temporary Impairment Loss Debt Securities Reserves Credit losses Available For Sale Other than temporary impairment loss debt securities reserves credit losses available for sale. Total liabilities Liabilities Fair Value Hierarchy and NAV [Domain] Total current assets Assets, Current Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Nonrefundable Upfront Payments Received Non-refundable upfront payment received Non-refundable upfront payments received Stock Issued During Period, Shares, New Issues At-the-market offerings, net of issuance costs (in shares) Common stock, shares issued Entity Filer Category Entity Filer Category Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Warrants to purchase shares of common stock Nature of the Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Purchases of marketable securities Payments to Acquire Marketable Securities Payments to Acquire Marketable Securities, Total Nonoperating Income (Expense) [Abstract] Other income: Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Redeemable convertible preferred stock Par or Stated Value Per Share Temporary Equity, Par or Stated Value Per Share Temporary Equity, Par or Stated Value Per Share Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Share-based Payment Arrangement, Noncash Expense, Total Aggregate Intrinsic Value, Options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Marketable securities, Accrued interest Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Entity Registrant Name Entity Registrant Name Securities, Total Unrealized loss Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total Specified regulatory and sales milestones for genetic context. Specified Regulatory And Sales Milestones For Genetic Context [Member] Specified Regulatory And Sales Milestones For Genetic Context [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net Loss Per Share Earnings Per Share [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Investment, Type [Extensible Enumeration] Weighted-average common stock outstanding - basic Weighted average number of common shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Marketable Securities [Abstract] Common Stock, Shares Authorized Common Stock, Shares Authorized Sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from Sale and Maturity of Marketable Securities, Total Fair Value, Inputs, Level 1 [Member] Level 1 [Member] Weighted Average Exercise Price Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Financial Instrument [Axis] Weighted Average Contractual Term, Options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term General and Administrative [Member] General and Administrative Expense [Member] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Accounting Policies [Abstract] Ownership percentage in common stock Percentage of Ownership Interest in Equity Investment Percentage of ownership interest in equity investment. Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Income Tax Disclosure [Abstract] Equity, Attributable to Parent [Abstract] Stockholders' equity: Supplemental disclosure of noncash investing and financing activity: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Statement [Table] Statement [Table] Property, Plant and Equipment [Table Text Block] Schedule of Property, Plant and Equipment Discovery Direct Program Expenses - R&D [Member] Discovery direct program expenses - R&D. Discovery direct program expenses - R&D [Member] Stock issued during period value common stock and pre funded warrants net. Stock Issued During Period Value Common Stock And Pre Funded Warrants Net Issuance of common stock from private placement financing, net Entity File Number Entity File Number Segment Information Segment Reporting Disclosure [Text Block] Non Rule 10B51 Arr Modified Flag Non-Rule 10b5-1 Arrangement Modified Flag. Non-Rule 10b5-1 Arrangement Modified Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Sesame Agreement Sesame Agreement [Member] Sesame Agreement. Earnings Per Share [Abstract] TNG456 Direct Program Expenses - R&D [Member] TNG456 direct program expenses - R&D. TNG456 direct program expenses - R&D [Member] Specified regulatory approval and sales milestones. Specified Regulatory Approval And Sales Milestones [Member] Specified Regulatory Approval And Sales Milestones [Member] Statement of Financial Position [Abstract] Loss from operations Operating Income (Loss) Entity Shell Company Entity Shell Company Collaboration Agreements [Abstract] Collaboration Agreements . Entity Tax Identification Number Entity Tax Identification Number Assets Assets [Abstract] Security Deposits [Member] Security deposits. Entity Current Reporting Status Entity Current Reporting Status Weighted Average Contractual Term Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Proceeds From Issuance of Common Stock and Pre-funded Warrants, Net Proceeds from issuance of common stock and pre-funded warrants, net. Proceeds from issuance of common stock and pre-funded warrants Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Document Fiscal Year Focus Document Fiscal Year Focus Cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments, Total Change in Accounting Principle, Accounting Standards Update, Adoption Date Change in accounting principle accounting standards update adoption date Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment included in accounts payable and accrued expenses Stock Options [Member] Stock Options [Member] Stock options. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Research extension fees, variable consideration Research extension fee variable consideration. Research Extension Fee Variable Consideration Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax, Total Other comprehensive loss City Area Code City Area Code Total current liabilities Liabilities, Current Federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] License fee amount Sponsored A Licence Program,Fee Amount Sponsored a license program, fee amount. Additional Paid in Capital, Total Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Additional paid-in capital Additional Paid in Capital Rule 10B51 Arr Modified Flag Rule 10b5-1 Arrangement Modified Flag. Rule 10b5-1 Arrangement Modified Securities Less than twelve months, Unrealized loss Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Two Thousand And Eighteen Gilead Agreement [Member] Two Thousand And Eighteen Gilead Agreement . 2018 Gilead Agreement [Member] Computer Software [Member] Computer Software Member Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Upfront payment. Upfront Payment Upfront payment Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Amortized Cost Operating lease liabilities Operating Lease, Liability, Current Temporary Equity Disclosure [Abstract] Accumulated Deficit [Member] Retained Earnings [Member] Non-refundable upfront payment received Non Refundable Upfront Payment Received Non-refundable upfront payment received. Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Payments to Acquire Property, Plant, and Equipment, Total Collaboration Revenue [Member] Collaboration Revenue Member Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Summary of Financial Assets Measured at Fair Value on a Recurring Basis Document Transition Report Document Transition Report Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Weighted Average Exercise Price Exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Minimum [Member] Minimum [Member] Common Stock [Member] Common Stock [Member] Restricted Cash Restricted Cash, Total Restricted cash Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Weighted Average Grant Date Fair Value Per Share, Unvested and outstanding Ending balance Weighted Average Grant Date Fair Value Per Share, Unvested and outstanding Beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other long-term assets Increase (Decrease) in Other Noncurrent Assets Noncash operating lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Operating Lease Liabilities from Obtaining Right-of-Use Assets Operating lease liabilities from obtaining right-of-use assets. Operating lease liabilities from obtaining right-of-use assets Fair Value Debt Securities, Available-for-Sale, Current Debt Securities, Available-for-sale, Current, Total Adjustments to reconcile net loss to net cash from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statement of Income Location, Balance [Domain] Other assets Other Assets, Noncurrent Other Assets, Noncurrent, Total Forecasting taxable loss position deferred tax assets member. Forecasting Taxable Loss Position Deferred Tax Assets [Member] Segments [Domain] Specified clinical milestones. Specified Clinical Milestones [Member] Specified Clinical Milestones [Member] Cummulative research extension fee Cummulative Research Extension Fee Cummulative research extension fee. Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Milestone payments receivable Milestone Payments Receivable Milestone payments receivable. Securities Less than twelve months, Fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months TNG908 Direct Program Expenses - R&D [Member] TNG908 direct program expenses - R&D . TNG908 direct program expenses - R&D [Member] Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock Disclosure [Text Block] Redeemable convertible preferred stock disclosure. Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 108,107,890 and 107,729,343 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Valuation Allowance by Deferred Tax Asset [Axis] Debt Securities, Available-for-Sale [Table Text Block] Summary of Debt Securities, Available-for-sale Revenue recognized, Cumulative catch-up adjustment Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract Revenue recognized, cumulative catch-up adjustment Measurement Frequency [Axis] Impairments to marketable securities or reserves for credit losses Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale Commitments and Contingencies Commitments and contingencies (Note 8) Securities Greater than twelve months, Unrealized loss Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Weighted-average common stock outstanding - diluted Weighted average number of common shares outstanding - diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Segment Expense Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Accounts Receivable, after Allowance for Credit Loss, Current, Total Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Number Of Licensed Product Number Of Licensed Product. Number of licensed product Fair value assets transfer from Level 2 to Level 1 Fair Value Asset Level2 To Level1 Transfer Amount Fair value asset level2 to level1 transfer amount. Entity Small Business Entity Small Business Segment Reporting Information [Line Items] Total revenue Revenues Total collaboration revenue US Treasury Securities [Member] U.S. Treasury Bills [Member] Investments, Fair Value Disclosure Marketable debt securities Marketable debt securities Contractual Obligation Contractual Obligation, Total Contractual obligation Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Weighted Average Exercise Price, Options outstanding Ending balance Weighted Average Exercise Price, Options outstanding Beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Measurement Frequency [Domain] Share-Based Payment Arrangement, Recognized Amount [Abstract] Redeemable convertible preferred stock, outstanding Temporary Equity, Shares Outstanding Balance at the beginning (in Shares) Balance at the ending (in Shares) Redeemable Convertible Preferred Stock Outstanding TNG961 direct program expenses - R&D [Member] TNG961 Direct Program Expenses - R&D [Member] TNG961 Direct Program Expenses - R&D [Member] Accounts payable Accounts Payable, Current Accounts Payable, Current, Total XML 8 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2025
May 05, 2025
Cover [Abstract]    
Entity Registrant Name TANGO THERAPEUTICS, INC.  
Trading Symbol TNGX  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
Entity Central Index Key 0001819133  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Document Period End Date Mar. 31, 2025  
Document Fiscal Year Focus 2025  
Document Fiscal Period Focus Q1  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity Incorporation, State or Country Code DE  
Entity File Number 001-39485  
Entity Tax Identification Number 85-1195036  
Entity Address, Address Line One 201 Brookline Ave.  
Entity Address, Address Line Two Suite 901  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02215  
City Area Code 857  
Local Phone Number 320-4900  
Title of 12(b) Security Common stock, par value $0.001 per share  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
Entity Common Stock, Shares Outstanding   108,394,190
XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 58,432 $ 69,530
Marketable securities 158,292 188,387
Restricted cash 428 0
Prepaid expenses and other current assets 7,778 8,426
Total current assets 224,930 266,343
Property and equipment, net 7,539 8,102
Operating lease right-of-use assets 39,697 39,476
Restricted cash, net of current portion 2,139 2,567
Other assets 1 4
Total assets 274,306 316,492
Current liabilities:    
Accounts payable 3,239 1,601
Accrued expenses and other current liabilities 10,374 16,497
Operating lease liabilities 2,824 2,454
Deferred revenue 19,480 17,618
Total current liabilities 35,917 38,170
Operating lease liabilities, net of current portion 34,122 34,039
Deferred revenue, net of current portion 37,511 44,766
Total liabilities 107,550 116,975
Commitments and contingencies (Note 8)
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively
Stockholders' equity:    
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 108,107,890 and 107,729,343 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 108 108
Additional paid-in capital 707,888 700,631
Accumulated other comprehensive income 194 336
Accumulated deficit (541,434) (501,558)
Total stockholders' equity 166,756 199,517
Total liabilities and stockholders' equity $ 274,306 $ 316,492
XML 10 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2025
Dec. 31, 2024
Temporary Equity, Par or Stated Value Per Share $ 0.001 $ 0.001
Temporary Equity, Shares Authorized 10,000,000 10,000,000
Temporary Equity, Shares Issued 0 0
Temporary Equity, Shares Outstanding 0 0
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Common Stock, Shares Authorized 200,000,000 200,000,000
Common Stock, Shares, Issued 108,107,890 107,729,343
Common Stock, Shares, Outstanding 108,107,890 107,729,343
XML 11 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Total revenue $ 5,392 $ 6,471
Operating expenses:    
Research and development 36,442 38,065
General and administrative 11,480 10,661
Total operating expenses 47,922 48,726
Loss from operations (42,530) (42,255)
Other income:    
Interest income 1,614 2,197
Other income, net 1,074 2,184
Total other income, net 2,688 4,381
Loss before income taxes (39,842) (37,874)
Provision for income taxes (34) (40)
Net loss $ (39,876) $ (37,914)
Net loss per common share - basic $ (0.36) $ (0.35)
Net loss per common share - diluted $ (0.36) $ (0.35)
Weighted average number of common shares outstanding - basic 110,301,256 108,171,463
Weighted average number of common shares outstanding - diluted 110,301,256 108,171,463
Net loss $ (39,876) $ (37,914)
Other comprehensive income (loss):    
Unrealized loss on marketable securities (142) (443)
Comprehensive loss (40,018) (38,357)
Collaboration Revenue [Member]    
Total revenue $ 5,392 $ 6,471
XML 12 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Balance at the beginning at Dec. 31, 2023 $ 253,108 $ 102 $ 624,076 $ 186 $ (371,256)
Balance at the beginning (in Shares) at Dec. 31, 2023   102,202,759      
Issuance of common stock under stock plans 1,259 $ 1 1,258    
Issuance of common stock under stock plans, (in shares)   526,826      
At-the-market offerings, net of issuance costs 41,723 $ 4 41,719    
At-the-market offerings, net of issuance costs (in shares)   4,001,200      
Stock based compensation expense 6,719   6,719    
Other comprehensive loss (443)     (443)  
Net Income (Loss) (37,914)       (37,914)
Balance at the ending at Mar. 31, 2024 264,452 $ 107 673,772 (257) (409,170)
Balance at the ending (in Shares) at Mar. 31, 2024   106,730,785      
Balance at the beginning at Dec. 31, 2024 199,517 $ 108 700,631 336 (501,558)
Balance at the beginning (in Shares) at Dec. 31, 2024   107,729,343      
Issuance of common stock under stock plans 2   2    
Issuance of common stock under stock plans, (in shares)   378,547      
Stock based compensation expense 7,255   7,255    
Other comprehensive loss (142)     (142)  
Net Income (Loss) (39,876)       (39,876)
Balance at the ending at Mar. 31, 2025 $ 166,756 $ 108 $ 707,888 $ 194 $ (541,434)
Balance at the ending (in Shares) at Mar. 31, 2025   108,107,890      
XML 13 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash flows from operating activities    
Net Income (Loss) $ (39,876) $ (37,914)
Adjustments to reconcile net loss to net cash from operating activities:    
Depreciation 622 625
Noncash operating lease expense 1,012 925
Stock-based compensation 7,255 6,719
Accretion on marketable securities (638) (1,371)
Other, net (56) (10)
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 649 360
Other long-term assets 1 35
Accounts payable 1,630 1,042
Accrued expenses and other liabilities (6,124) (1,609)
Operating lease liabilities (780) (188)
Deferred revenue (5,392) (6,471)
Net cash used in operating activities (41,697) (37,857)
Cash flows from investing activities    
Purchase of property and equipment (51) (195)
Sales and maturities of marketable securities 77,812 109,255
Purchases of marketable securities (47,164) (120,263)
Net cash provided by (used in) investing activities 30,597 (11,203)
Cash flows from financing activities    
Proceeds from issuance of common stock and pre-funded warrants   41,723
Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under ESPP 2 1,259
Net cash provided by financing activities 2 42,982
Net change in cash, cash equivalents and restricted cash (11,098) (6,078)
Cash, cash equivalents and restricted cash, beginning of period 72,097 69,808
Cash, cash equivalents and restricted cash, end of period 60,999 63,730
Supplemental cash flow information:    
Cash paid for leases 1,935 1,351
Supplemental disclosure of noncash investing and financing activity:    
Purchases of property and equipment included in accounts payable and accrued expenses 8 71
Operating lease liabilities from obtaining right-of-use assets 1,308  
Revaluation of right-of-use asset and lease liability upon lease remeasurement $ 75 $ 497
XML 14 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Pay vs Performance Disclosure    
Net Income (Loss) $ (39,876) $ (37,914)
XML 15 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
3 Months Ended
Mar. 31, 2025
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Rule 10b5-1 Arrangement Modified false
Non-Rule 10b5-1 Arrangement Modified false
XML 16 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Nature of the Business and Basis of Presentation
3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business and Basis of Presentation
1.
Nature of the Business and Basis of Presentation

Tango Therapeutics, Inc. is a precision oncology company committed to the discovery and development of novel drugs in defined patient populations with high unmet medical need.

Tango Therapeutics, Inc. (together with its consolidated subsidiaries, Tango or the Company), formerly known as BCTG Acquisition Corp. (BCTG), was incorporated in Delaware on May 21, 2020. BCTG was a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements reflect the operations of Tango and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.

In the opinion of management, all adjustments necessary for a fair statement of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three months ended March 31, 2025 and 2024 are not necessarily indicative of the results for the year ending December 31, 2025, any other interim periods, or any future year or period. The unaudited condensed consolidated financial statements for the three months ended March 31, 2025 and 2024 have been prepared on the same basis as and should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on February 27, 2025.

Liquidity and Capital Resources

The Company expects that its existing cash, cash equivalents and marketable securities as of March 31, 2025 of $216.7 million will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of these financial statements with an expected cash runway into the first quarter of 2027.

Since inception, the Company has incurred significant operating losses and expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future. The Company will need to finance its operations through public or private securities offerings, debt financings or other sources, which may include licensing, collaborations or other strategic transactions or arrangements. If the Company is unable to obtain funding, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.

XML 17 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2.
Summary of Significant Accounting Policies

There have been no significant changes from the significant accounting policies disclosed in Note 2, Summary of Significant Accounting Policies, of the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.

Use of Estimates

The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated

financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Recently Adopted Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its consolidated financial statements and disclosures.

Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The standard is intended to enhance the existing income tax disclosures to provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The standard is effective for annual periods beginning after December 15, 2024. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, "Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

XML 18 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements
3 Months Ended
Mar. 31, 2025
Collaboration Agreements [Abstract]  
Collaboration Agreements
3.
Collaboration Agreements

In October 2018, the Company entered into a Research Collaboration and License Agreement (the 2018 Gilead Agreement) with Gilead Sciences, Inc. (Gilead). Pursuant to the terms of the 2018 Gilead Agreement, the Company received an initial upfront payment of $50.0 million. Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to five validated programs (Gilead Program License).

In August 2020, the Company and Gilead entered into an Amended Research Collaboration and License Agreement (the Gilead Agreement), which superseded and replaced the 2018 Gilead Agreement. The Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the 2018 Gilead Agreement. Under the Gilead Agreement:

The Company received upfront, non-refundable consideration of $125.0 million from Gilead upon execution of the Gilead Agreement in 2020;
The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement has a research term of seven years;
Gilead expanded its option to license up to 15 programs for which Gilead may obtain exclusive, worldwide licenses to develop and commercialize therapies, subject to applicable license fees;
Prior to exercising its option to license a program, Gilead may “extend” such program, in which case Gilead will pay research option-extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development;
Gilead has the option to “reserve” a target during which Gilead may: (i) license the target, (ii) “extend” the target, or (iii) decline the target, during the designated reserve target period. If, during the reserve target period Tango elects to work on the reserved target, Tango will retain full rights to the target program and Gilead receives a right of first negotiation in connection with any future partnering or licensing of such target by Tango, if any; and
For up to five programs licensed by Gilead, the Company has the option to co-develop and co-promote the lead product in the U.S., subject to certain exceptions, and is eligible to receive tiered royalties in the first decile on ex-U.S. sales.

The Company is eligible to receive up to $410.0 million per program in license, research option-extension, and clinical, regulatory, and commercial milestones and royalties on future sales of commercialized products, if any.

In August 2020, Gilead also made an equity investment of $20.0 million into the Company as a participant in the Company’s Series B-1 preferred stock offering. At the time of the original investment, as of the March 31, 2025 balance sheet date, and based on current ownership of common stock, Gilead is not considered to be a related party to the Company.

Accounting for the Gilead Collaboration

The Gilead Agreement is accounted for under ASC 606. The Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering committee during the research term. For research option-extension fees, the Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the on-going research plan. Consideration pertaining to each of the research option-extensions is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. The research option-extension consideration are added to the transaction price under the Gilead Agreement. License fees are recognized as revenue immediately as the Company has no continued involvement in the advancement of the program, Gilead can benefit from the license on its own, and the license is separately identifiable from the research services.

Gilead Revenue Recognized

The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $199.0 million at March 31, 2025. The total transaction price was comprised of the $50.0 million upfront payment pursuant to the 2018 Gilead Agreement, the $125.0 million upfront payment pursuant to the Gilead Agreement, and $24.0 million payment pursuant to the research option-extension fee in December 2020 and in September 2021. During the three months ended March 31, 2025 and 2024, the Company recognized $5.4 million and $6.5 million, respectively, of collaboration revenue associated with the Gilead agreements based on performance completed during each period.

The Company reevaluates the transaction price and the total estimated costs expected to be incurred to satisfy the performance obligations at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the Company is responsible for, are resolved or other changes in circumstances occur. As of March 31, 2025 and December 31, 2024, the Company had short-term deferred revenue of $19.5 million and $17.6 million, respectively, and long-term deferred revenue of $37.5 million and $44.8 million, respectively, related to the Gilead collaboration. The remaining long-term deferred revenue is expected to be recognized proportionally to the completed obligations over an expected remaining contractual term of approximately 2.4 years.

Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company’s condensed consolidated balance sheets.

Costs incurred pursuant to the Gilead Agreement and the 2018 Gilead Agreement are recorded as research and development expense.

XML 19 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Fair Value Measurements
4.
Fair Value Measurements

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis:

 

 

Fair Market Value Measurements
as of March 31, 2025

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

(in thousands)

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

14,801

 

 

$

 

 

$

 

 

$

14,801

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

 

 

 

 

147,386

 

 

 

 

 

 

147,386

 

U.S. government agency bonds

 

 

 

 

 

10,906

 

 

 

 

 

 

10,906

 

Total assets

 

$

14,801

 

 

$

158,292

 

 

$

 

 

$

173,093

 

 

 

Fair Market Value Measurements
as of December 31, 2024

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

(in thousands)

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

14,915

 

 

$

 

 

$

 

 

$

14,915

 

U.S. Treasury bills

 

 

 

 

 

10,112

 

 

 

 

 

 

10,112

 

Marketable debt securities

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

 

 

 

 

176,374

 

 

 

 

 

 

176,374

 

U.S. government agency bonds

 

 

 

 

 

12,013

 

 

 

 

 

 

12,013

 

Total assets

 

$

14,915

 

 

$

198,499

 

 

$

 

 

$

213,414

 

 

There were no transfers between fair value levels during the three months ended March 31, 2025.

XML 20 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Marketable Securities
3 Months Ended
Mar. 31, 2025
Marketable Securities [Abstract]  
Marketable Securities
5.
Marketable Securities

The Company values its marketable securities using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources.

The following table summarizes the Company’s marketable debt securities, classified as available-for-sale:

 

Fair Value Measurements
as of March 31, 2025

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gains

 

 

Gross
Unrealized
Loss

 

 

Fair
Value

 

 

(in thousands)

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

$

147,194

 

 

$

218

 

 

$

(26

)

 

$

147,386

 

U.S. government agency bonds

 

 

10,904

 

 

 

3

 

 

 

(1

)

 

 

10,906

 

 

$

158,098

 

 

$

221

 

 

$

(27

)

 

$

158,292

 

 

 

Fair Value Measurements
as of December 31, 2024

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gains

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

 

(in thousands)

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

$

176,049

 

 

$

364

 

 

$

(39

)

 

$

176,374

 

U.S. government agency bonds

 

 

12,002

 

 

 

11

 

 

 

 

 

 

12,013

 

 

$

188,051

 

 

$

375

 

 

$

(39

)

 

$

188,387

 

 

The aggregate fair value of marketable debt securities with a contractual maturity date of greater than one year was $7.2 million as of March 31, 2025.

The following table summarizes the fair value and gross unrealized losses aggregated by category and the length of time that individual securities have been in an unrealized loss position:

 

March 31, 2025

 

 

Less than twelve months

 

 

Greater than twelve months

 

 

Total

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

(in thousands)

 

U.S. Treasury bills

$

53,897

 

 

$

(26

)

 

$

-

 

 

$

-

 

 

$

53,897

 

 

$

(26

)

U.S. government agency bonds

 

2,957

 

 

 

(1

)

 

 

-

 

 

 

-

 

 

 

2,957

 

 

 

(1

)

 

$

56,854

 

 

$

(27

)

 

$

-

 

 

$

-

 

 

$

56,854

 

 

$

(27

)

 

 

December 31, 2024

 

 

Less than twelve months

 

 

Greater than twelve months

 

 

Total

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

(in thousands)

 

U.S. Treasury bills

$

46,016

 

 

$

(39

)

 

$

-

 

 

$

-

 

 

$

46,016

 

 

$

(39

)

 

$

46,016

 

 

$

(39

)

 

$

-

 

 

$

-

 

 

$

46,016

 

 

$

(39

)

The Company holds investment grade marketable securities considered to be in an unrealized loss position. Although these marketable securities are held at an unrealized loss position at March 31, 2025, the Company does not intend to sell the marketable securities prior to the value of the securities being recovered and the Company has concluded that it is more likely than not that the marketable securities cost basis values will be recovered prior to sale of the securities and that there are no conditions or events that might require the Company to sell the securities before recovery of the cost basis occurs. Further, the Company did not record any impairments to marketable securities or reserves for credit losses related to its marketable debt securities during the periods then ended. Marketable securities include $0.9 million and $1.4 million in accrued interest at March 31, 2025 and December 31, 2024, respectively.

XML 21 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Supplemental Balance Sheet Information
3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Balance Sheet Information
6.
Supplemental Balance Sheet Information

Property and Equipment

Property and equipment, net consists of the following:

 

March 31,

 

 

December 31,

 

 

2025

 

 

2024

 

 

(in thousands)

 

Laboratory equipment

 

$

8,936

 

 

$

8,936

 

Computer equipment

 

 

2,437

 

 

 

2,437

 

Computer software

 

 

125

 

 

 

125

 

Furniture and fixtures

 

 

1,945

 

 

 

1,945

 

Leasehold improvements

 

 

2,870

 

 

 

2,870

 

Construction in progress

 

 

211

 

 

 

152

 

 

 

16,524

 

 

 

16,465

 

Less: Accumulated depreciation

 

 

(8,985

)

 

 

(8,363

)

Property and equipment, net

 

$

7,539

 

 

$

8,102

 

 

Depreciation expense was $0.6 million and $0.6 million for the three months ended March 31, 2025 and 2024, respectively.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities include the following:

 

March 31,

 

 

December 31,

 

 

2025

 

 

2024

 

 

(in thousands)

 

Payroll and employee-related costs

 

$

3,180

 

 

$

8,951

 

Research and development costs

 

 

5,216

 

 

 

5,811

 

Other

 

 

1,978

 

 

 

1,735

 

Total accrued expenses and other current liabilities

 

$

10,374

 

 

$

16,497

 

Restricted Cash

As of March 31, 2025 and 2024, the Company maintained a restricted cash balance of $2.6 million and $2.6 million, respectively, all of which was related to a security deposit associated with the Company’s facility lease. The cash will remain restricted in accordance with the lease agreement absent the event of a lease termination or modification. The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the condensed consolidated statements of cash flows are as follows:

 

 

March 31,
2025

 

 

March 31,
2024

 

 

 

(in thousands)

 

Cash and cash equivalents

 

$

58,432

 

 

$

61,163

 

Restricted cash

 

 

2,567

 

 

 

2,567

 

Cash, cash equivalents and restricted cash

 

$

60,999

 

 

$

63,730

 

XML 22 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
7.
Commitments and Contingencies

License Agreements

Sesame Therapeutics, Inc.

In June 2024, the Company and Sesame Therapeutics, Inc. (Sesame) entered into a license agreement pursuant to which the Company granted Sesame a non-exclusive license to certain know-how associated with preclinical research (the Sesame Agreement). Pursuant to the Sesame Agreement, the Company received a $0.1 million upfront, non-refundable payment in June 2024. Under the terms of the Sesame Agreement, the Company is eligible to receive up to $25.9 million in potential future clinical, regulatory, and commercial milestone event payments. The Company is also eligible to receive low single-digit tiered royalties on net sales of any product covered by a licensed patent.

The Company evaluated the Sesame Agreement under ASC 606. The Company identified the following promises under the agreement: (1) the non-exclusive license and (2) the initial know-how transfer, and determined that the promises were immaterial as the upfront license payment at contract inception was an inconsequential payment amount. The initial upfront license payment was recorded as license revenue on the consolidated statements of operations and comprehensive loss during the period ended June 30, 2024.

All potential future milestone payments are considered to be variable consideration and have been excluded from the transaction price. Revenue for all potential clinical and regulatory milestone achievements will be recognized when the related milestones are achieved or when it becomes probable that a significant reversal in the amount of revenue recognized relating to the milestone event will not occur. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Additionally, revenue related to potential sales milestones and royalties from the sales of the licensed products will be recognized when the related sales occur.

Due to common relationships amongst members of management and the boards of directors, the transaction above with Sesame is a related party transaction.

Medivir AB

In March 2020, the Company entered into a license agreement (the Medivir Agreement) with Medivir AB (Medivir), pursuant to which the Company obtained an exclusive license to all patents, know-how and other intellectual property associated with certain USP1 assets. Pursuant to the Medivir Agreement, the Company made an upfront payment of $0.4 million.

Under the terms of the Medivir Agreement, the Company is obligated to pay Medivir in connection with development, regulatory and commercial activities. The Company has agreed to make certain milestone payments of $1.4 million in the aggregate for the first licensed product that achieves specified clinical milestones, plus $25.0 million for the first licensed product that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and $0.7 million in the aggregate if that first licensed product achieves specified clinical milestones, plus $5.0 million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development, regulatory and sales milestones in either of the first two specified genetic contexts. The Company has the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir’s patents or if payments are due to a third party for a license under such third party’s intellectual property rights. The Company is also obligated to pay Medivir a low single-digit royalty on net sales of any product covered by a licensed patent. The Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party.

Upfront fees and subsequent milestone amounts paid pursuant to the Medivir Agreement were recorded to research and development expense.

In May 2024, the Company made the decision to discontinue further development of TNG348, the basis of the USP1 program, due to liver toxicity experienced by patients in the dose escalation portion of the Phase1/2 clinical trial. As a result, the Company does not expect any on-going material obligations under the Medivir Agreement.

Clinical Trial Collaboration and Supply Agreement

In November 2024, the Company and Revolution Medicines, Inc. (RevMed) entered into a Clinical Trial Collaboration and Supply Agreement. The agreement provides that RevMed will supply daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, at no cost to the Company for use in trials that will include TNG462 and each of these RAS(ON) inhibitors. The Company will be the sponsor of any combination trials and bear associated costs. Each company will retain commercial rights to its respective compounds, and the agreement is mutually non-exclusive. Due to common relationships amongst members of management and the boards of directors, this transaction is a related party transaction.

Other Funding Commitments

As of March 31, 2025, the Company had ongoing preclinical and clinical studies. The Company enters into contracts in the normal course of business with contract research organizations in connection with the preparation and operation of clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other preclinical and clinical services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.

Guarantees

The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, construction companies, contract research organizations, clinical trial sites, and other parties. Under these provisions, the Company generally indemnifies, defends and holds harmless the indemnified party for losses suffered or incurred by the indemnified party under the terms of the contract, including as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.

Litigation

The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of March 31, 2025, and no material legal proceedings are currently pending or threatened. Because of uncertainties related to claims, proceedings and litigation, assessments of potential liabilities are based on the Company's best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse effect on the operating results of the Company. Costs associated with involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were to be unable to prevail in any such proceedings, the consolidated financial position, results of operations, and future cash flows of the Company may be materially impacted.

XML 23 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Redeemable Convertible Preferred Stock
3 Months Ended
Mar. 31, 2025
Temporary Equity Disclosure [Abstract]  
Redeemable Convertible Preferred Stock
8.
Preferred Stock

The Company’s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of preferred stock with a par value of $0.001 per share. The number of shares of preferred stock authorized to be issued is 10,000,000 shares as of March 31, 2025 and December 31, 2024. The shares of preferred stock are currently undesignated and no shares are issued or outstanding.

XML 24 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation
9.
Stock-Based Compensation

Stock Incentive Plan

In March 2017, the Company’s stockholders approved the 2017 Stock Option and Grant Plan (the 2017 Plan), under which stock options and restricted stock awards were granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances under the 2017 Plan were subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors at the time of issuance.

Upon effectiveness of the 2021 Stock Option and Incentive Plan (the 2021 Plan) in August 2021, the remaining shares available under the 2017 Plan ceased to be available for issuance and no future issuances will be made under the 2017 Plan. The shares of common stock underlying outstanding awards under the 2017 Plan that are forfeited, cancelled, reacquired by the Company prior to vesting, expire or are otherwise terminated (other than by exercise) will be added to the shares of common stock available for issuance under the 2021 Plan.

In August 2021, the Company's board of directors and stockholders approved the 2021 Plan, under which stock options, restricted stock units (RSUs) and other equity-based awards or any combination of these may be granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances are subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors at the time of issuance. As of March 31, 2025, the Company had 7,471,496 shares available for future issuance under the 2021 Plan.

In February 2023, the Company's board of directors approved the 2023 Inducement Plan (the Inducement Plan), under which the Company reserved shares of common stock, to be used exclusively for grants of non-qualified stock options, restricted stock units and other equity-based awards, or any combination of these to individuals who were not previously employees or directors of the Company. As of March 31, 2025, the Company had 2,041,015 shares available for future issuance under the Inducement Plan.

The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations:

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Research and development

 

$

3,986

 

 

$

3,806

 

General and administrative

 

 

3,269

 

 

 

2,913

 

Total

 

$

7,255

 

 

$

6,719

 

 

Stock Option Activity

The following table summarizes the stock option activity for the three months ended March 31, 2025:

 

Number of
shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Contractual
Term

 

 

Aggregate
Intrinsic
Value

 

 

 

 

 

 

 

 

(in years)

 

 

 

 

Options outstanding as of December 31, 2024

 

 

19,615,023

 

 

$

7.41

 

 

 

7.43

 

 

$

2,157,177

 

Granted

 

 

4,467,208

 

 

$

2.89

 

 

 

 

 

 

 

Exercised

 

 

(1,062

)

 

$

1.65

 

 

 

 

 

 

 

Cancelled

 

 

(269,912

)

 

$

6.35

 

 

 

 

 

 

 

Options outstanding as of March 31, 2025

 

 

23,811,257

 

 

$

6.57

 

 

 

7.61

 

 

$

 

Options exercisable as of March 31, 2025

 

 

12,934,117

 

 

$

6.72

 

 

 

6.58

 

 

$

 

As of March 31, 2025, total unrecognized compensation expense related to stock options was $45.1 million, which the Company expects to recognize over a remaining weighted-average period of 2.7 years.

Restricted Stock Unit Activity

The following table summarizes the RSU activity for the three months ended March 31, 2025:

 

 

Number of
Stock Units

 

 

Weighted Average
Grant Date Fair Value Per Share

 

Unvested and outstanding as of December 31, 2024

 

 

1,209,333

 

 

$

8.92

 

Granted

 

 

732,830

 

 

 

2.89

 

Vested

 

 

(377,485

)

 

 

8.86

 

Forfeited

 

 

(27,523

)

 

 

6.22

 

Unvested and outstanding as of March 31, 2025

 

 

1,537,155

 

 

$

6.11

 

As of March 31, 2025, total unrecognized compensation expense related to RSUs was $8.3 million, which the Company expects to recognize over a remaining weighted-average period of 2.2 years.

2021 Employee Stock Purchase Plan

The 2021 Employee Stock Purchase Plan (the 2021 ESPP) was adopted and approved by the Company’s board of directors and by the Company’s stockholders and became effective in August 2021. No shares of common stock were issued under the 2021 ESPP during the three months ended March 31, 2025.

XML 25 R18.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Net Loss Per Share
10.
Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

 

Three Months Ended March 31,

 

 

(in thousands, except share and per
share data)

 

 

2025

 

 

2024

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(39,876

)

 

$

(37,914

)

Denominator:

 

 

 

 

 

 

Weighted-average common stock outstanding – basic and diluted

 

$

110,301,256

 

 

$

108,171,463

 

Net loss per common share – basic and diluted

 

$

(0.36

)

 

$

(0.35

)

In August 2023, the Company completed a private placement, in which 13,196,671 shares of common stock were sold together with pre-funded warrants to purchase 2,340,579 shares of common stock with an exercise price of $0.0001 per share. The pre-funded warrants were classified as a component of permanent equity in the Company's condensed consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the

shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate basic and diluted net loss per common share because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.

The Company’s potential dilutive securities, which include common stock options and unvested restricted common stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

Stock options to purchase common stock

 

 

23,811,257

 

 

 

20,589,225

 

Unvested restricted common stock

 

 

1,537,155

 

 

 

1,254,456

 

Total

 

 

25,348,412

 

 

 

21,843,681

 

XML 26 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes
3 Months Ended
Mar. 31, 2025
Income Tax Disclosure [Abstract]  
Income Taxes
11.
Income Taxes

The Company’s effective income tax rate was -0.1% and -0.1% for the three months ended March 31, 2025 and 2024, respectively. The income tax provision was less than $0.1 million for both the three months ended March 31, 2025 and 2024, respectively. Consistent with the prior year, for 2025 the Company assessed the requirement to capitalize and amortize research and experimentation expenditures for US tax purposes, which remains effective as of March 31, 2025. The Company is forecasting a taxable loss position in 2025 for which no tax benefit is recorded due to the valuation allowance maintained against the Company’s deferred tax assets.

The effective income tax rate for the three months ended March 31, 2025 and 2024 differed from the 21.0% federal statutory rate primarily due to the valuation allowance maintained against the Company’s deferred tax assets.

XML 27 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Information
12.
Segment Information

The Company operates in the U.S. and has one operating segment that is managed on a consolidated basis. The Company’s revenues are primarily generated through its license and collaboration agreement with Gilead. The accounting policies, as described in the summary of significant accounting policies, is applicable across all Company operations. The Company’s chief executive officer (CEO), as the chief operating decision maker (CODM), manages and allocates resources to the operations of our company on a consolidated basis. Managing and allocating resources on a total company basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across departments and research and development programs that are in-line with our long-term company-wide strategic goals. Consistent with this decision-making process, the Company’s CODM uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results and allocating resources.

The CODM assesses performance and decides how to allocate resources based on segment net income (loss). This measure is used to monitor budget versus actual results to assess performance of the segment.

The following table presents the Company’s segment expense for the three months ended March 31, 2025 and 2024:

 

Oncology Segment

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Revenue

 

$

5,392

 

 

$

6,471

 

Less R&D expenses:

 

 

 

 

 

 

       TNG462 direct program expenses

 

 

5,461

 

 

 

5,086

 

       TNG456 direct program expenses

 

 

1,324

 

 

 

-

 

       TNG260 direct program expenses

 

 

1,730

 

 

 

2,236

 

       TNG961 direct program expenses

 

 

2,221

 

 

 

-

 

       TNG908 direct program expenses*

 

 

1,712

 

 

 

4,258

 

       TNG348 direct program expenses**

 

 

-

 

 

 

3,300

 

       Discovery direct program expenses

 

 

4,679

 

 

 

5,511

 

       Personnel-related expenses

 

 

13,850

 

 

 

12,798

 

       Facilities and other related expenses

 

 

5,465

 

 

 

4,876

 

Less G&A and other expenses:

 

 

 

 

 

 

       Other segment expenses (a)

 

 

8,826

 

 

 

6,320

 

Segment net loss

 

$

(39,876

)

 

$

(37,914

)

*In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.

**In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.

(a) Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.

The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. The CODM reviews cash, cash equivalents and marketable securities as a measure of segment assets. As of March 31, 2025, the Company’s cash, cash equivalents and marketable securities were $216.7 million. All long-lived assets of the Company reside in the U.S.

XML 28 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated

financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Recently Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its consolidated financial statements and disclosures.

Recently Issued Accounting Pronouncements

In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The standard is intended to enhance the existing income tax disclosures to provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The standard is effective for annual periods beginning after December 15, 2024. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, "Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses." The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.

XML 29 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Summary of Financial Assets Measured at Fair Value on a Recurring Basis

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis:

 

 

Fair Market Value Measurements
as of March 31, 2025

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

(in thousands)

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

14,801

 

 

$

 

 

$

 

 

$

14,801

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

 

 

 

 

147,386

 

 

 

 

 

 

147,386

 

U.S. government agency bonds

 

 

 

 

 

10,906

 

 

 

 

 

 

10,906

 

Total assets

 

$

14,801

 

 

$

158,292

 

 

$

 

 

$

173,093

 

 

 

Fair Market Value Measurements
as of December 31, 2024

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

(in thousands)

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

14,915

 

 

$

 

 

$

 

 

$

14,915

 

U.S. Treasury bills

 

 

 

 

 

10,112

 

 

 

 

 

 

10,112

 

Marketable debt securities

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

 

 

 

 

176,374

 

 

 

 

 

 

176,374

 

U.S. government agency bonds

 

 

 

 

 

12,013

 

 

 

 

 

 

12,013

 

Total assets

 

$

14,915

 

 

$

198,499

 

 

$

 

 

$

213,414

 

XML 30 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2025
Marketable Securities [Abstract]  
Summary of Debt Securities, Available-for-sale

The following table summarizes the Company’s marketable debt securities, classified as available-for-sale:

 

Fair Value Measurements
as of March 31, 2025

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gains

 

 

Gross
Unrealized
Loss

 

 

Fair
Value

 

 

(in thousands)

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

$

147,194

 

 

$

218

 

 

$

(26

)

 

$

147,386

 

U.S. government agency bonds

 

 

10,904

 

 

 

3

 

 

 

(1

)

 

 

10,906

 

 

$

158,098

 

 

$

221

 

 

$

(27

)

 

$

158,292

 

 

 

Fair Value Measurements
as of December 31, 2024

 

 

Amortized
Cost

 

 

Gross
Unrealized
Gains

 

 

Gross
Unrealized
Loss

 

 

Fair Value

 

 

(in thousands)

 

Marketable debt securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury bills

 

$

176,049

 

 

$

364

 

 

$

(39

)

 

$

176,374

 

U.S. government agency bonds

 

 

12,002

 

 

 

11

 

 

 

 

 

 

12,013

 

 

$

188,051

 

 

$

375

 

 

$

(39

)

 

$

188,387

 

 

Summary of Fair value and Gross Unrealized Losses on Securities

The following table summarizes the fair value and gross unrealized losses aggregated by category and the length of time that individual securities have been in an unrealized loss position:

 

March 31, 2025

 

 

Less than twelve months

 

 

Greater than twelve months

 

 

Total

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

(in thousands)

 

U.S. Treasury bills

$

53,897

 

 

$

(26

)

 

$

-

 

 

$

-

 

 

$

53,897

 

 

$

(26

)

U.S. government agency bonds

 

2,957

 

 

 

(1

)

 

 

-

 

 

 

-

 

 

 

2,957

 

 

 

(1

)

 

$

56,854

 

 

$

(27

)

 

$

-

 

 

$

-

 

 

$

56,854

 

 

$

(27

)

 

 

December 31, 2024

 

 

Less than twelve months

 

 

Greater than twelve months

 

 

Total

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

Fair value

 

 

Unrealized loss

 

 

(in thousands)

 

U.S. Treasury bills

$

46,016

 

 

$

(39

)

 

$

-

 

 

$

-

 

 

$

46,016

 

 

$

(39

)

 

$

46,016

 

 

$

(39

)

 

$

-

 

 

$

-

 

 

$

46,016

 

 

$

(39

)

XML 31 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Supplemental Balance Sheet Information (Tables)
3 Months Ended
Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Property, Plant and Equipment

Property and equipment, net consists of the following:

 

March 31,

 

 

December 31,

 

 

2025

 

 

2024

 

 

(in thousands)

 

Laboratory equipment

 

$

8,936

 

 

$

8,936

 

Computer equipment

 

 

2,437

 

 

 

2,437

 

Computer software

 

 

125

 

 

 

125

 

Furniture and fixtures

 

 

1,945

 

 

 

1,945

 

Leasehold improvements

 

 

2,870

 

 

 

2,870

 

Construction in progress

 

 

211

 

 

 

152

 

 

 

16,524

 

 

 

16,465

 

Less: Accumulated depreciation

 

 

(8,985

)

 

 

(8,363

)

Property and equipment, net

 

$

7,539

 

 

$

8,102

 

 

Schedule of Accrued Expenses and Other Current Liabilities Current

Accrued expenses and other current liabilities include the following:

 

March 31,

 

 

December 31,

 

 

2025

 

 

2024

 

 

(in thousands)

 

Payroll and employee-related costs

 

$

3,180

 

 

$

8,951

 

Research and development costs

 

 

5,216

 

 

 

5,811

 

Other

 

 

1,978

 

 

 

1,735

 

Total accrued expenses and other current liabilities

 

$

10,374

 

 

$

16,497

 

Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the condensed consolidated statements of cash flows are as follows:

 

 

March 31,
2025

 

 

March 31,
2024

 

 

 

(in thousands)

 

Cash and cash equivalents

 

$

58,432

 

 

$

61,163

 

Restricted cash

 

 

2,567

 

 

 

2,567

 

Cash, cash equivalents and restricted cash

 

$

60,999

 

 

$

63,730

 

XML 32 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Schedule of Stock-based Compensation Expense

The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations:

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Research and development

 

$

3,986

 

 

$

3,806

 

General and administrative

 

 

3,269

 

 

 

2,913

 

Total

 

$

7,255

 

 

$

6,719

 

 

Schedule of Stock Option Activity

The following table summarizes the stock option activity for the three months ended March 31, 2025:

 

Number of
shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Contractual
Term

 

 

Aggregate
Intrinsic
Value

 

 

 

 

 

 

 

 

(in years)

 

 

 

 

Options outstanding as of December 31, 2024

 

 

19,615,023

 

 

$

7.41

 

 

 

7.43

 

 

$

2,157,177

 

Granted

 

 

4,467,208

 

 

$

2.89

 

 

 

 

 

 

 

Exercised

 

 

(1,062

)

 

$

1.65

 

 

 

 

 

 

 

Cancelled

 

 

(269,912

)

 

$

6.35

 

 

 

 

 

 

 

Options outstanding as of March 31, 2025

 

 

23,811,257

 

 

$

6.57

 

 

 

7.61

 

 

$

 

Options exercisable as of March 31, 2025

 

 

12,934,117

 

 

$

6.72

 

 

 

6.58

 

 

$

 

Summary of Restricted Stock Unit Activity

The following table summarizes the RSU activity for the three months ended March 31, 2025:

 

 

Number of
Stock Units

 

 

Weighted Average
Grant Date Fair Value Per Share

 

Unvested and outstanding as of December 31, 2024

 

 

1,209,333

 

 

$

8.92

 

Granted

 

 

732,830

 

 

 

2.89

 

Vested

 

 

(377,485

)

 

 

8.86

 

Forfeited

 

 

(27,523

)

 

 

6.22

 

Unvested and outstanding as of March 31, 2025

 

 

1,537,155

 

 

$

6.11

 

XML 33 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

 

Three Months Ended March 31,

 

 

(in thousands, except share and per
share data)

 

 

2025

 

 

2024

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(39,876

)

 

$

(37,914

)

Denominator:

 

 

 

 

 

 

Weighted-average common stock outstanding – basic and diluted

 

$

110,301,256

 

 

$

108,171,463

 

Net loss per common share – basic and diluted

 

$

(0.36

)

 

$

(0.35

)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

 

Three Months Ended March 31,

 

 

2025

 

 

2024

 

Stock options to purchase common stock

 

 

23,811,257

 

 

 

20,589,225

 

Unvested restricted common stock

 

 

1,537,155

 

 

 

1,254,456

 

Total

 

 

25,348,412

 

 

 

21,843,681

 

XML 34 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Expense

The following table presents the Company’s segment expense for the three months ended March 31, 2025 and 2024:

 

Oncology Segment

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Revenue

 

$

5,392

 

 

$

6,471

 

Less R&D expenses:

 

 

 

 

 

 

       TNG462 direct program expenses

 

 

5,461

 

 

 

5,086

 

       TNG456 direct program expenses

 

 

1,324

 

 

 

-

 

       TNG260 direct program expenses

 

 

1,730

 

 

 

2,236

 

       TNG961 direct program expenses

 

 

2,221

 

 

 

-

 

       TNG908 direct program expenses*

 

 

1,712

 

 

 

4,258

 

       TNG348 direct program expenses**

 

 

-

 

 

 

3,300

 

       Discovery direct program expenses

 

 

4,679

 

 

 

5,511

 

       Personnel-related expenses

 

 

13,850

 

 

 

12,798

 

       Facilities and other related expenses

 

 

5,465

 

 

 

4,876

 

Less G&A and other expenses:

 

 

 

 

 

 

       Other segment expenses (a)

 

 

8,826

 

 

 

6,320

 

Segment net loss

 

$

(39,876

)

 

$

(37,914

)

*In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.

**In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.

(a) Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.

XML 35 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Nature of the Business and Basis of Presentation - Additional Information (Details)
$ in Millions
Mar. 31, 2025
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash cash equivalents and marketable securities $ 216.7
XML 36 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2020
USD ($)
Program
Oct. 31, 2018
Program
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2024
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
2018 Gilead Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Number of licensed product | Program   5            
Non-refundable upfront payment received     $ 50,000,000   $ 50,000,000      
Amended Gilead Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Research term 7 years              
Number of licensed product | Program 15              
Non-refundable upfront payment received     125,000,000          
Milestone payments receivable $ 410,000,000              
Temporary equity, par value 125,000,000              
Research extension fee             $ 24,000,000 $ 24,000,000
Amended Gilead Agreement [Member] | Series B-1 Preferred Stock [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Temporary equity, par value $ 20,000,000              
Gilead Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Transaction price allocated to performance obligation     199,000,000          
Short-term deferred revenue     19,500,000     $ 17,600,000    
Long-term deferred revenue     37,500,000     $ 44,800,000    
Collaboration Revenue [Member] | Gilead Agreement [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with customer liability, revenue recognized     $ 5,400,000 $ 6,500,000        
XML 37 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Collaboration Agreements - Additional Information (Details1)
Mar. 31, 2025
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-04-01  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Revenue remaining performance obligations expected remaining contractual term 2 years 4 months 24 days
XML 38 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Investment, Type [Extensible Enumeration] Marketable Debt Securities [Member] Marketable Debt Securities [Member]
Fair Value Measurements Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, Money market funds $ 14,801 $ 14,915
Cash equivalents, U.S. Treasury bills   10,112
Total assets 173,093 213,414
Fair Value Measurements Recurring [Member] | U.S. Treasury Bills [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 147,386 176,374
Fair Value Measurements Recurring [Member] | U.S. Government Agency Bonds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 10,906 12,013
Level 1 [Member] | Fair Value Measurements Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, Money market funds 14,801 14,915
Total assets 14,801 14,915
Level 2 [Member] | Fair Value Measurements Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents, U.S. Treasury bills   10,112
Total assets 158,292 198,499
Level 2 [Member] | Fair Value Measurements Recurring [Member] | U.S. Treasury Bills [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities 147,386 176,374
Level 2 [Member] | Fair Value Measurements Recurring [Member] | U.S. Government Agency Bonds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable debt securities $ 10,906 $ 12,013
XML 39 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements - Additional Information (Details)
$ in Thousands
Mar. 31, 2025
USD ($)
Fair Value Disclosures [Abstract]  
Fair value assets transfer from Level 1 to Level 2 $ 0
Fair value assets transfer from Level 2 to Level 1 0
Fair value liabilities transfer from Level 1 to Level 2 0
Fair value liabilities transfer from Level 2 to Level 1 $ 0
XML 40 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Marketable Securities - Summary of Debt Securities, Available For Sale (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost $ 158,098 $ 188,051
Gross Unrealized Gains 221 375
Gross Unrealized Loss (27) (39)
Fair Value 158,292 188,387
U.S. Treasury Bills [Member]    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 147,194 176,049
Gross Unrealized Gains 218 364
Gross Unrealized Loss (26) (39)
Fair Value 147,386 176,374
U.S. Government Agency Bonds [Member]    
Debt Securities, Available-for-Sale [Line Items]    
Amortized Cost 10,904 12,002
Gross Unrealized Gains 3 11
Gross Unrealized Loss (1) 0
Fair Value $ 10,906 $ 12,013
XML 41 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Marketable Securities - Summary of Fair Value and Gross Unrealized Losses on Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Debt Securities, Available-for-Sale [Line Items]    
Securities Less than twelve months, Fair value $ 56,854 $ 46,016
Securities Less than twelve months, Unrealized loss (27) (39)
Securities, Total Fair value 56,854 46,016
Securities, Total Unrealized loss (27) (39)
U.S. Treasury Bills [Member]    
Debt Securities, Available-for-Sale [Line Items]    
Securities Less than twelve months, Fair value 53,897 46,016
Securities Less than twelve months, Unrealized loss (26) (39)
Securities, Total Fair value 53,897 46,016
Securities, Total Unrealized loss (26) $ (39)
U.S. Government Agency Bonds [Member]    
Debt Securities, Available-for-Sale [Line Items]    
Securities Less than twelve months, Fair value 2,957  
Securities Less than twelve months, Unrealized loss (1)  
Securities, Total Fair value 2,957  
Securities, Total Unrealized loss $ (1)  
XML 42 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Marketable Securities - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Debt Securities, Available-for-Sale [Line Items]    
Marketable securities, Accrued interest $ 900,000 $ 1,400,000
Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration] Marketable Securities, Current Marketable Securities, Current
Fair Value $ 158,292,000 $ 188,387,000
Marketable Debt Securities [Member]    
Debt Securities, Available-for-Sale [Line Items]    
Impairments to marketable securities or reserves for credit losses 0 $ 0
Fair Value $ 7,200,000  
XML 43 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 16,524 $ 16,465
Less: Accumulated depreciation (8,985) (8,363)
Property and equipment, net 7,539 8,102
Laboratory Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 8,936 8,936
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 2,437 2,437
Computer Software [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 125 125
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 1,945 1,945
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross 2,870 2,870
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Gross $ 211 $ 152
XML 44 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Supplemental Balance Sheet Information - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Depreciation expense $ 622 $ 625
Security Deposits [Member]    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Restricted cash $ 2,600 $ 2,600
XML 45 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Payables and Accruals [Abstract]    
Payroll and employee-related costs $ 3,180 $ 8,951
Research and development costs 5,216 5,811
Other current liabilities 1,978 1,735
Total accrued expenses and other current liabilities $ 10,374 $ 16,497
XML 46 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Supplemental Balance Sheet Information - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Mar. 31, 2024
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]      
Cash and cash equivalents $ 58,432 $ 69,530 $ 61,163
Restricted cash 2,567   2,567
Cash, cash equivalents and restricted cash $ 60,999   $ 63,730
XML 47 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Mar. 31, 2020
Sesame Agreement [Member]    
Commitments and Contingencies (Details) [Line Items]    
Non-refundable upfront payment received $ 0.1  
Milestone payments receivable $ 25.9  
Medivir Agreement [Member]    
Commitments and Contingencies (Details) [Line Items]    
Upfront payment   $ 0.4
Milestone payments   1.4
Medivir Agreement [Member] | Specified Regulatory Approval And Sales Milestones [Member]    
Commitments and Contingencies (Details) [Line Items]    
Contractual obligation   25.0
Medivir Agreement [Member] | Specified Clinical Milestones [Member]    
Commitments and Contingencies (Details) [Line Items]    
Contractual obligation   0.7
Medivir Agreement [Member] | Specified Regulatory And Sales Milestones For Genetic Context [Member]    
Commitments and Contingencies (Details) [Line Items]    
Contractual obligation   $ 5.0
XML 48 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Redeemable Convertible Preferred Stock - Additional Information (Details) - $ / shares
Mar. 31, 2025
Dec. 31, 2024
Stockholders' Equity Note [Abstract]    
Redeemable convertible preferred stock shares authorized 10,000,000 10,000,000
Redeemable convertible preferred stock Par or Stated Value Per Share $ 0.001 $ 0.001
Redeemable convertible preferred stock, issued 0 0
Redeemable convertible preferred stock, outstanding 0 0
XML 49 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation - Additional Information (Details)
$ in Millions
3 Months Ended
Mar. 31, 2025
USD ($)
shares
Stock Options [Member]  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Unrecognized stock-based compensation expense | $ $ 45.1
Weighted-average amortization period 2 years 8 months 12 days
2021 Plan [Member]  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of shares reserved for issuance 7,471,496
2023 Inducement Plan [Member]  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of shares reserved for issuance 2,041,015
2021 Employee Stock Purchase Plan [Member]  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Common stock, shares issued 0
RSU [Member]  
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Unrecognized stock-based compensation expense | $ $ 8.3
Weighted-average amortization period 2 years 2 months 12 days
XML 50 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense $ 7,255 $ 6,719
Research and Development [Member]    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense 3,986 3,806
General and Administrative [Member]    
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]    
Stock-based compensation expense $ 3,269 $ 2,913
XML 51 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Number of shares, Options outstanding Beginning balance 19,615,023  
Number of shares Granted 4,467,208  
Number of shares Exercised (1,062)  
Number of shares Cancelled (269,912)  
Number of shares, Options outstanding Ending balance 23,811,257 19,615,023
Number of shares Options exercisable 12,934,117  
Weighted Average Exercise Price, Options outstanding Beginning balance $ 7.41  
Weighted Average Exercise Price Granted 2.89  
Weighted Average Exercise Price Exercised 1.65  
Weighted Average Exercise Price Cancelled 6.35  
Weighted Average Exercise Price, Options outstanding Ending balance 6.57 $ 7.41
Weighted Average Exercise Price Options exercisable $ 6.72  
Weighted Average Contractual Term, Options outstanding 7 years 7 months 9 days 7 years 5 months 4 days
Weighted Average Contractual Term Options exercisable 6 years 6 months 29 days  
Aggregate Intrinsic Value, Options outstanding $ 0 $ 2,157,177
Aggregate Intrinsic Value Options exercisable $ 0  
XML 52 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) - RSU [Member]
3 Months Ended
Mar. 31, 2025
$ / shares
shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]  
Number of Stock Units, Unvested and outstanding Beginning balance | shares 1,209,333
Number of Stock Units, Granted | shares 732,830
Number of Stock Units, Vested | shares (377,485)
Number of Stock Units, Forfeited | shares (27,523)
Number of Stock Units, Unvested and outstanding Ending balance | shares 1,537,155
Weighted Average Grant Date Fair Value Per Share, Unvested and outstanding Beginning balance | $ / shares $ 8.92
Weighted Average Grant Date Fair Value Per Share, Granted | $ / shares 2.89
Weighted Average Grant Date Fair Value Per Share, Vested | $ / shares 8.86
Weighted Average Grant Date Fair Value Per Share, Forfeited | $ / shares 6.22
Weighted Average Grant Date Fair Value Per Share, Unvested and outstanding Ending balance | $ / shares $ 6.11
XML 53 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Numerator:    
Net loss $ (39,876) $ (37,914)
Denominator:    
Weighted-average common stock outstanding - basic 110,301,256 108,171,463
Weighted-average common stock outstanding - diluted 110,301,256 108,171,463
Net loss per common share - basic $ (0.36) $ (0.35)
Net loss per common share - diluted $ (0.36) $ (0.35)
XML 54 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share - Additional Information (Details)
Aug. 11, 2023
$ / shares
shares
Private Placement [Member]  
Class of Warrant or Right [Line Items]  
Number of shares sold 13,196,671
Pre-funded Warrants [Member]  
Class of Warrant or Right [Line Items]  
Warrants to purchase shares of common stock 2,340,579
Exercise price | $ / shares $ 0.0001
XML 55 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 25,348,412 21,843,681
Stock options to purchase common stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 23,811,257 20,589,225
Unvested restricted common stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,537,155 1,254,456
XML 56 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes - Additional Information (Details) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Provision for income taxes $ 34,000 $ 40,000
Effective income tax rate (0.10%) (0.10%)
Federal statutory rate 21.00% 21.00%
Maximum [Member]    
Provision for income taxes $ 100,000 $ 100,000
Forecasting Taxable Loss Position Deferred Tax Assets [Member]    
Provision for income taxes $ 0  
XML 57 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Additional Information (Details)
$ in Millions
3 Months Ended
Mar. 31, 2025
USD ($)
Segment
Segment Reporting [Abstract]  
Number of operating segments | Segment 1
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] srt:ChiefExecutiveOfficerMember
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description Consistent with this decision-making process, the Company’s CODM uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results and allocating resources.
Cash, cash equivalents and marketable securities | $ $ 216.7
XML 58 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Schedule of Segment Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenues $ 5,392 $ 6,471
Research and development 36,442 38,065
Other segment expenses [1] 8,826 6,320
Net loss (39,876) (37,914)
TNG462 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 5,461 5,086
TNG456 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 1,324 0
TNG260 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 1,730 2,236
TNG961 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 2,221 0
TNG908 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development [2] 1,712 4,258
TNG348 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development [3] 0 3,300
Discovery direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 4,679 5,511
Personnel-related expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 13,850 12,798
Facilities and Other Related Expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development $ 5,465 $ 4,876
[1] Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.
[2] In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.
[3] In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $TYK%I&QTU(E0 ,T 0 9&]C4')O<',O87!P+GAM M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ) M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$, M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2B4^BQ-+.9<"YX)>KF8W*]\CL+.V_LUOXSX[L+XY.@;.'77&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^ M[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZ MFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, * MI4Q>M5II ,,X? M+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N M,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8 MSG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CV MVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI M)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN M.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K( M@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\ M+ GQ^R-;88C'(C MN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6 MH8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V M5;SCFED)O816:I^JAS0^J!XR"@7QN1X^ MY7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N! MLT$DN/R+RO JQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T M/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUV MY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1 MT?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q M+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW M&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07 MIDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_IN MDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZS MAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT M>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$, M>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X* M/-S^[PVPPL2.X>V+OP%02P,$% @ 33FL6@F,.47Y!0 TA\ !@ !X M;"]W;W)KBE*R5XD ?%48\Y MSGDOYF'2&5WFUQ[5Z%)F.@H3\:A(FL4Q5V_7(I*;JP[M;"\\A8NE-A=ZH\L5 M7XBIT%]6CPK.>I5*$,8B24.9$"7F5YTQ?>>YK@G(G_@]%)MTYY@8E&1?I);CZ($JAO]'P9I?E?LBF>/3OK$#]+M8S+8&A!'";%?_Y: MOHC= -H0P,H ]DT =1L"W#(@?W.]HF4YU@W7?'2IY(8H\S2HF8/\W>310!,F MIANG6L'=$.+TZ$;Z&?2*)N,D(+>)#O4;F23%\#"ON4O2)5QI^#43T_-+ MY>M"F34HN^1>)GJ9@FH@@J_C>]#*JJELV]1KA@K>7(M%/EG_)QJ!6/Q7]L+*A3.[ KF WV7KK@OKCKP M!:9"K45G]-,/]-SYU4;WG<2^@CVK8,\P]5$Y,)[$(C2X,%P>>"QLR+C.;/SP M_A.9?;A]&C_>?IE-O.D)F3QXIS9>5*DE;[_B[>/M5#P(DP69OL7/,K)Q[HE_ M>/^GC0F-:LET7C&=HVVJOO39V\K:=7@X=;J?;4AH5$NDBPKI FV3EREEB.[" MU.<1^4MP9;(-@4QH)<35NEW*NBZU0:*!+2$'%>0 ;=88.BW(.^XNX@L;%AX_ MYU%J>QL>&M82:EA!#0])*!Y@*>BY"4P1K^0W\6;#PY4>6YV#*,MA^B164ND\KVBN,_N>.AZ"'<-Z%$4R)'GQ\ M"ZFL7;E'YR-7"T'&O@\N3X%,4$A:B5&EML2L)F:')=-'H4(9H%EGCU1E:QI] M#2[0EK4V.A2U%C7K;IJ]@XOV 8R+-3(>P][0VM]0W)A\RUAV:S,E+O?9.HO@ M06T9:T]#<5-2?J73F$<1N,*RU4]%;.G%9&7$NKS(YX#/-#:_=#<=-2>W%83*5AOM)&&'&QYGX\AOMA MM?MA![F?2>)+!6CY?L));GT$D> 39 ;F#]R1#*S3YA[UFUOK%L QC!"KC1 [ MV B1ARQ^MGJ7ZSTB8&B[[O!L8-_C.(;O8;7O8;A9*0%G_)5, AC X3STBXTB M!!>7'/2[E [[CGMNY3V&]V&U]V&X72EYQT$ ZNG)]H!\A.?(I\0^3#]6Q M$KP9#!<8]"^L6,=P2*QV2 PW-1]EO@Q;R@2=27$1ESG=LZ'C6/F.88[;]OE:Q0Z^=JIH:]'E%G '::#B$-K'SM54[-GD!>34^*; M=4E10*VN5@7K<5ZF[=6/%]7N>VZV'%(2B3F$.J<7\/NJ*" 7)UJN\AKLL]1: MQOGA4O! */, W)]+J;J,O[H?U!+ P04 " !-.:Q:D3BL= L& #& M&0 & 'AL+W=OGYXY' M/G?T^IZ+.[FC5(&'(B_E^6*GU/YLM9+ICA9$GO(]+?4W6RX*HO14W*[D7E"2 MU4I%OL(0AJN"L'*Q6=?/KL1FS2N5LY)>"2"KHB#B\2/-^?WY BV>'GQBMSME M'JPVZSVYI==4?=E?"3U;=58R5M!2,EX"0;?GBP_H[,*#1J&6^)O1>SD8 ^/* M#>=W9O)[=KZ !A'-::J,":(_#O2"YKFQI'%\;8TNNG<:Q>'XR?JOM?/:F1LB MZ07/_V&9VITOX@7(Z)94N?K$[W^CK4.!L9?R7-;_P7TK"Q<@K:3B1:NL$12L M;#[)0QN(@0+R9Q1PJX!?JN"U"E[M:(.L=NN2*+)9"WX/A)'6ULR@CDVMK;UA MI5G&:R7TMTSKJB1YSC*B].0CR4F94G!M#$MP KY<7X*W;]Z! M-X"5X/..5Y*4F5ROE,9@+*W2]GT?F_?AF??]0<0I\- 28(@#B_J%6_V2IIVZ M?ZR^TIYW[N/.?5S;\^;+_0VDE0< MZ&+S\T\HA.]MWOT@8T>^>IVOGLOZYH+('="K!E(SH%\K=B"Y=MZZBHVIL#9E MCH+#)HA]#Z]7AZ$[4ZDP"3S821WA]#N"[@G+ 'W8FWTMZQ7G:D>%/DZ&R6Y#'$[01%$TACP5BGTK( MB?HS5R1_ KYG!QEW(.-G0JO94ZC'.J1F_^PUGZDE M**FR88VGP0R\9(1T*A0CB.TXDPYGXL3YET9)%"MO04XUPS4'B#!\=L*W)]73 MD_DH)Q-07A(FT0BZ3P+==T.\L!"T^C$?D>#,?8 MIG(>"OUD)E=1STK(>Q$%YXSY#FO)* M4R_8DT?#=%:'I\3EX6DV6^@MA&AF57IV0VYZTP!%19TT,E@P*_PIM2'H1?X8 MOT5,I]7<=NQI$+EY<'0(/HMVRFHXQA.P%BD_F-NC/?DA-_M=TBW5,A[$;AX<)\5KH.,IQ7E1@,9\8Q'S M-8//4#CNJ1"[J;!)EF>2!%OX$$9!,,YHFQS2U4@P@W+0^KF9\8(7!5.FA&M. MMY27)FEHF6K$X.V?7%$0O[-"_X8V#EC;P>\W=.Q\S[K8W0SJ-J%-+ZEX>K<$ M;^ IA$CSD0"Z+:SH>X#@$L+Z#\@=$88#*K7C@OU+L_>@Y$]/F92&*6J"J)14 M>F#V'I$F674SE^ZZAK\6TCT\+6XTD3SU\4N=XG)/ZPN=_-$:\&]@:WO O]_0 M<^L\RY-F'>\3RC0OY2=P_JT7[?X*P<7GWA\(.L'7O=EQ'874:8/<;+ M^1S#T)%D@*AOR!^3N/%2'R7+.(&U@AE'.%GJ!O#_S%E;_3/NI9\1.HYZ7_M@ M=^WS(%$'87 M0KKJK(HJKZ\@VV*3%SHQ=^;>^$ !*_7<6AYA:WDTQCT5\KPYMNM+(^PNC8:@ M,[IE*;->!^!IM7,2^,CW)BAM@A %P5Q>](41=A=]+RTED!3PM;% 81L&X M,[3))4F 9DIXKZ^ /'<%-"DCZJWX4OBM\>'EI+6QM%$/=Y1HV$9 ?[_ENL)H)^8JO_OI M9O,?4$L#!!0 ( $TYK%K4I&PO=V]R:W-H965T M&ULG99=;YLP%(;_BH5VL4E=^$Q(*H+4IIO6BVE1LW77+IP$ MJ\:FMFG:_?K9AJ+0TB1-+H)MWO?X.>: G6RYN)<%@$)/)65R[A1*5>>N*[," M2BQ'O *F[ZRY*+'27;%Q924 Y]944C?PO(E;8L*<-+%C2Y$FO%:4,%@*).NR MQ.+Y$BC?SAW?>1FX(9M"F0$W32J\@16H/]52Z)[;1 0(*F3(1L+X\P@(H-8$TQD,;T^FF-,;= M]DOT[S9WGT^8Q-O(Q3:?_1MM%.8@=E MM52\;,V:H"2LN>*G=AUV#'[TCB%H#<&QAK UA#;1ALRF=8453A/!MT@8M8YF M&G9MK%MG0YAYBBLE]%VB?2I=<);K9P(YTBW)*0=?:H;W=U]MT2!-T2!#9>]$Z\WU!67.@21M\>:J*>SY#.%G&!5LJNQ2VF M-: EZ &3\%"^S02QG<"\-X^I-_(\/W$?=],ZI.K1AQU]^$%Z2RG11:T*+L@_ MR(>(FZ#C'1;?:WZOH(\0]KBCCCLZC?M:RGJ8.7J#\AIVGZ)'.>XHQZ=1_JJ5 M5)CEA&V&4,<'4?JB3#G6R%W7!RU)_%U>*9_]33CGKZ8>JS/=4['7B1IKX73V>OD8>4<1S,PB@<1IYU MR+,3D ^4\NQH[B'E,+>[LV&9PX+>$3:$241AK;W>*-9!1+,!-QW%*[N'W7&E M=T3;+/29!801Z/MKSM5+QVR+W2DH_0]02P,$% @ 33FL6I' "K@:!0 MX10 !@ !X;"]W;W)KK)1:7WF>G*]80>4E7[,2_EEP45 %2['TY%HP MFAJE(O>([T=>0;-R,!F;9_=B,N8;E6'WPD"U7 M2C_P)N,U7;)'II[6]P)67F,ES0I6RHR72+#%]> &7TW)4"L8B3\RMI-[]TB[ M,N/\62\^I]<#7R-B.9LK;8+"92;M(,5,_1!7IZ_(3./IRC#R@KT9<5WTA0DV-/ 6#] M6F]>@[NMP)$>< &ZXZ5:2?0C@$P/]3UPM/&6O'I[2YP&[ZBX1 '^B(A/AA8\ MT]/50P>?L>@#U(IG8LL'D M^^]PY/]@B_T[&3OP=]CX.W1FX@$L4C%?F?I.(2$Y7^ORMSE=61KNQ3N(PO X M*Q:IQ(^&]K1$#H<(69X.8 M=%Y^$9)A=A)-T$41)X+XHM>6$W>[V"0[#7(@AA M ?&4*PH%<*%'\6QN15W93/;1^)=!![1=K&?KQ2V/83>1N3"G6;Y1QW-IC3H^ M#;5=K ]U2VO8S6M?S=<+S/%T"[2V9*C<%#-P &;Y?1]@N-\HJ6":T!SM2D*7 MV3#V Q^38< L\TZ'/K4$*<1/I?IY+WLG88@I94B9M4 MGTK!:)[] Z5G-@.HM(**9Z;H+&=(LOE&9"JSLP'I\N<%[E"732H,^PJK95GB M9MG#3_7>$K/P9NC[^'@4L,D%23#L&:M(RZ_$S:]3GN=TQJL)'#U4'\3HSSNF MV_LO*^1W_?1\+VN'[K>L3=RL_>8Y .E2LN4@P")E.0GP]@Z+"B:6Y@Q-0G]O M2E6=I#1/JW.Z6WPU-<=91\]O\-6-.;7R6C/5X=\=%,IDQH ?A_P;EZ7>@7-*>:DW\!4$L#!!0 ( $TY MK%HB(^6G[ 4 +&PO=V]R:W-H965T&ULK5I= M;]LV%/TKA%=L+5#7(O5E=8Z!UI:P NL6--WV,.Q!D>A8B"2Z(IVT_WY7LB); M%,U8 5]BR>$]ESJ'E^2AM7ADU3W?4BK0]R(O^=5D*\3N_6S&DRTM8OZ.[6@) M_]FPJH@%W%9W,[ZK:)PV044^(Y;ES8HX*R?+1?/==;55XCOBR*N M?GRD.7N\FN#)TQ=?LKNMJ+^8+1>[^([>4/'7[KJ"NUF'DF8%+7G&2E31S=7D M WX?D2:@:?%W1A_YR36J'^66L?OZYE-Z-;'J'M&<)J*&B.'C@:YHGM=(T(]O M+>BDRUD'GEX_H4?-P\/#W,:VK35!R9X+5K3!T(,B*P^?\?>6B), ;)\)(&T D0((.1-@MP&V%&![ M9P*<-L"1 IQS 6X;X,I="LX$>&V UW!_(*MA>AV+>+FHV".JZM: 5E\TOWJ#7J&L1%^W;,_C,N6+F8!^U>BSI.W#QT,?R)D^ M?&4BSA5A*WW8BA4%C,VF<^C?S[2XI=5_"IBU'N9#FF;U((]S=!UGZ12>917O M,NB2#C1\!C1)]L4^;[C\4VQI!?064/K;NB8?*/J=<:Z#CRZ'7]--EF3B#-H, MQD,W*$@W*$@#[YR!_QCG<9E0% L$?4>W]"XKRZR\J[]8T^0=LO%;1"QBJ[0^ M0'L-=#VO/2R):V-KOI@]G&H[;(8MTF^S'K;QB&/Y7K]9J(":2VVB89NI[6/B M'MOUF+([INR7,?4:AM'--JXH?W,1:]HT]?+RGN_BA%Y-8!!Q6CW0R?+GG[!G M_:JJFP.8V^<6,OMN(#%L,FUH$BPR!-93U>E4=;2J?N)\W\@*P9;V' M/3+;;&@%07O%Y V*R9'T4>)@J2A#[=., M)=X06(]XOR/>-TC\ M-KNUE4KK:1+\)8\;AT:_U]=4)=]\P+@W&/HK;=J1#*TOR1B:S!@9 NMI$G2: M!%I-#OO[I+>_SV%_K](B&# S=1QY.M.F&ZN%2;#PDNY'AC+VM,#6T<]:6C7^ M@!GN4PEJ4/2Z=EG*&:W%Z#V([0=86C96^EQCI3"*%AI%BYYGI*_'R?D"'N.0 M:)FV1O)S7'66R%&*A ==(I[CN$06"2NLI"\M)PHPS[=]7P(+%>VFQ)70(E4K MQPJP;YVAZ^B\\2CKW=(ENSPIP"\\*I".!]2"*BQ]$+C8EVO!5M3"7!9I".9;EF=CN1:&[6Q;/EA1-)JZ M%G9/K&J?L*,)QWH7_I*S%35Y)EWR"BN,N04326#+*^'::.+0*%ID"JTO[M'N M8U-^7ZGHT)8/5@63+GK]?,+0:,+(%%I?GJ-QQWKG;O X1I]I=/4-G;P-RY S M6.]-9@V-HD6FT/K:'L\&L/YPX"4>$@]MNT]<5ZXYDSY[?5'.T&C.R!1:7YJC MN\=Z>S_&2N*ARYYB9S -&C7V1M'"BYX@,I6S+\G1W&.]N[_,3RJ,L1W,Y5^J M5OIWU_D)UWE#Y/6<&_L>;XKBZ1J-]A#*QKY MX(?F\@\T*K! .F:(%(VFKH,=^XS[)D?W35[BOC5V4LV<-LG8)9P,S3/P"WOH M>2 ? AM-'!I%BTRA'92=G;S"4;_2 YJ W>$HIQN M][Y0%=U>$OF<"/8KGFK MXY8)P8KF#_&\;$TTW]HDCWKM+R?U!+ P04 " !-.:Q:+\%1 M,"8' !U'P & 'AL+W=OGN^>./'T0\EZM.-?H<9T7ZFRTTKH\F4Q4LN)KICZ(DA?PRU+(-=-P M*^\FJI233!<_%P]D( MCYX??,_N5MH\F"Q.2W;';[C^45Y+N)MLM:39FA:*-"@9_-OR2Y[G1!#A^MDI'VW>:A;O7 MS]H_U<:#,;=,\4N1_YNE>G4VFH]0RI>LRO5W\? G;PV:&7V)R%7]/WIH98,1 M2BJEQ;I=# C66='\98^M(W86@![W M(N(/T%TX$%M%U :T,;9+595TRSQ:D4 M#T@::=!F+FK?U*O!FJPP8;S1$G[-8)U>7(HBA:#P%,&5$GF6,@TW-QK^0+2T M0F*)+IE:H4\0<86.?A2L2C.0>8_&Z,?-%3IZ]QZ]0UF!_EZ)2K$B5:<3#*?01T*3[ZR=@T=8L\FS6!?$J_,+D!T3Q,2(!F3GP M7+Y^^=0#AVZ]3&M]=,C+QH'+VH%+*=8(LE RG15WS6>&CQ>^_X3#XPV7R@93M.6"Z=<#4IWWQ%0K2YR(1:XZ._A)* MO7=9VZ@(:Q6F_&P68QK/H_!TLMFUPR46Q7BZ%=M#.-LBG'E#=)[^!]G6?/): M0(5*1)%D.4<%0,\!LGEJKI,ZED-1/'$9-CMD& ^D;,])X=9)H3>,5QR4)ADS M%=AE:+-ZMA.:D)!>^%PR,W?LHBVLR/]U0:A,5+J Y!Q*.^*/I:EM+J21A0(' MN _5%HJ'H,ZW4.=>J#=:)/=C0SPI@G0P^ :].;=>'Y'9K(?1%@HC'+M!QEN0 ML1?D>9)(7K,L_ -VO^>:W4(J*)Y4(/:7 M/HW[0;2%:#@4Q(Z]L9<;FZ\+2*"X&VLNUSZ0U*XK?8BV"!TH*KBC5^SG5\A8 M41GJ*MF3254GMJF-+:1!'YY#*IB2 8 =NV(O+]4EI>+.T.^D@!/VS%%7,)GV M<3O$X,,=J(2X8SSLI[QO/4YY":U-;^-H;CG9(87G\P&L'0UB/P]>\26'-$JA M>]GPHG)_!3:IC6C^2P:0-YQ(H[?U,-GQ8:KUP#WW3^BH3?OWKTX?XJ#+8&:EO4-LC,&0(3,Z M9B73-Z7],BL8#(8OX_82]EO3_E#:]IW0L3?QL_>U% GGZ7/E4ZH"']1% &:8 M-0P)RHPU=9;!^\?+RFSCH !WY$_\Y/]*NZL2 M+ODCETG6E,;FL2C-#-44GW*G<*H5 YN0<9)$'V^NKYT.LEL$J^38(IC,!CH> MTG41Y(5IVI6XK_[L[;[!@FV+3$D\'V@Q2==:D%>T%O6X9?H*8\%Q8X?AI@W0 M0-'.7.!\+;/$['.:WYUF.+H(#/6\/\ZZY,(@&NCD2-=L$/\$?OEJ],?HEM]E M16%"8TB9RTRD3I/LT3LB@5U(;;$PG@<#%M&N'G26/Y2V M?1]T;0GUMR4U+];3/!C=S$;N+6R[P< Q[>]BN:3H;&#:H#O;[OY]][U I9E* MZ?7[*V%?CUUB S-G+3K7JB_>_&,\.U&_JUF65U!I3GU&XOE M&/I4SS8/M?L-3 /+F%^Q54^[YH7ZFY?O'(ILQ9I]W*7#M&8#"JW% MNKY<<08MFA& WY="Z.<;\X+M2?OB?U!+ P04 " !-.:Q:,*>S7TP" "C M!0 & 'AL+W=O,Y>\<#W>;*.' 2560+*U"/U5)H M"_?&39BJ/G6L'9; A=:$>>/,% M.CTCPY?R0MI?U+2QHY&#TEHJ7G9@74%)6?LESUT?#@#>,8#? ?RW@/ ((.@ M@17:5F9E+8@B221X@X2)UFSF8'MCT5H-9>9?7"FA;ZG&J61)7M!.HB4(^R)8 M"FA!95IP60M E^AQM4#G9Q?H#%&&ON>\EH1E,L)*YS8,..WRS-H\_I$\ ;KG M3.42?6(99*_Q6-?<%^[O"Y_Y)PGOB;A"@?.\E MB*U= Q*EO&:J?4&]M]TT,[UI[$2^\>L-=&L'#_^A:=>7?A];RB0J8*,IW:N) MGE_1KH364+RR4[7F2L^H/>9ZBX(P ?I^P[G:&R9!OY>3WU!+ P04 " !- M.:Q:,R..46 " #"!P & 'AL+W=O MB&_G\W<.LCW?"?FB*@"-WFK&U2*JM&YF<:SR"FJL>J(!;F8*(6NL35>6L6HD M8.*":A:G23**:TQYE,W=V(/,YJ+5C')XD$BU=8WE^PJ8V"VB?G08>*1EI>U MG,T;7,(3Z!_-@S2]V%,(K8$K*CB24"RB97^VFMKU;L%/"CMUU$8VDZT0+[:S M)HLHL4+ (->6@,WG%>Z!,0LR&K_WS,AO:0./VP?Z5Y>[R66+%=P+]HL272VB M280(%+AE^E'LOL$^GZ'EY8(I]XMVW=K!-$)YJ[2H]\'&H*:\^^*W?1V. @SG M=$"Z#TB==[>1L_R,-<[F4NR0M*L-S398F64F)>@BF[5O-8FQWLNCC?TU8=+3U#&Z"-X+I2Z LG0/Z-CXV9UTL/ M>JLT"-Q@V4.#_@U*DW08X U\N@/'&YSAG4KS!FW?T9H3^DI)B]FIK#OHW6FH M/3 <%I$Y& KD*T39QP_]4?(IH'SGE>]"].RQ98#ZR79XVS_61DLB&OU_ MD3O=,+# 3$% ;.C%AD'.=\%OKY +0R_)C;SYJG8;06A!3YN%B9?,IMYL>G7E0G9AZEF[^.A>K4&6[O50 M*!4*,2A,:-(;FV,@NQ>CZVC1N%MZ*[2Y M\UVS,H\L2+O S!="Z$/';N"?[>P/4$L#!!0 ( $TYK%JT&%*$3@< &H1 M 8 >&PO=V]R:W-H965T&ULK5AM;]M&$OXK"_50)( J MV;(3%ZEM0%;:7G!-SXB3NP]%/ZS(H;CU3.J4VC?S>2QJ:G2<^982( 9&E(K$&C:\[6I&UK @P/O1OE4V_[LT40574R^Z86!H#$N?^O[ MGH?_16#1"RP$=S8D*-_JI"_/@]^JP*>AC2_$59$&..,X*#8Q*NU)=Z6@B/[D.%,DES32>SQ.LLNR\Z"U<90N+)RR MI3JJ[UU)Y4/Y.=".D!<#Y*O%LPK?ZS!3)\=3M3A:O'I&W\E(P8GH.WE"WS_# M1COSN[@W52OOHK>FU#EIP,.A^TS'#\9I5QAMU0UN$C(T1?7+777QV_/OKN&?=.1_=.G]/^ET3X>0O',_7_ M&E$?M=MX];&FH%OJDBGB5+USQ4SAK%:@H3!2]]XAP_UFIPK?M-K)=V-2HE(E M+\9*$PM_1V$GUDJZ0Z-I.2ALT^&)567H-E$9Q^4*8*5J 8)/M+[MK "*J+M4 MJQI%K#K7H!LV5)H"079$Y>QIO"^2WQ!PA*S (!>*,85@*G;K:$JC@R&(9#4^ M"/)5=NGE5'%SI6!WZM;Y+;(NJJO5QQ_5LOC<@08A;.5#"VM\'P);S?X4N.># MF(%S;\GJK>8H./5>[]0BE\C1+"MC$:UB2Y*Z;0?12.B*>Q,#Q2]NKI>KEQE4 MR5^"=I JU15W%3=!@J!>T-AJ@K=F@3%Z%C%K:+[HH:K-(4O$60>F)GV1Z / M9R*.!/(')085W:EZIR< 3J60F1]D.@570CDBMW0NE:#D1[8(1;N M31),IJD$8!Y$[USOG'']?&BTPSK#_D^%;5W^ACF>^7!4()VQ_4A9:55I$_9\ M#2#V5!J7]RZIFVUM"J1>[K,:4<63P1_V@_UQTHBG!U0T&E$?BEB(-(U"*(PO M8T\$L_2!(A89"1!3CS(T6)0O^,<%ABX.!5\G'"#JP9Q-8Y[ M*>]?@XNA-S<8X+1GQ>S#6T@V:W3403EX1$B\=-DO/)ARN^"G52<32/3@5GZ< M@__G4O=/N/Y([_ Y/:)NB+='GFXY<6/M.XNJ8RKTT&-^Z],T-QD6/$#^7_"R M4O!.<2CUL?GT.?WU5]\NCL^^BVKI7 ?9#Q)[1LC[K3H^^N8?_Q$.*/DR&J?L M064L'HTH;[Y?B1Y:AXZ3>W&6J9FIGPS:2\E]D_&M^B&!9/-H_\#Z\:#FZ![# M*7&-Z23%1_)6XIZ;4%R5P%F#$D)"/1OH@3[OP- M4_'U[ R;M+699Q0H8A"[JC*%[ 18*] M)T8"I"Y[::BZO? MA"H38.XS(H 288WP^FRF;@Q;X8\V]Y'#/E?G18*[('+2;)P!#YI;T>@Z)L7@ M^!@ASPF)IQWQ=9Y[B1X7O8@121>O)%) MF(0J.HP4ZT+!^@YK7-NMK2FD&6!D,KR#!/%88;AAHH&4M$X#[;C! KG5]#DZ M--Y&N,Y3%(KYQ=1MD)4\"-9^'&VC=&)*-D#P8$9Q9H3 NY&$%@/DX>!!AT"_ M8O_AH5\GO%=+/HJMPX,,9TW[^8WC)3; W53Q[$N\5I4=V&%F*>1I""8\;J:' M:W(8FB?OUIBS2+YA%\.FAQXAJ#>!TR+P6V[,QD3%01$.VF/F/%M",I72MOJZ M/G1A*RU0Z-J:R.@(47E".:),MIH]]D8T/WC_E7V4W_)Y:<2:D%^%Q[OC'PG+ M_/Z\/Y[_A4#+V!B$R5(%T:/9V:M)]GGXD7PK;]-KG_!N+I1"JRO%L,GDU MKJ32@^O+\.RSO;XTC2^5IL]6N*:JI-W?4&EV5X/IH'WP16T*SP_&UY>UW-"2 M_-?ZL\7=N-.2JXJT4T8+2^NKP6+Z]F;.^\.&?RC:N=ZU8$M6QCSPS5U^-9@P M("HI\ZQ!XF]+[ZDL61%@_)YT#KHC6;!_W6K_&&R'+2OIZ+TI_ZER7UP-W@Q$ M3FO9E/Z+V?U&R9Z7K"\SI0N_8A?WSB\&(FN<-U42!H)*Z?@O'Y,?>@)O)D\( MS)+ +.".!P64'Z27UY?6[(3EW=#&%\'4( UP2G-0EMYB54'.7R]C,(19BZ7: M:+56F=1>+++,--HKO1&?3:DR1>YR['$>2XVSI/LFZIX]H?M"?#+:%T[B)9(?4&V];65,(7=+0H#_KJ5E^N7%8:1[E0 M6OS->!*SX9_!,^1-?)!LH*-X)J7/ ]A!6 M.BN;/)[-.MZ;JI9Z_^LO;V;3U^^<6&C=0/8+U<9Z@4+"U4!,)R_^*E 3@\B> MI!7$)!EOS.4FTDGLAUVM4Q:#%!KMPJJS8KX[10(8\ M-)5*KE2IO&*U?+[?#R&P)=U0U$Z/Z XNW5@J _X4S@9H1T>QZT!^AZR2.;4! M^+$O4LB&8M6 4* B(@FP58B]-\-D6,")_\P PA^LC F)BEG*E4F^EQM+/4H$ M$F69Y8AS=#F+IEV2A6>]_3P&WG&VDF8J'0'BQ<6P8X5I'.*.C"XE9:91KL Q3[ M/0O8:RLJ%4QBE^$:MDIGM%R5U#K0H;4%0NP*!1_P"!!6@I'!/^ >6]VS9(7. M'\,HK=WS(IM/3_$JLBA0ZQ" P$06.,FUD5BX-N&9)'RM8)]DZ^-S]Q,L.@X2 M[&$2R1T[AJ'BF:LI8^H*1@$\5F3*9DT%'7Q4\./.-&7>)N>11CBUJ0.^DR$/ MY-HJ1R>H>*!H7)IAUL1Y\+;)/1 M*)I\-Q+O4^5&)O9RU3(7UCQ'Q2K9E8P604ID1 MJF@&".5>+')3LXI^.;=&XSI+Z?@QV((!D#W)_T.A,>3U^\>Q .-D'D#K:A\ M?>S"WCMFB>CETN9.W!C\B;./B^7-.7LBIHI+ZP*^#P(KDZM3=5>R"3BV(V/B M"\ZG4%\Q;@:"H@7HDES*Q1W'G$MDX[CCK7@N/N9B;BBR,27HX>AP9&H9MG5E MLMEU=H7&'))S'Z^EX$A:=H3"$5EH8UQ.?JY/'M7S+H)W\=BG WBG#]T0G? B M&LG>;B$OEE_#RHO)7X9B (% E7OY"/O/[DV-U'L]GYR_%7<58KU->D&'PT[Q MX0!.C :A;'815$Q-'QLSI$@7*7&1'H\HG@Q:154>JGIV\G8^4H6V%-]]V.^A M4GH?*RJ'M, ,A_(/8*A@W_FR+?W*>N.,) M<=NQ:OXDJ^8O)A<]5BU;W2)$:?HN372,G2VR5/"K)CR3!-IMM['M,-'D!M/" M)C*AS[NS9;/R@:ZSV>1%8.PWN^&([W#<=OWL>=JVS:4R^,G)2U4>.R4UW4/Y MR7#$!I-![+K=C'86YR:VF*JZ-'OB2%2\&E .H1U^0"CB71C2*O;1'^')^=&L MG)$%%-VJQZ&IIX17'\V!2]%>RZXQM^G619HI!7LY9M_1KG],SE<1 M+\NQ\ZRJ.E[O%$BH_YRZUR-Q*VVY/U 7\* 0,R8LBXD@84 >ZW1/NX]&B_BM MY+ ]?G'Z)"U(X$1):XA.1J]?#E">PU><>(.<#E].5L9[4X7+@O"F8GD#UM<& M/D@W?$#W*>WZOU!+ P04 " !-.:Q:_PEH"/\) D' &0 'AL+W=O M54D9W//9H[V]-XPM=J4WD]$%GCO"GC8FA0ZBK\+U\B#IT% M[R8G%LSB@AGK'39B+3]++^]OK=D(2[,AC7ZPJ;P:RNF*G/+D+=YJK//WL*:0 M"V,E8_2PLDH!CVY.:/RO%5Y?D[Z'_+.64G'];PJDPA$^30#P9HKV4AFGIIP5Y1RRTK"6FOQ-5D-$',%06,&26A M:_PC::9F&ZC@D/Z%>LJ)Q$#RD1%3DB&,EBF"^HWFY>D8.K!F6S)2ELAFV MUO]5V)W>+[%6/&,DEQ[:U=:LK(1ET7+Q& 82I$ "/GIH5D@2%"*3OI6T2US8 M]Q;6P$2$Z)]PVX''8.M:0X)K:F6=RAG5'!#7!;B6GW;)2/Q\1!XM)'82 25 MJKRNFJ!5]&]RF)=VA9*5:Y>99V6#O1&\4"^B;30>D><=U!*5#.(7:M54H@$0 M]IR6W]L)^^\^B!]_>#>;7=^P)0?DBHP:BLI4%Z@TV$DN"D5&.3##ME:]$M/9 MU8YH LO*M%E3&R*6RIHN!@>H@7U$@)N>1A069Z-"!!80B3&%2'=<^D:ZJ(/* M3[AM+9I:P?<*['%H!,[Y1(K7P 8*:#AC5TTQ8B),3&]VL4!_!;9%B64 MM7+NP16C*IN\+1^&(K:8">*PF*++:QI5FL!5?"4H>P MM:(;<0>.)[+T,VC$(M:E!(9L@[RQA.Z^[S^(U_I-BS)7 IX_Q#A>' 6X.PON MPT3,S!7IW1<1]^3(4$ZO*L[)4<.D&'*>-HB)+\O>@J.SQ,^R6H$MU(XR(ZE; M3<$75^3M]F$R^\PJ9OBRH=_48[JV\$7YL2YT,G[,0AR4M(2"<:DM"D6E5@:N M8^0A%82H8G_,'""F+!O?6 6.65\I-@I(!9CY81EH&G=?;(.RH.N2EM^P'LGE MZ)R[U:V-Y>BUG)8'G?O5ZY CF;GHQ_ %A)4F)BVV&@-YDW$ZI+'OHZ=1+Z8S M95.R4"P77"99&OFMT"M-P8YI$3SA-5=-:[:RP&^7Y 8@01KH+3@_7]!6PLE" MN5&O&IR0'!!Y)>;33H=!/&E]B:TB1,/3@1ZT3S%'$U=-(;VQV^%>GJ,]%,X2 M<'_(##NC*%\$A[/^Y-Y>?FQA= M:M:UF!N27M-"C"7BZ4S7LFI=&=\3JZ9O;YQX B^AZ\>+*;132V7)4; O0T0M METS:D7CP(4IPADQUT" := 4\=FH-:=/X^BO#G(X<..T5$AVH"*=C*I !5SH% MWK$V+30@0F5\6_P5I]F%XJ)9A'8/5F]%'P_8D&6F MH9R]XO+7J<_]GNUH5<:F,JR'?%H>NIV'IT_B>G*]Q]2<4OI24P,G*,ZY52D7 MR(LY,9./_P2&68#08=/F9&\4#'4^YHN4XAA>RG2@MHL4#04IWWD]=#K![[\8 M4 10JI"'"%KM\;2?;=NN8\09YWQI[&>:7-$Z-M.O9:",S'--"T&4E3%Y4+75 MFSW&NP=G[6PXM'$#7[/G8C;.UK&%?/">;DZ"DY!5RQ;"KY2N\"7U!2V ML,.TE2%-VO5HNRLZU'5[S#JDO:BQDH3+GD_V<7+$G5KJ?(^0%(\(;.""/Q; M%30$&XJ"W1Z/3PBHT#T(28R(?6PZ6]'%4MX4*A#PM*_ZG;*T[!?5JH03>^5D MJ%VU!6AG^#AJ#S2A-[*T;V96%27:41;D-JQ7>H!?H++G3="I0B2#IG,LW4X8ZR Y?< MW2ZU);1+)W)PH6AE3.^PP M)D!'Z2NG[M[0(;C5B,X%VF9-B<1.-W#"9, 'S0@W2D>8U?(UCL[WFWE4SS7@ MN>"+@3PU;(DRX1+D_8YLD7[3MZ/K."0."$A3"E.MSLF\?'L@6ZJC@(\5W?Y=#IQX_#0"%/)PFJ64PZ0*UU[X[ZHHH M]-M8/Y/30]U**>3XY=F^LJ&ULM59+C^,V#+[G5Q#>8M$"1OS,"VGF067M9AI%IJBP9J:O-BCI9*5TS2R)>AV9C496>J-:1&D<#Z.: M<1DL9O[=HU[,5&,%E_BHP31US?3K'0JUFP=)<'CQF:\KZUY$B]F&K?$)[9?- MHR8IZE!*7J,T7$G0N)H'M\GT+G?Z7N$KQYTYVH.+9*G4BQ-^*>=![ BAP,(Z M!$;+%N]1" =$-+[M,8/.I3,\WA_0/_K8*98E,WBOQ&^\M-4\& =0XHHUPGY6 MNT^XCV?@\ HEC'_"KM7-\@"*QEA5[XV)0ENY0GJ^F4DYU=?&1+_OG2#]P4PCE@C7P^^W26$T?QQ_G8FXA\_.0KF"F9L,*G =4 M$0;U%H/%^W?),+ZY0CCO".?7T/_+U5P%.D\S[\,%!_!<(:R4H'KE<@V6+07E MR5M*"URVG<"7U)+*'"RIWZMZP^3K^W?C-!G=&%AQR63!F0!F#!)FW3HH@5E8 M.;];[]>!4&T7C=;.%]47-].>)T;W_T)-Z>_\>K_B%@4DT*[I?LW@65DF>C]R M29148Y@LS4^]>V8JP&\-)X?.>MJC[Q1?J88\_*HA+?@!DCP]AK&;ET4-TO+1C'FUN.!/JE_]2'9^UIOL*2"V$Z@"0?A=EX>"JW-FNU12U= M8$!-4!9DK!RE3CD.)_'P1.SY4 ^Y/6*?#,9A.DG?LA]E83S)_M>L7DSJ)!E< M3BH=7D]<'"9)>B)>N8;K8*-AF(WR4_E?WD(:QDEV(IZYA3;<9#(.\\GD3;AI MDH5YDKOBT@@[]Y *J/-(LT)M8(EVARB/BT.X&S!0-KXV7)G92B-"W39:=(W6 M76A1=7T2^G"N\T1' Z)&O?9CT$"A&FG;6=&][2;M;3M@_E)OQS3Y6W-IB-R* M3./^:!" ;D=?*UBU\>-FJ2P-+[^MZ&\!M5.@\Y52]B X!]W_Q^)/4$L#!!0 M ( $TYK%HDX4TS) 8 !D0 9 >&PO=V]R:W-H965TVXLS4WHEM7AO MF2N+@MO=E5!F>]X==>\6/LA5[FEA<'&VYBMQ(_RG]7N+V:#1DLE":">-9E8L MS[N7H].K,?$'AL]2;%UKS,B2Q)A;FOR:G7>'!$@HD7K2P/&U$:^$4J0(,+[4 M.KO-EB38'M]I?QMLART)=^*54;_+S.?GW7F796+)2^4_F.TOHK9G0OI2HUSX M9-N*-XZ[+"V=-T4M# 2%U-4W_UK[H24P'SX@$-4"47YQ9LV66 MN*&-!L'4( UP4M.AW'@+JH25 MFN@!-3&[-MKGCKW1F U."*[G!=18\J!*X^BT<]%@VCR2/ZXL;...B+ M?\1.]L=EXKQ%9/QYS.1*X_BX1LJ64[?FJ3CO(AV?RZ-JCH.<]-EQ=WS,!7MEBC77.[;AJL22] [AUC"[>^;22;UB$N>- M"R(3VK.UE2FMT38R!"NM"(XMG-9X'RP9\;>6>-< M_4G=2 X@I'=>9>]&Y?G#_T\ZG_@ULLD'Q#AY1RK&G;#2>]4:+,4;1:([/ MYRR:LA8!1/QP%:O*B@@1#/QM\P..H-AQ$; MC5@X\^AE6!G%9/,<-D_(VG@VV5,,0CR?A7CBJY45*P0Y6W(&HT+.4P ^'#DH M3SX/$:O#Q5DB*1'P54)3OI XM&)DX1J.>-:"[002=LO)XED_0AU3*I1D1]SP M&C+O[J[_KDA?\@8M/(_]Z%Q*C6U5."Z%.5@;^S*6[%B*P4\[^\9T?A/.56[P6Z&@ MI*C*Y+NVA_9)'XWGJ@K)RL)/!YO]%.DP5(^'XR3NS1>S=N*=U'\'E,?C,NHM M)K,Z"T_PTYHC-"?3WGPR;N=AL\D^I?,:1:%(X*;:G^/_FS_'R.[1M)U^=Z8> M4#H_P+M7IG.CX'"I-Z(J?,@%*D3'2S:2UJ&66JJN!O'\C6A&651DXBJO*])Q MK=P*E@N%0N(?TT;D_>Q@O7;98IF!,FTH![W0 2*Z=Q5XCN^,!@+E$WS$TEQ> M-&DQ)8*N$?07%*Q4[NKL;SS(@V-"&<_J2P"_*)\&ABEY*]"5A+@B;('^,*+4 M.$^M!\3K!FJ+4"!7WP-H4%.=/0*X EAM P3D7FT(8A;\&%H&L0E-3F KZ.$! M_5]*:<6>:6T/[GED2:;5B'9W$%K830IF-!UO2TL@#LY)9@3(!P66'(HV""1I MJ\X+N^XYAS4; WC=A%9]70IWP-?U;6V%"EI%Z>J MMU*T_%*#Z9N&Z>T%EVIS-HI'NXDKL:XM34P6IQU;\VMN?^\N-8XF>Y12-+PU M0K6@>74V.H]/+J8D[P3^$'QC#OI GJR4^D&#S^79*"*#N.2%)02&OQN^Y%(2 M$)KQ<\ <[;JTT3C14E*NK<95@7IV<=UWG>0895]_@C;N#4UVAEXDSP)^97H,:1Q"$B79 M,WCIWO'4X:5/X'W3:]:*?YQ[(2Q5:Y04)?-4:4NXU-Q05-R$JN"C:#$V J-T MC9,N8@;^.E\9JY%9?S\6(6_ ]'$#Z+2=F(X5_&S4T5[ZAH\6KU_%>?3N&?>F M>_>FSZ'_0EZ?Q7WH&I$0:# MC4FP-8=*2:PDHEV?!,B)HG:D>,\+WJRXID% #"&:3(,WHD4=U1O$-6^#+VRE M-+-*;^\V@2.8A\=IOOL'2]5TO46H.Y$DG*8SW]XM&U79#=,<8MP-O^!CKUMA M>YPA+RIQ2WT#<7@\S7P;?.%80&HE2Q!-I]7-0*,DG,\BWP;$1*M[7[/0?!1; M(PP*Q3'$61+$>9@E4\#?-"=$8T[@O"CZII?(RQ)+$B8&B>H WI!3\PS>NEZ: MI_ V>"[81S +L_38!2..$HSK 1B_Q:L #(<-,R@1C7.L2%+N3LS]F4J!=OFR MM>8<&E\-.%4#N,N;2Q4I4[I"K/*FXZY.R^V8O-(]BG^@?0V&D@2_(::&9:\U M9>:+8"LAA16XNA/GA^+*B1>#N#P0%VTA^Y+_*J19U@6!U=X;MPNI%-R=%9YGGGQ+$SB'-MY' ?>6R3/;([M+,V" M[XI.&/M_OAY!'(7I;$H=Y,WQ#- &JT5!1BZ9J>'&LAJ./8$>0_(BLC+#!C%!$3!3;"UH<6OGXU3^+9.P,5*R@"6Y!T[L;P'66UFD#PV/HSBNP%=T,;@F3ASTTFPU26!GPEAYN#8VT+T4E"C?V M^^-Q4BV9M;]9G$44'M>A WG#I*L+-/DPP!2-1O6TW/DKRAM.UB!R270H7='T M]QD.S-V%M=NN0KHC/M4J,[#?'')_WWM(]^63QAY!-L<*F6 GC\,X3X.K!Z8G M89;/?.MPPI=YC'A1>'Q,12E/\0Q$\-C].#EX S5O^+OW]OJ5&?I:M^J]%6YH&FDW;U1MUJ\GYY/XQ0>]7/7TQ>GU MJTXNU9WJ?^O>6WPZ35(JW:C6:=,*JQ:O)S?G+]]\ ^MUB[[6]!)"F,^ MTH3,S)(U:KL28+$?_?J5M4U"8(9OP>9DZ22-N9_1^G?\=EQED(Z=6OJ M?^JJ7[V>O)B(2BWD4/+EW0K:5N#5MK]NE:DNMW*O3'BIHX6D9Q+WQXN9'Q%V(=Q"P MQ5\YKWBK M75D;-U@E_G53N-XB:?Y]R M>R>5A)51(+UTG2_5Z@DIQRMZKR?577YQ?G7WS MR!$NTQ$N'Y/^^2%[5-QA8Y_/Q..>^DF7J$PE;I96*;_H3CG9*/'K2EG9J:'7 MI9N*']MRAG_$WX=640POIZ)?*1+>R7;#@H_O._&/G@C(5U950K>]$5+40;F, MRD4W6#=(_('GZY4N5UM:EA:/5-(D16O:I^JAK <'2$CBL+=4M@>2B8^M63]= M(2[2.5-J2;O7NE\)N*B$!W4I:T'>DA:Z3DA9$)X<\F0FWF=6'5JR[0M(5C"G M@GU?BK/9.PK&: M\\*:C:Q[RDO8UZ*5.5DK/CI)[*RIAK*'*?>\NMB,.53!"CK+M@WJ7M8#!_V0 MZ\3 +KZYNQ579U<[UE?DF(4.6Q>FALVPF(QHM(-10XI/2M^7XN3\"7]U.#') MCR=SOP)^9L>G# 5(M6ZAK'=WI2CJ*''2+WO>DE2O<7RAT7VQAF1(Q\]#?B5U M,:\DN:QE$(3:4G7<1]>2\("^,%C\^Q 2(6UJS!#=&6T]IH!$(;3&5I3U+CVW ME!^#HF"2?:3(U+KB@+@>_WG 07A!3JPDLUQ,-A3HBC@#9XMSHAHLN9_]@%.; M"F!"ZKAB+LZFH6INZGH_J\>$C:DJI/7V(,Z42LC-0HE["7=2JL8GTC,.6+22 M,*10JA4<5M(,7S2^/BERTK.3SN+L,_$AG!QL"U60FY10AZ2.19;9*,N5QG9O MYQK%2J:1>Y>M_H/P"WYAO5;5[,JTU1\K[*\$=/-:U%>![0V>(X4*/B$GE401 M0N@"]B"*%"V+@B-@X+3F#*#HQ#AF1K!N#HB'Q%U,8+M;@^UE.:#UO]L/@3?! M*EY&H*Q3FO06!"H 7JQ(XXLMY)::@G\"LCGSDA-EAP.BYM%XHN LR.GPD%PH M,CZY"@?5->0;JM(HA&5$-$=J596F&".>FVGF$Q\$^&$,LH>M/"YM#FXIK(L[]N> '$=[+;P??_8#5S+5K7U,KW3D*9[MTO6A44R#.I+61+0B[+_?6 M UUAI*WX8:6A%EYUT[TDEP40V/?1@*D$]LFD3MI^DV] ^%6E[S6P]@V1B'?< M;5&P9]O=ZY/T@!MTDI4ZM#*FN4NJ]@[U[9S&EE1!TD@ M',$7H2*:<1G[^E'F\ GY"*$IT*M3-LM-V@+344=MF,#X2!7ROS:=EY.7X#97 MX&E-4]9O]]<5=1\RA'4U\J-*3CJ UGS&\_&,":*6$$$6,]!RH];6]7NE%+#& M5[L3KE.E[^T)C<=:14"\^/^TDOO*U'SO&9+LH]]/F2=[)F#S2Y>4*H MMGMGC=W 1FQ]1%MU"1&E8]E[9[^OQ2$_31GM*9+!<^ 81^U7\PTH M/?3@$$;?6@_U"JI>W^T2-0ZU^]47+^;GS[]Q$<7(&]U> $GK&3D(-PB_JV->8<(#B32O@439OX6^3Q MA64("-EF1O' ](#Z"Q78A!N*P-ISZLCI0K'6U5;G.VP0SQ&)N'-VADG8CR"I M5L@EY-"9[]Z; S< W)[8B\A=ONJ#O$J[DJ\;B H/E@^4B\5)?_WY^XO+%UY6 M(9U.[8I[):*+H;^9QA2MT9Y1^>9!EQI>)[.L5IAI./"(MN:D#O52$9U3#N#E MH]D9&Z-*C]^C.M7YZ7R$N)[" *;GV8P;ZIT>61GEZXP4$\P0A6B?+@V1R13& M+$NR*7'/_3-Q&_7^ROMN,62"6F53Q]W0=?4FBQC<_S,2G1C75^9R6M?#"M17P+F/'N M]NG5_.(*[$R*#S=W)[_\_$0T<+9^&JYY[VGF7.E" YS]//R'J:LM 5^_.'NV M)>#[\_G;(_M[Q P X5(I1(<1Q@U.<;[0V<,)V'0,QC3G48)>7LW9B*PZL2DJ M3IIVD"ZR=^Y3'+X8^!0;C,9XE/30Z_,&A\ MAQ-0C>67F3_24*\3Y HEW)PE6 M6GJ-@$G> &#], F?H;4YF7B%$0*[*<5J4$.A.@U*"U?%C@)S9R66;!^ANBV:7# M5X9AEF]=\CN**,W#N6K]0#T3WP^2[X:!04?#&,8+.=YTLSECF]4JA1@=$?5I M-X>"S!!!QR5I&OC>>//"_0^@T'F"X!W3;SIR&%P1$677@E0>/E0+"%-4*TDC M&=?R5]'+7$LUEM>PU'_O>COXE/)0H56V_D@N3G<2"[[N54"*+;]D0Z53V2&W MZVV,>G(+2:O4 HGG3[<"CCO$U3:U]Z7*UN;4DR[]F+\O%MRKB+827PH<[_#& MX?#D&[TP#2'@JY^QQ^_<-"52NS.[.O5(M+.SNP&5<:\2'LH ]8K68JE:+,=)2:!QH; M54]K'MU'=]H4F;9'&@(=JP#E_0J#!?**(OQ&E7+P]F+^\)C(R)=%QL=JNBV< MQ^SHC2G?8CF7KF?&O*VU+'3-9<,6T;OV*HY8(]@7B&6*IQM7Z=;_0H%=?B\U M=X[8*SA8H99& T 2L#:\%L HSF/$E"L\7=ENR8VWX4G^E+R43 CC=^GG;9[$Y3]![1']&S@SW_;O9K M"AGM0#QT! JDQCKD%YJ HJ14L1?AQ T3)K\_B@#C"RES.;F&HY'MYGL<,$WN)\$@ ML&)-%[::9*&-^8I(^8XQ=OO= @_"_AW0T,KPLA+4A_*#77-0[]X[K040H64Z MWAFG?69DKAI?P,]2(Y-KM<#6L]GS9Q,_9,0/O>GX MYRB%Z7O3\)\K)=%S: &>+PQ2-GP@!>GW2=?_!5!+ P04 " !-.:Q:>]#] M*]$" !B!@ &0 'AL+W=O$(^' ME5CB$]*W:F9Y%;_N,]' M4>(%H<*,/(/@88535,H3L8S7+6?4AO3 _?F._4O(G7.9"X=3HW[(G(I1-(@@ MQX6H%3V:]5?/;^QQ!5CLRY1;,"DJIFU&\;<]A#S!(#@#2 M+2 -NIM 0>6M(#$>6K,&Z[V9S4]"J@'-XJ3VE_)$EG/!A-A8,[G6/^-SYFC:W0 M="=TDAXE?!"V [WN&:1)>GZ$K])0[O":'QZTKU(KH^H[K>J^\?8 M_^.ZCO,..O]RP'/A8Y25T)O3DT':O;QV,/4!%S(3A& 6<*\S8_TI^@([ ^% M<+WR?8/0.9>L(W;,>:.FPECY&QW0.RN0 >E *PL6I%N"!B+:D 96P ML!*J#E$_0=))DBY4:!MD)VC5=3EG"SL!$H M^-UE1?OP0F*WF&&(M;7V&P%'PO*;RFHV:%(;J/F$G%QJ?S:!3YLVI&TE&4ZE M)CY!G4N]A,Y'CR?>J_L2[3)T-P>9J34U+:"UM@WTIND;[^Y-]^4TEU([4+A@ M:-*Y/(_ -AVM69"I0A>9&^*>%*8%?P30>@?>7QA#NX4/T'Y6QG\ 4$L#!!0 M ( $TYK%HW!*FV5 < %84 9 >&PO=V]R:W-H965T@-*E9NXJA1%)7QW:5G$DR\S S+CN>>=C:!XB$)&Q( M0@% R]JOW], 15TL:9*JW=I]D4"B<="7T]T KU=*?S$+(2Q[*?+2W+07UBZO M.AV3+D3!3:B6HL3,3.F"6SSJ><"96U3DG;C;'70*+LOV[;5[=Z]OKU5E M\U,511?$@YPM++SJWUTL^%X_"/BWO-9XZ#4HF"U$: MJ4JFQ>RF/8FN[GHD[P3^D&)E=L:,+)DJ]84>?LENVEU22.0BM83 \?]5_J?,[.*F/6JS3,QXE=L'M?I9U/;T M"2]5N7&_;.5E>TF;I96QJJ@70X-"EOZ?O]1^V%DPZIY8$-<+8J>WW\AI^1.W M_/9:JQ73) TT&CA3W6HH)TL*RJ/5F)589V\?K4J_O+V#71E[KPK$VG!RUW7' M IUD.FF-=.>1XA-("?M5E79AV(".9JN%Q(X.ERFWT+B5\*S5,K6 ]Y-\ MQ75FV$IHP>8$2QLK)G(YE]-<,%$L<[46P@1,S68RA88!RZ1&25 T3(&,],5" MDM!,01_-OH@U6T*4METM%".+9"88A148AK;8<01<6D%=:4S%2YKV1NR9YE4T MU?2?V)K6/\,46R3RG907/CH*'[#,>:S5@9ZJ* H9YXCCY?$V*HE,9,""C<L,HZ(T'K_.7.'20A">I]%%, M=84S'KU.OH5,!]Q) ))5J>_+V^)S\/*@7^S:4O?@[$1J!'7)J8A0XB7-*X,R MEZ^=D8XV;DFIRK=?*Y[+F6PH^E?D/1SP.NKTHZ$;][XWX03!\N=WZ/U4ZV[BF]D&Z M>]I $<184!=Q?MMC-7K<\++<3>&77KG)9S#GYZK0NG$#R-0)K+U@,"XZ0HKID M2=32V?R&)<%X-'#_H^Z@]0D-5?/APEK<_*0N@- M$BWN]_$_"(;1>+_U3J@]@SG.H5N_6!<3?WF2_Z*:0Y5_AY/^AD,+*7"N"CB3 M"V^RV#?9\>&J]5M53!%0^.I/=X&!2#.8S.=:S.%/YY0U_ "'_%Z?Q_;:IG/V M3P)T(+ :O<>B<3"(^@'E,RP.>Q']T#@.HOXPB(;#UJ>Z1O>"W@ ^Z8YH-AR- M6Q_JEH=>R,#/0A5_]Y"!,^F?T.T@%%*91%"$,0[<4 M?\-P$&'L#K;QNP:I;K[._4>1(H0VZ051Y)&&,<&-MDBG:J^C0E52KLQ+A/1H MAC Z5.6\[F/[9^(5U'G#>OTPPM4PS_$N.%(+"2>UKDIWTGEZG0<#GWT0_:P+7J>LT\H>M_%6/3V_Q11)U[3UE-)#96*+-7> M;^$EB#8.DH2H. K'<(-.=P9 MX$/=G6I^W%>P!M7?=_'/FY/"6:GM1>/#X_W]I3.$9R!][=GFM+!_TFXNI"=. MJR>D]P^Q)"=2SG!\:FY*!S>=D/VF3AVY7;^F9@GM#@Y'9 O+*NTRXULXS\)C MGPXZ.]]Z"J'G[HN6@195:?UGG^9M\]%LXK\5;<7]%S=L-Y>@42YF6-H-A_TV MT_XKEG^P:NF^'$V5M:IPPX7 =4N3 .9G2MG- VW0?$J\_3=02P,$% @ M33FL6G5F],2>!0 H0T !D !X;"]W;W)K&UL MG5==;]LX$'SWKR#9I.!@T7JG]Y'I[=F,MSW3HI%-T89MNFX69] M35*O+OI9?_/@DUC4SC\87)XO^8)NR7U9WAC,!EN44C2DK-"*&:HN^E?9V?7( MKP\+_A:TLCMCYB.9:_W-3]Z7%_W4.T22"N<1.'[NZ U)Z8'@QO<.L[_=TAON MCC?H?X38$2O=)K_ZD+IZQQRNTM.$_6\6UP[3/ MBM8ZW73&\* 1*O[R^RX/.P:SQPSRSB /?L>-@I=ON>.7YT:OF/&K@>8'(=1@ M#>>$\J3<.H.W G;N\B-X_TM;RV[(L-N:&SH?..#ZMX.BP[B.&/DC&$/V02M7 M6_9.E53NVP_@S]:I?./4=7X4\ ,W)VR8)2Q/\_$1O.$VR&' &SZ"]XX;)=1B M)TCVS]7<.@--_'LHW@@W.@SGZ^3,+GE!%WT4@B5S1_W+WYYED_3U$6='6V=' MQ]!_D9&C&(<]S-(3]C,XN^96%(RKDI5"MHY*IK!(^D5+++)A$7?.B'GK^%P2 MRIAX+BH/;,+HO:.DV^\(M>-'S0O!J&/4^M@T9[K0YZWW<^/F]E[2TJC:N+ZKZ%$J7S%[P"QH+TH&#J6==@/0F&_/9OE6?;: MU_L/N7G.LBQ-AFF6Y..)GZ6S))MFR6@R?/#'YVV#'<(XAO>"I2?#C>,8CC%\ MK]A5NT#U^YB'"=)#[(UNEERM/?!24L@P6QIQAV2SI037:)4N84CFJA9(;39, MLM-),IEFT0G+=+4?\8K@F@5[8'1!V,.@^;@:J/2J:@-+*VX,5\YZSI'KZ*+!'X0I4DBD$+.!G07[9.X! M&%9KYIFJ(-2M#"HH1Q6"2P"C6[0^PWXM=V&M:!HJ!0#E>A.JKX^$E9HI#:>: MN2[7/A%Z+L6"AV,(Y^@>G4BLH6UJ!?#U2FT2V\F_$2[8;"HMV!2$XPP9J<2] MK]FVF2.E2,HCG+1(VY:0$W8EI5_B43L#GWTCUSYN]P@C-0J'S8D4\E'(UK_K M,K[ZL;2>]L>3XCO)IF,<* [U:$'-J>! V/6_X6L\9L+:%J8^S5(XAW:%D=*! M?U'ZU@$6DLAU*\'<'?CVZL*^_N$.D8Q7CB);VH@%Q" #?)".%](F@P=R%67= MD1S*?_H:<6@'"7E!A1 ]@9:*U@@G"*TO%FZ7VQ^ZT]+['171JLYGA(VV7+@@ M[]W<*N@HV:$+/37251G=!)=]':&=!TDBBF.M/U0'HZK"10IWK!;]8DY1@V5; M1 Y^M@L)P U+&TJ>DL@NM7:O$1]0B49O>4(JOWYFB1B MGP<"]WQ.6#AF5>PMWF=_X6QTZZMF-QYT#N+@&%X*73)29?*_./F%T#:-)FZ% M4.%!$;M?5SQ1:%W!-QVU030U]P6!/R=>;94:%?#$8?YP4-_NZ7;W_-C3*HZW M6>9/TRG,DO'L-,GS<>_+4Q+/DC$.^6P\9MYVE(S&D]YG[4!,/L;Q-$M&6<[R M+)F-ALEDEK%#%[/!SK49EXI%^#CP9P9HBS?H[=/M]\=5O'8_+(\?+T@ ^H-E MDBJ8IB?3<9^9^$$0)TXOPR4<\L65/@QK?$.1\0OPOM)05C?Q&VR_RB[_ U!+ M P04 " !-.:Q:O0B3)EL# 3" &0 'AL+W=O9IJ%L ML%5AX3JTO%,[WRKBJ=^GH?.HJFC4FK3(LE=IJ[1-MNNX=NNW:]>3T19O/82^ M;94_7*-QPR;)D\>%#WK?D"RDVW6G]GB']*F[]3Q+)Y1*MVB#=A8\UIOD*K^\ M7LGY>. WC4.8C4$\V3GW62;OJDV2B2 T6)(@*/ZYQQLT1H!8QIQRF4#9 M!W+MT9@5M-J.O^KA&(>9P47VC$%Q-"BB[I$HJGRK2&W7W@W@Y32CR2"Z&JU9 MG+:2E#ORO*O9CK;O;.E:A(_J <,Z)4:4];0\6E^/UL4SUDMX[RPU 7ZV%59_ MMT]9R22G>)1S79P$?*_\ I;Y&119<7X";SFYMXQXR^^Z!V]U*(T+O4?XXVH7 MR'-!_/F4RR/BZFE$N227H5,E;A*^!0']/2;;ER_R5]F;$WI7D][5*?3OIN.T M=9XO8(X 'QN$&]=VRAY>OK@H\M=O F!=8[P*H,>CQ,'QBA &!0%^@FR1PX^@ M;#6-^>X#,10U'A':,>4H*0=.6-E,&8M6/%B=\84-W7>OX[T> M5 "#(3"VLO!#)&RU,;(GM#M'S7_DOG'<0@*A);Y;1[3.:P8_H/)GD28"T+=H M@0J!53&)+'K\TFN/K4"0@U)UFI317S%RJM9YDHF40Y0DJ_C0H9?V12JV'YG; M2A/77XB4G^[&4/2^<\QU!D.CV99IN)7.T\01"51)_^*3:BV*:QV^J-FZ0Z+W$D6DDJ/R$1.G/E^&_KS:H-*,)2^U=&XV+ M?)%)Y6*%7AD(G(6>G#^,%)Q^?H*T.?R/7C[5#=)9HV[1[^-S%*!TO:6Q9T^K MTXMW-3;Z;\?'YY)#L9&PO M=V]R:W-H965T2;?(F3)@&2 MM-,98#,-DG;W8;$/M$3;1&E20U)VLK]^OT-*LM+:F5V@<$3I7+]S92]WQGYW M:R$\>]XH[:ZZ:^^+B\' 96NQX:YO"J'Q96GLAGL<[6K@"BMX'I@V:I .A[/! MADO=O;X,[Q[L]:4IO9):/%CFRLV&VY=;HY6KMZ<7@^K+@*_$D M_+?BP>(T:*3DV$Z /!/Z38N=8S(T\6QGRGP^_Y57=( M!@DE,D\2./YLQ9U0B@3!C#\KF=U&)3&VGVOIOP;?XXW4?DS)7F942[\LEVD3<^[+"N=-YN*&19LI(Y_^7.%0XMA/CS" MD%8,:; [*@I6?N2>7U]:LV.6J"&-'H*K@1O&24U!>?(67R7X_/636 %BSW[7 M,V MS\:CA*7#=/J&O''CY3C(&_^%EX^B,-9+O6+_NEDX;Y$3_S[D;I0V.2R-ZN3" M%3P35UT4@A-V*[K7[WX9S88?WK!UTM@Z>4OZ_QJ1MX6,TCX[((A]70MV9S8% MUR\,A6VY%XY)S3S>?^L_]1G7.5MSQXP6%0&AY2I1?LT]DPX)J%&Q.:.R8IG1 MSBB90U9.%2)=OZWGW2_S='3VP:&$MT*7T,>M8(65: )2O;"5T,&.'-*M*5=K M)KUC2F:H?!'L08XKOC VNL!75HA@S4[Z-?LL%7I1U,BSS)0Z6%S HDP*ES X MDPN76;F BLK5J@4QLV1.KK1^4*3"&HV MEF+)Q+/(2NI 4 IUPK(3=O?I"SL-%I)1D6X/>BXR&7K?AG\G\KLO'^]!';%W M 1F88;(00^2A*6V&)V^"M+U5Y"6^ <;*WF-!NR?)I+DEFHY[V8'5&\]5(RWP M,J$)G>@'V4E6<.>$BZ_,%L8 ,H444&3/7B3?D[E&]Q/PA9)31 MJYX7=E-[U4,31I9XRLN5S-C*< 6 [@":=+[)/;^6K@E3#V$*F6,-S$3B^ .Y M$+ I@/'$BM(6AO@!HMAR5<80(=B!3FD@NX,+?1FZ1.V8QIHA-5 6[$0AC*>DAQJ*X([LQ&-)+!"W,5IZ>+PH\Q6XD$&NI.C[ MLF7^/LW:Q@&;4.51:71EB29B=N2C#]D6.C:*YR)T(4*>Z-"AA"#+ M:-@)&G8H&DJZ>E8%7/ PN>A\@9O*K%[J/MSY&IC;DW+/W G,Q-@Y"3W*E ZB MW&GG,79-]C8[9$QF(_P.Y[- .IT=)1TEXW3">D26SH9OD)V-ARQ-TG&0> [QQTA!E(ZB MQ//A_!C9>Q(Y2MDD2:=SHAU/CM.^9STV3L;#8>>C=!FUF9>CZB?)[.P2:5]+)JN 998-E// 3K% KF M9[,8F,\A,#-STL%. MX^$L.1]-<'B/&<_^@/>;!213%B5L1S6J,\\*M):F3=/^A5*4AC8 8X'L?T)SZ[-/-1 +\6) ^/U*1P:X1 \WD!\]R8S##8:]#WC=\Y=#4!$B.>42[0%E;+P *N8A9C7[ M]O0P@FMKN:#VE-3P>/,,;."U682-L-DU;1SI]RK?KHJNU,Q3F1XP(BPU2D/::2A U)8W;2Q(Z= M/:DRONKS(>K6;.,N0YE2??#\N9XS=?NG?:PRA=HZXBEIM2'(XAP)>]+KU46% MEA]OL+1)5=M)BR:*:DTT2B#<[AB&Y#H)OTS\64J,TR:'L!Y^%W%2."QNMFH! M^'?&PO=V]R:W-H965TPDMUYL?F!WW^Z^_1#/5L[?A4*I*!Y*8\/YH(BQ.AV/ M0U:H4H:1JY3%FX7SI8RX]?]+*(]&!\<5;)I9JI^*6Z];@;=UIR72H;M+/" MJ\7YX/+@].J8SO.!/[1:A=ZU($_FSMW1S4U^/I@0(&54%DF#Q+][]4X90XH MX]]&YZ S28+]ZU;[!_8=OLQE4.^<^5/GL3@?O!F(7"UD;>(GM_I5-?XPP,R9 MP'_%*IT]/AJ(K [1E8TP$)3:IO_RH8E#3^#-Y F!:2,P9=S)$*-\+Z.\./-N M)3R=AC:Z8%=9&N"TI:3,HL=;#;EX,4O)$&XA9GII]4)GTD9QF66NME';I;AU M1F=:!;'77NV?C2-,DX)QUIBY2F:F3Y@Y%!^=C440US97^;;\&) [W-,6]]7T M684?I1^)PX.AF$ZFQ\_H.^SB<,CZ#I_0M\OAOR[G(7KPYN]=#B=]1[OU42V= MADIFZGR 8@G*WZO!Q]2A/7I.^\67H"ACUR%J$%.%7?A^3H/X M7"@!I)7TDLL%+S-G V*1XWTN%MI*FVEI1(AX@+J, 57Y;ZWAGHB%C/BCQ#M7 M5M*N0=$[)52K?2C^J?-EDI$V%S*@"51DIQ$MY5K(Q0*EREJ PWFR*DO*2B T MD%$1FHR6VEJ]EK#RI.)*E4L7.Z,6VI2^[FG@7KA-](P* J-GN416L-PO%8V M4ZP++^^EUZ[&.4#QCUE 49LKH^$2A0S7\%4&9^79^>AQ]@T7:2X ^12*XH, 05ST*E,J*N(!3 XT6F?5:7T$&F.(XK5YN\ M+Q&#^UDD?K;YH8+.-2K:)X(G_S=, MJ3$'?'."_.AS@7QR-M=\-Q+O"FF71#7;KU5/7%C0<$KSE:'SI.]LS,0*U< M^CR(*X=_8N_#Y>QJG]*4ZC@T[P6(P0)SE^M=0T&2"S#;54I#9MA7W/RQH''U MC,07:U1H&L6*"$G]NP;U>;;4#8^A\ZO0D*& M.\]QN)PCJ-AK#I.3%.T6 M\N7L"[]Y-?EE* 808!Y_E@^TGWUV%?K"R=%D_U3A[MF$.*N,M):@L$CI95" M"EQ%#:"V30=/RP2EC'50RR,)0"32Q30I%G4$=C2Z@$$"5C4CKA^.#3%) +:I MRZ6F$N#94C=H%N1BE[V#8]Y,C[9')JE+/) M90>L^HVHT+#JZ$E6';V:'/98-6MU"\[2P5LPF4),V,DCKPKZ<8;(- +ML>LT M$XEH1Z;K=#IYQ8S]YC0"\0C'=3=LGZ=M._E*AS^YBE*; M[: T&\&F_60PL<3:DE:";H'<2TL=>:S*RKBUHDR4])91#J$=<4 JTAUOD"7% MZ"L_V6^W0AY F?* 8EOU,-H,//Z%8"EQ3;87LML:VG+K,DV4@K^4LT?T7,!% ML&*-]?#[Y'R=\)(5'T M(+DWW8=T_-:@-"AQ:/*=PDV&FK5B%Z;_0;'OVF7&O:\#I?)+_@9"DPQ#*'TH MZ)YVGUDNT]>%S?'TC0:_ND&"((Q:0'0R.L'NXM-WCW2#FN9O#7,7HROYLE#X M&>7I -XO'&+0W)"![N/3Q7]02P,$% @ 33FL6I#A%+]/ P 2 @ !D M !X;"]W;W)K&ULM59-;QLW$+WK5PPV19 "^VG M/BT)L)P:*1 #ANVDAZ(':C4K$>:2"LF5XG_?(5?:R(JL]M*+R%G./+XW)&.YN"4+)1Z=L8?RVD0.T(H ML+ .@=&PQ1L4P@$1C>][S*#=T@4>SP_HMUX[:5DP@S=*_,F7=CT-A@$LL62U ML ]J]QGW>GH.KU#"^%_8-;Z#-("B-E95^V!B4''9C.S'/@]' /2'UDK./%[V[Y(_<5,(Y50;^.MZ8:RF6_+W. MTKVHO![/V[I!]?72","BUIK+%:W,X7W** !)HQW8\9/"G+1.<#ET1)U8;)I?G8N6%F#?B]YK2A MBQYWZ/+B"[TP#U_6Y 6_09*'PSBAB9>07KV:-8N=AI%+!U6%A07C>'/+D4"_ M=A^[\*0]S1=8<"%,"Y#D@S ;]D_M)F:EMJBE$P94(F5!PVTFEQ^AQDH M5"UM4^C;KVV;O&ZZPT_WIL=2)"+[S2F,W,]W560D7UJ=R 0,M:JHH:W*K"UQL%-'=! M%?>C(!CY%67"6\[=V8U:SF5M.!-PHXBNJXJJQPO@2_L=R4"V_B MD1S6M.;FL]S] FT]CF FN7:?9-?XCA*/9+4VLFJ#D4'%1/--O[9]Z 5,@C<" MHC8@36$8R> M"%Y$!P&1X"F)PR&)@B@]@!=W!<<.+_ZN@G\_7VFC\(K\L:_D!C'9CVAE,],; MFL'"0UUH4%OPEN_?A:/@[ #?I..;'$)?WC9J(7)-KF!E>J2'Y'Q+&;>EG* Z M3S3EL(_]0?S][.]*(&O)4;%,%*3I5B-;]A=VRZ#Y4E8;*A[?OYM$X?A,XYWL M^II;GKK',^-4:[9FD!.J"?T'Z]G@ V6*?*&\!G(-5-<*4/A&#\XKJ0SFS,E' M);5N/ZWWX(@))")K346NCP?7;^:?#>Y/;T_)G7+ CV3%.-?D)Q(FXV$X37 5 MA1/\/"+1B!RWAG@R:L(*N04E+!N"+RF18;S$A"0,AM,@(3&&A1CEMJ,!!J>3 M83"U>%$4-JCC!A4-T33Z@5(;[_^@X/%H&"137,6CQ%&+IPTU-,3CY%\*CH9! M$)$P).Z91V?N)(QMS1.L.;75QN/T!3 :XLF8'-!!VND@_58=N)YL70>Q%6VC M[@66RUW_/N$>;RF^\Y_%LD\8AQ-^@P;6+XD4CDC]3(0W1&A1*"BHP9/5(\EP M44BLQ(98% ZB,*4MS.#/'1Y10YC(V9;E->6]YTI*N@6R A!HQ_#7J -JG^E.&LH'O5;?OTKV0Z;7EWC_ M14WCX60Z[DORI/U_93E\8Z/A-!VW^CS!O]X>+VTZ&D[2I*_0+LE+R^ *,JA6 MV*:VG\G_K9\)ZCX<]87Y5.HKR^ [?/=IVN\-(A6HPHU;FF2R%J:92;K3;J([ M;P:99_=F',0;7#"A41UK# U.QZA6U8Q8S<;(C1MK5M+@D.26)4ZEH*P#VM=2 MFJ>-3=#-N(;BR(]EU9R.?%*W2HNJ4$4'%:O>ESUT>WJ.0= J)Q>T<692?J*:S MB10[(LUIM&8$&ZK51G"L-D59:HF[#/7T;-DV#0?,LJ:*W-8EE/_4#Q%LCSC9([Y) MSAK\0N5'DL8!2:(D.V,O[3.06GOI&_:^R@VMV5\VSH#,1:T$9Z4+F]8E64A0 M)CUV0:S)':LQ20S3M<1%FSI%_KA>*2V18G^>RI #,#@-P%R[*]70 J9^8WS) M)_!G/_X0Y]'/9\(;].$-SEF?+?$:ERT' WTA\3)+_1*0!19:V_!NO[>L,4&< M G[6]&G@>Q_6..R-!Z1&1A687*8P78A%;X&L!<>FP.K-E8=5+;:VK)^@@&H% MTDP\4V-3Z('W@=6H(UJ%=M6E=T]70E(MY,O!";D@HV"\.?=M;)FNL45$\6:/1M9D3@8#S(W>O> O6 K>$E8 MU4CQU!$A"4;#R(V>X9*6K6L_"!^/;= ,'HIC$F>)%^=!E@P(?@:YL:C4%;DN MBK9J.3*KQ.Z">46JN2MH@AIEY-)*:9Z22^]RGDO9 MN[F$.&6+&&^?\?]!87(,A*]854GFK90FU_>,KAAGFN%NMW:*9&=]GB;9WCD< M.Q?6>=$YYT?.65WPMH3_R[D%?9&H[9)=-5R\ /PDP=6J$(;8%R0-XE'D&)C% MW@,BMEZ,3@E/^"?H>.B.9T$2YSB.XMASN4-R#4Q2F*=/_%NL%B:,@ M'0Z,@+P:#\\5/N\+G[^[\ ^ U[A =WU'G%/E K2":2A/E-O;8!8Q!5JRPN3( M[)]BP%GGIQGPB*64_T)2[)%8 5XAD0W=KI!/:-[U"=>Q2Q]SJI==TFK\)]H)D(^Q0"0IY',1YZCV\ M@IX$63YTH[43O"]BM!<%X[%I"GF*'(M.DB,\>DY4(#?VT:0P$9@J][+H5_MW MV;5[CAR.NT<=!K]AM2(0F6C3V<;(2&I\Z5MSBVQ*D.8#[ M:R'T?F(<]*_5V=]02P,$% @ 33FL6LU>[IM)! G@H !D !X;"]W M;W)K&ULK5;;;N,V$'W75Q#:Q2(!5%L7Z^*L;<#) MIML%NFV0R^Y#T0=:&LO$2J1+TG;9L[,Z!R..=D)^4VM M #1Y;!NNIOY*Z_7%<*C*%;14#<0:.)XLA6RIQJ6LAVHM@5;6J6V&<1AFPY8R M[L\F=N]&SB9BHQO&X482M6E;*O>7T(C=U(_\IXU;5J^TV1C.)FM:PQWHA_6- MQ-6P0ZE8"UPQP8F$Y=2?1Q>7F;&W!E\8[-31G)A*%D)\,XM/U=0/34+00*D- M L5A"U?0- 8(T_CM@.EW(8WC\?P)_7M;.]:RH JN1/.557HU]0N?5+"DFT;? MBMT/<*@G-7BE:)3])3MGFX]]4FZ4%NW!&3-H&7P,]4#D@2!20.X[0'+^EJ3BQ>\EK-*RKA5,US*2FO 36GR6)/CNUNZ-YN MSW=45N27'Q&2?-+0JE]/?2 7?W0ZOKEG%VI-2YCZ>)$4R"WXLW=OHBQ\WU/= MJ*MNU(<^N\-[6VT:(&))'+N+OU9Z_6CF<"KW7O33N=^OP,)3OL>+6@J)O!-U M%+L\C@TN-F&<:'1J*.UBN1,,J MM#?Q<# <*5,Y=BUIPZD+[WXE 5Z(DJ"DRI71E&+ MU5DK7.(]WV+_6EL)O"5),"XR.Q9AYGT$CK$::TZ%1J.W) _B-,4Q"_)H3'H(3SO"TW]'./EY[>1L.A[3^U,L]T*^SO(S6=JT MAT,O9[\C589+RSE^^^>&B^'12=I3;7EH'0_PD@=[MR^\GS;M J2IY*OMIVC2 M3>9U+:%&DBU3>R0'67*E(N4;C0+@E4F-6@5\@!(LV %]1*)QD$5I$,:)H6$P MBLR/F<=!E.9!E.?>1VP )M8H&&5(5%B8TT$Q]JX?09;,B.Z,1$&8Q>0]EZ21&,441:B.WKCCD@RS"^;LW11S%[SLD M<)G8SW\2*4*]):,@BAQ2'ANXXAFI3W-9I[FL7W/N/]Q$QWNB)2O-5W/J>^!, M]VJO%_H_:^_V[N'_DMQ\BQ>Z!N^!;[$XW#!7^Q\I#"4S#I+$B*H8C.-.3WD2 M!T42.BU]<:!G),GS8%2DJ)9B4&0>/C.6P-Q1G C.T(&O[,E+84C=,G:[P 0G2&.#Y4@C]M# !NB?I[ ]02P,$% M @ 33FL6B?@R(7F P PD !D !X;"]W;W)K&ULI59M;]LV$/[N7W%0BR(!U.C==ES;0%XZ;, :!'6Z?ACV@9;.%A&*U$@J M3O_]CI3MQ)WK%=@76Z1XSSUW]QQ/TXW2CZ9&M/#<"&EF06UM.XDB4];8,'.A M6I3T9J5TPRPM]3HRK496>:-&1&D<#Z.&<1G,IW[O7L^GJK."2[S78+JF8?K; M-0JUF05)L-OXS->U=1O1?-JR-2[0?FGO-:VB/4K%&Y2&*PD:5[/@*IE<%^Z\ M/_ 'QXUY]0PNDJ52CV[Q6S4+8D<(!9;6(3#Z>\(;%,(!$8V_MYC!WJ4S?/V\ M0__%QTZQ+)G!&R6^\LK6LV <0(4KU@G[66U^Q6T\GF"IA/&_L-F>C0,H.V-5 MLS4F!@V7_3][WN;A9PS2K4'J>?>./,M;9ME\JM4&M#M-:.[!A^JMB1R7KB@+ MJ^DM)SL[OZ.Z_ZZ,@7O4L*B91CA[8$N!YGP:67+@CD7E%NRZ!TM_ );!)R5M M;>"CK+ ZM(^(V)Y=NF-WG9X$_,3T!61)"&F<%B?PLGVTF+8W5)(Z_CL7;P^7'X5S#3$S+2IP%U!$&]1,&\W=ODF'\X039?$\V/X4^ M7U #5IU 4"OX-_$0KIGA)3!9P2T7G?T^X7T IUV\0%0]!$C2@W!Z:,F1\1EB MUFJ^[*Q3!5@%I6H:ZB>29OE8*U&A-K!A!DHFRDXPAT*KE1+4\&8R>*@UXH$P M@,I:UJZN@S,NP=:J,\3!A(#/);9VYY=H$8N!J[T30#ZXZQK4S"H]&=SM>+Z% M,\@NP_%H".?]8A1>)CF<#VY1*NJ8_OQ7WYY8O6=/!+'&@RB ;BMCR1^E&-Z] M&:=)\L'U^G>Y>0M)$H=9G(1I,72K>!PFHR3,A]D+'Y>W';8/XQ3>&<07V8XX M/19P?D(XQ5XXQ4\+YTI:[OW1W0<++#O-+4+E58-W*BFI0+[>_*H MVHY)ZR2)X[WQ4*/WQ>0W5^N>@:7-7BTN_:VR2)R9.,@B:<.C2)GUO\22=09I MQ\7H:-&YA@94)RJH28+T0UU"$5"H[_?UP=6*AM5_M,Q+.RQZ[;8N'.-(MAT= MHN0.!61(6U$I)48"SS<.\ M& X>E*7"I$68Y>,P3U)(DW"<9^%PG, QX4:O!A.U[MJ/7[HI7-GZ&;7?W4_X MJWZPO1SO/P\H 6M.80I&ULA599;]LX$'[WKQBH19 $2JS+5V(;R-%F M"VQ:(TEW'Q;[0$MCFZA$NB1EQ_OK=TC:CM/$[HO$8^:;;RZ2_:54/_0,T;A0<^G1F[T!SVYVR*CVB^ST>*9LTM M2L$K%)I+ 0HG@^ JOKC.K+P3^(OC4N^,P7HREO*'G7PI!D%D"6&)N;$(C'X+ MO,&RM$!$X^<:,]B:M(J[XPWZ9^<[^3)F&F]D^3%I9=->@'DM3:R6BL3@XH+_V?/ZSCL*'2C/0K)6B%QO+TAQ_*6 M&3;L*[D$9:4)S0Z^9.H0$-KP_/5,W:GR/ZF&PIQG"1);4 M@]9I8Q,,CK,P&@QMWLAJSL3JZ$,WB3N7&O3:(GJ+I*R-/U!H>CE@UO[S=\-07C:>O=UD[@8(KZGQR4DX5J[;[ MA)&U8_I&W;83;;7WBL9AFF1P9L62=G1 K)-&D(1)ZA![!+]/E(22V"/VHNX^ ML5,+&2>0A4FK:V73;+_L*9Q!&J91U+CE.I<+5*N]YK.PW>F1[ZTX;HQ0:2D$ MEF<*2V8H%2\.I6&W%4&M_&9Y;SDAM.&3:VD*E#P1L>&M44&NIVV3\R= M2\S5CLY+BKZY^2\EIN&8G4 W["9M2G":1(U-U0NZG$I)F!_A&-*>M0$G?M() M>W%&DU,ZP> K>5^-"=E640A+).-"UB(GHC2APW0^MYR%HDYPR-1:MJC7Z1C- MZ'R'N)E 3OW#_)0*W))^>%2463_<^?N^::[-8QQ)4GRE3_;D!NKB M. M_5&NUL[0\BL;.84+S^@2_M637&JZQ.'4Q>N>K=X+E8U(86M)T E9^SN! N7K M, 0&WQ]',;DVXV-NI HWX3'RF6)#7LNQ.PL+<'U,8$0&4!,+#^;.7@\J:[4W M[&\#LB&\&XO?N6J+:D^]<9&7=>%YOJFU]::&*0I4-JE$@!5T!W-[8=C'Q 8I M)&&#=)H:JR4K6O 5[V<^ZTHNN'O*V$I9;QCVC/K\O;NBN7.E5ZBF[N&BR:=: M&'^[;U>W;Z,K_R1X$?&& M,WK?H;("M#^1TFPFUL#VQ3C\'U!+ P04 " !-.:Q:*^'GGDX" "=! M&0 'AL+W=OYCVX";7QL*Q@^VT;'_]SDX:%8GRDISOQW??ESLGW6GS M9$M$!R^55';*2N?J2139O,2*VX&N45%DK4W%'1W-)K*U05Z$HDI&21Q?1!47 MBF5I\"U,ENK&2:%P8< V5<7-WQE*O9NR(=L['L2F=-X196G--[A$]U@O#)VB M'J40%2HKM *#ZRF[&DYF(Y\?$GX*W-D#&[R2E=9/_G!73%GL":'$W'D$3J\M MSE%*#T0TGCM,UK?TA8?V'OTF:"].X6.SUC MCY=K:<,3=EUNS"!OK--55TP,*J':-W_IOL-!09(<*4BZ@B3P;AL%EM?<\2PU M>@?&9Q.:-X+44$WDA/)#63I#44%U+OO.76,0]!IFP&,AN>0Q,D8'I?7<'IR]AHF(I6]U*27F@34M82^#SVP3\_9K8 MFN3^@<^-V'(9^'IA=-N>:#8K MB6 Q;PQ-#]^<2]O@:VC@;_,V2X87@\LTVA[RB@ZVS5]KUG$'ZY:1NMIP5VXV$= [-Z!?!/3/#1@4 8-S X9%P/#<@%$1,#HW8%P$C#,YY+]?]N-; M5-+I1/ '(M*U%2V=R!241:O?/(Q3L2^D4-^&*DY.E4@BNN2"9M*;;01C2LHR M(1=DMEJ%Z5(:$3_.#ZMTG3<6DS2,DM\G;:D:D&+:09'L.D]F/I/,(#<\EMN$ MV/&*K6KB+7U\]Z5XYX7\I@;05GONN/O,I]UW;6J)L\/F'>D:;XG9,3ODT\(B M;W[]G=P*OA%T5]/ N1[W(9!/.&.DP5AZS T5QU;UGUI5@['/Q_0T&$>/L5AP MLE'/8]RS,=K6>'K,@NT5II-A# W&/[\UG7I,15#=X_'8S;B]9[C9/G+#2%VW MRJ.1?+YANR43_]0=>JV\3/8T8%EOOQB#SA]U\D3"+"3, M1L(<),Q%PCPDS ?!*D+N'875^0]RRP216QJ3 M:M#G]XI)?,EV2:WR>TCE(V$6$F8C80X2YB)A'A+F@V 5Y?>/RN]K3^%_'M)S M->%K$H6!*@O8BNP%7QT"2?[37-.OM=2FO7:?=X14/A)F(6$V M$N8@82X2YB%A/@A64?[XJ/RQ]BQ^IXA4!%LBF:CMW.K#A^11A2=U&M4&-M4H M$F8C80X2YB)A'A+F@V 5C1J=\EYWYZ=49@7VM)HROBNGYOK4384*I=E0F@.E MN5":!Z7Y*%I5KB?6C/&SBC0]N6D_ 4JS"EKE:#+[M84:-+$#I;E0F@>E^2A: M5;AF*5Q3*]P;5X'KQEJVJIA9,A"PAUQ>&*JS8 MF@FA A:2!U^T-W;UF1MK%DFSH#0;2G.@-!=*\Z T'T6K:K_TS8S!:]_B-: . M&Y1F06DVE.9 :2Z4YD%I/HI6/09*Q\[06W9-^\O#'Z]$S]1V4"L.2K.A- =* MU?C,"[77H#0;2G.@-!=*\Z T'T6KJKET MV8SQJ_<^D'[/'$JSH#0;2G.@-!=*\Z T'T6KOG!1FGBFWL3[J$2>T/Q5J;T( M T9H%/& 2E5@2D[V3&3OJL3J"[Z,PDWVUDJ=TO5YFBH=2K/,&L=Q/*[U2*") M'2C-A=(\*,U'T:HR+LT]4V_N+;9J_N/8\W#62(]'WF M4)I5T$YEV!W6RQ#JTT%IKEECA?9&M3*$>G H6E6&I0=GZCVXZGNH=[D"3V\H M-RKD],D:RQ3JXD%I-I3F0&DNE.9!:3Z*5I5[Z>*9O=E65":#:4Y M4)H+I7E0FH^B58^!TD8T]3;BG,=2J$*./(1R6XQUH*0>A7091MEMY:(CDCX\ MQ#=Q^&_]LV[Z-(V%#O4,"UKE[:!>;9?DQQ4'=7T7!]H^%TKSH#0?1?UR:#^)R;5S.L[%.OEMN&9=VW?*9<3G+ACIIE_A\ MQ)@;*C9AG)"(K56JSKNAVC"1#\*2STB^ST;H6'*ICH%L&PO=V]R M:W-H965TGB.*G&RU>; UHH.=%,I. MH]JY9AS'-J]1,GNF&U1T4FHCF2/35+%M#+(B!$D1ITER$4O&591-PM[<9!.] M=H(KG!NP:RF9>;Q$H;?3:!#M-Q:\JIW?B+-)PRIS U9<8]2<(G*R4KK!V_<%-,H\8108.X\ J/?!J]0" ]$-'YU MF%&?T@<>KO?HGX)VTK)B%J^T^,D+5T^C]Q$46+*U< N]_8R=GG./EVMAPQ>V MG6\20;ZV3LLNF!A(KMH_VW7W#=)@HLKYECV<3H+1CO36A^ M$:2&:"+'E2_*TADZY13G,E(CV$H;%NYH5AE$NG)GX11F1<']+A-PH]KR>Y\W MU^@8%W;P=A([8N!QXKS+=MEF2Y_)]I69,Q@.3B!-TO.GX3$1[]FG/?LTX(V> MP5O@!M4:3V"!_@%R5<$<3>"J!58'T"'W<-/00LX!N7WD^7L*0C6[*\ M=5@Z9AS0)2+>,6)F,"2L).S=]3'IAT-K>%T$]IQI1TU M=UC6-$W1> \-W>#^?L]]02P,$% @ 33FL6C0\:#/&ULS5EM3^,X$/XK5FYUVI4X M$CM]Y=I*4)8])#@A"GL?T'UPVVD;D<1=VVE!NA]_=AJ2!EQ#($C] DDS\WCF M&4_\V.FM&;\7"P")'J(P%GUG(>7RR'7%9 $1%8=L";%Z,F,\HE+=\KDKEASH M-'6*0I=X7LN-:! [@U[ZVQ4?]%@BPR"&*XY$$D64/YY R-9]!SM//UP'\X74 M/[B#WI+.803R=GG%U9V;HTR#"&(1L!AQF/6=8WPT)!WMD%K\#& MMJZ13F7, MV+V^.9_V'4]'!"%,I(:@ZM\*AA"&&DG%\2L#=?(QM>/V]1/Z69J\2F9,!0Q9 M^$\PE8N^TW'0%&8T">4U6_\%64)-C3=AH4C_HG5FZSEHD@C)HLQ911 %\>8_ M?@J1!*+XIP-O1*?KZY1OZ@H(8W2Q8(F@\ M%3U7JC1T,.XD"_ED$S+9$?(EY8?(QP>(>*1I&5%[H(J#C( QD %N,*8X*AK35WRSFSRB[NU #H',)D?C71,XF MFH8Y&MWU1V)))]!W5%L+X"MP!K__AEO>GR:J:@(K$>?GQ/DV],%YO (A]70[ M0#>/2T!WWQ^D?D&,0T#?XR0"3G6K&UFP0ZLI'Z(:G!7Y$JN*A,68K;-6B;<":VZEY M&!-S:IT\M8XUM1LFU<))TPELRJ#SP5$LG;JW=1%DY-W-6%5B9O2U_BMZZ:4[UJ MBGS5-*:.7S9$H^UW6L\:PF37;OGM'1V!"S&'K9+G'3WQ@ZV Q]H*'<\AGJCF M8.H=:VT.>Q"5*_P9*@X7,@[[^]4>5IE6F;R:T,KD%6H/V^5>Q?9H&!:IKO>B M.PQFQ,/^CN8H-!FV*I?!!:P@1'B[!3XF5^WC52[E9^@N7 @OW-JO/K *PM(K;JN+K0R>86N(W9=]^Y-FQVW,@L&(;A[ MVT:V#O7L.O"UQL[<2^,V.Z1+GG6VR:[;:72[.P(L5!>QGT9]J+7?L9^SAU.Y M;)^ANDBANDACOSJ_UG.YNM#*Y!4JD-A58#7)FH&]NJ,SV5EV=*209<1^(%9+ MH[QGDV>/JW+1/T.?D4*?D?9^=4RM9WMUH97)*U0BL:O$BAW3>7G(:MCDFVN[M8 @ )08 !D !X M;"]W;W)K&ULK95=3]LP%(;_RE&&)I VDJ9MF%@: M":C0D(94P6 7TR[]_BCZ4;I!ZH0 M#3S60M(LJ(QI3L.0\@IK1L>J06EG2J5K9FQ7KT)J-++"!]4BC*,H"6O&99"E M?FRALU2U1G")"PW4UC73O\]1J,TL& 5/ S=\51DW$&9IPU9XB^:N66C;"P>5 M@MK_@GN.&MMK@G"R5>G"=JV(61 X(!>;&*3#[6>,% M"N&$+,:O7C,84KK [?:3^J7W;KTL&>&%$M]Y8:I9\"F DO6"G.C-E^P]S-U M>KD2Y']ATZT]F020MV14W0=;@IK+[LL>^SIL!<3Q,P%Q'Q![[BZ1IYPSP[)4 MJPUHM]JJN8:WZJ,M')=N4VZ-MK/)AGF?^KQ+'3^3^IKI8QB/ M/D )>#+D?B<[BKN,ZB-%SOP)H,6),WP(K_8HUV874YIONQ MI@/6]+58@K,E%_:4XO^5;/I:MF1@2]Z*;5_=DKW;&6[=>O> VONTXI) 8&EC MHN,3:TQWCU+7,:KQ#\%2&?NL^&9EWW'4;H&=+Y4R3QWWM@S_#-D?4$L#!!0 M ( $TYK%I^PALXT , $00 9 >&PO=V]R:W-H965T"R&V2 M,/'S%F*^'QK4>+KQ*5JM57;#' TV; 534 ^;>X$CLV191 FD,N(I$; <&C?T M>DS##)!'?(E@+T^N29;*C//';/!^,32L3!'$,%<9!<.?'8PACC,FU/&](#7* M.3/@Z?43^]L\>4QFQB2,>?Q?M%#KH1$:9 %+MHW5)[Y_!T5"7L8WY[',_Y)] M$6L99+Z5BB<%&!4D47KX93^*0IP J-L"L N _;L IP X>:('97E:$Z;8:"#X MGH@L&MFRB[PV.1JSB=)L&:=*X-,(<6KTD8E'4&P6 YG"?"LB%8$D5V1Z6%;" MEV0",W7R\ VYV;$HSB%823)E>/%J@B11+%\C]&$Z(:]>OB8O2922SVN^E2Q= MR(&I4&XVJ3DOI-T>I-GMTGK$H6^(;=F>!C[NAD]@7L+=*MS$(I65LLM*V3F? MT\K75H8KW$U7>1F^?D 0>:\@D=]T"1]F>+R3^6V;UC0V8YS MTPOT2H'>>0(_X%BGSVO,?64'-7V:&*>OU^>7^OQ.?6]9),@7%F]!)\IO3(AK M:_?MFBY-6!@Z8:"7%I32@DYI#[UICWS&PLDM^M-M%,>2?/T(R0R$=L]ULIV[ MYRY$5DD\+!,/_[H!A9^:EW(@@JBB@?1ND]J@AS?;1%YTOSI96RHX*GZD%_7J EJ,R)Z;+NTLY$] M8T4%N+;,3MC0IHD+?"=H*^&Q$=+N3IC;T1W?@4CQZU:1FQ6D<_0ECM\\G;[4 MS7ON7KP46[4*QWY+W;_N3;2SIY]=D NQ50MR[.^TN\$_[T^TV;:IU;?J_J0+ MPS.:W?+>'AL\[>[P9_A3LX\[=9&:5M_R"4>/?9YV-_K?-Z>@Z3OU;SA-C-4B M\-B/:6>'>\Z9PN:G+:YOPY@T8;9%G9HX\^2(EYVO\7"TPO4B,2P19_4"S$P< MCJR'@>*;_-0WXPK/D/GE&H_Y(+( ?+[D7#T-LH-D^8^#T?]02P,$% @ M33FL6F5O,M7$ P !( !D !X;"]W;W)K&UL MO5A=C]HZ$/TK5EI5K;1+XD ";"'2?J@?TE9:E=W>A^H^F#"0:)V8V@9Z[Z^_ MXY -81.R0-G[ G$R9+ 2\E%% )K\3GBJAE:D]?S"ME480<)42\PA MQ2=3(1.F<2AGMII+8)/,*>&VZSB^G; XM8)!=N].!@.QT#Q.X4X2M4@2)O^Y M BY60XM:3S>^Q[-(FQMV,)BS&8Q /\SO)([L F42)Y"J6*1$PG1H7=*+:]HS M#IG%CQA6JG1-3"AC(1[-X.MD:#F&$7 (M8%@^+>$:^#<("&/7SFH5!KIEE8=TPS8*!%"LBC36B MF8M,F\P;HXE3LXPC+?%IC'XZ^,;D(V@VYD!&$"YDK&-0Y)R,ULM*Q)1\8K$D M/QA? &'IA'R60BGRD.*FX?&_,"&W.$8?7),2POL;1(VY^H!8#Z,;\O[M!_*6 MQ"FYC\1"(8X:V!KY&Q9VF'.]6G-U=W-MD38](Z[C>C7NU\WN-Q 6[IUM=QM5 M*Z1S"^G<#*^]$V^L2R&?DQ"MQ.W>[S_C7V+3[]>R]@KVW)_LSS;%-F\_MK,I]%DN0*3;GFES.( VQW GLT!K+73/NH2E^ M*K1M%3;G/^V\>LFCC3W&P8*<"&U;D$U+0??M*8XM>[3:0+A]KY*&C32.#7/3 MCM!]^Y$_*X\U[0=]'FDCDV,CW30SM+F;.;B,=O=:OM?H4^BF4:&-1_^1Q;97 MK:.5Q3IIRV&77L_-MQ%\CYW%J2(64# "S"P M&0 'AL+W=ODB18?N^B'JA\4>8!5[E^ZN(?WWG5T[CKD8*Z=2/L"N/?/,S#,O MS/@@U;/>(AIXR5*A)][6F-VU[^MXBQG35W*'@MZLI$,/ M$ERS/#5?Y>$/+ /J6;Q8IMI]PZ&4#3R(-3]&M4>O>EOOX3]X/>F\,\$=D1&MR*C MVX9>KU!=IR2.58X)<&&0C)HF#@K@O@.V\VP_'07V,_;W]>C>BX7=8[DCQWN5 MX[U6QS^0Q;K>Q2MHC:!P.%S#/E2+S385R/KPCROL5 MY?U6 _>,*_C.TAR;@NV_SW-O&(VB]Q71(#D<=H:#DS4QJ!PK6=K,%( M^E=O&'1 W5]:UFX4Q,4H2&D4H&ZBI[#9J]7NC]4]>E?=)ZHZ#-ZVB. _-%ZI M7+ML^K/9AC*]C M5&#HS& G_WYG@/!ADW$&9$@-F:3[+4%FTUH*L(@ MA@5#/(TBPIZO(:3[J8&-EQ>^!H];H5XP9Y.$/,(2Q+=DP>2=6:*L@PAB'M 8 M,=A,C2_X:FX[JB&K^![ GM>ND1IE1>E/=7.WGAJ68@0A^$)!$/EK!W,(0X4D M>?PJ0(WR;ZK&^O4+^FTVO!QF13C,:?@C6(OMU!@9: T;DH;B*]W_#<5 KL+S M:_R5,A1*T!#UYIL(L&^ZT-3M&0*6?FS+*Q M;H@@LPFC>\14M413%YDV6;><)HC5,2X%D^\&LD_,EFF2A"#/19 079.0Q#Z@ M96:@NSAWB5+[,UI* ZW3$!#=H 63-F+B^0(M9(- )%ZC/W^E0:)PT,<;$"0( M^2?9]6UY@SY^^(0^H"!&_VQIRF4MGYA"4E<$3+^@>9W3M%^A^4#8)7+P!;(M MVVUIG^O;;\ OVP?-=E,*5JIFEZK9&9[S"IY>@'_O93FZ$Q#Q_]I&S;$'[=CJ MN;WB"?%A:L@'DP/;@3'[_3?L67^T#=X16$,&IY3!T:'K9;A ?S'*6\\Z1_4R M5/4YLYMASU4'LZM/UE8U\-RRJD%Y4%(>:"G? ^=7Z(OOIU$:$@%K^B5/3R\J65%&!&7/]:?@ :(5L-8G0 MW[A/0$5AC\F$Y^;#'#X)A MES)T!-:0853*,.KE@V!T;,:QXQTX]D11@_"X)#S6$I[3*$D%L#?Z50MV[D%U M!-:8&UO5][W5HV,+\(Z4Z JM*44M^N!>7%O UAUI#YSA@6U/535)5\D#:[_1 M*^O%O'L(^L(K3E_E9&PUZ=[ M.XU,7:$UI:A"$]:&D?>[=WALS/'@R+XGJIJDJXB#]1GG'@B'+0W7Z"Y*&-UE M_S2?\*\6\>Q#ZPBM.7^5F/"X3_]V&J&Z0FO^\U]E*%L;3-[MWP*V$0E&0^O MOZ>JFJ2KM&/KT\Z!;%:XCQ*O:OH"*VI0&UIT^O6IMNU M31]1RJZBE-W/YL8^7LK8&!\:N&5SXQZN&,S:SE(MC!\(>PQBCD+8R"[K&PO=V]R:W-H965TU 3&):M3)X0#RXR;6QYMC!=MJ-7\_9 M24,[L@)2)5Y:W_GN\_?=6;X,-U+=ZPS D(><"SWR,F.*"]_7208YU>>R ($[ M2ZER:M!4*U\7"FCJDG+NAT$0^3EEPHN'SC=3\5"6AC,!,T5TF>=4/4Z R\W( MZWA;QRU;9<8Z_'A8T!7,P=P5,X66WZ"D+ >AF11$P7+DC3L7TX&-=P&?&6ST MSII8)0LI[ZUQE8Z\P!("#HFQ"!3_UC %SBT0TOA>8WK-D39Q=[U%?^^THY8% MU3"5_ M+33;RWG@DA24MN;F5FP]0Z^E;O$1R[7[)IHX-/)*4VLB\3D8&.1/5 M/WVHZ["3@#CM"6&=$#Y-Z#V3T*T3NDYHQ M@J&,ZS,,N9M?DM.3,W)"F""?,EEJ*E(]] WRM*?Y2!+RFZIQT.Z](&(3]%C[3OT_O':#3;6K>=7C=9_!N MU(H*]J,JX%0*+3E+*VLL4C)3H&T_G.-F2=XS@5UA6/@Y.EVO-/GZ$4')%9KZ M6UN%*P:]=@;V:;C0!4U@Y!7V-+4&+W[YHA,%;]O*4K-;&>N(5^ :NW*0:Q_[B8Q3H2V%ZQ!DVQ!@?OR"UH MHUAB("4)U5F;UL%O-S.,@N#)]?U#4,7-WYD%.:B5&Y&:)+(4IGHQ&V\UA2N+'Z3QV0\G_!5.-=GP/5TQHPF&)D,'Y &^BJL9E91A9N(FSD ;GEUMF M^(4!R@;@_E)*LS7L &PO=V]R:W-H965T+,=J#]][MV0D9I0)NT%^*/>P[G7/M>#S=" M/JH,0).GG!=JY&1:EU>NJY(,&C79G(\%)7FK("9)*K*W"'5MEVBRXXV%)5S '_5#. M),[)G#1/@W!"AC%\-I]/^I0'NCK?L'ZUW]+*@"B:"?V>ISD;.P"$I+&G%]9W8 M?(+&3V3X$L&5_26;)M9S2%(I+?(&C IR5M1?^M3D80?@]PX @@80_"T@; "A M-5HKL[:F5-/Q4(H-D28:VR_A+F:R36?0IC.P?.$!OAE]I@O> M9,2FB7)%?EPOE)9X8W]V&:P9>]V,IHJO5$D3&#E8I@KD&ISQVS=^[+WOLON? MR%Z8#UOSX3%V8UX*SJUWR$LNG@'.)7"J\:XD0NG.\ZTY8\MI>LYZ'/H#;^BN M=VV]#AI<1GX;]$)NKY7;.RKW#A- 99)9O2FLL:.5IA .2ZWYHAT54>#'>U([ M@@;^ :E1*S4Z*K6NK:2I(_ZGMKI41J\$^)?]P9[*CJ!^&'6KC%N5\5&5]\(T M$=HT!]AM#N)?#,2O#MOWPGYOST%'5-R[[.]9<'=:HWF6L%^L6*$(AR7BO(L^ MID#6K;Z>:%':;KD0&GNO'6;X.H(T ;B_%$)O)Z8!M^_M^#=02P,$% @ M33FL6G$R58?" @ ;@@ !D !X;"]W;W)K&UL MK59=;YLP%/TK%JNF5LH*X2-M.H+4ADWKPZ0J6;>':0\.W 2K!E/;)-V_GVTH M(PE)6ZDOX(][CN\YU]B$&\8?1 8@T5-."S&Q,BG+*]L6208Y%N>LA$+-+!G/ ML51=OK)%R0&G!I13VW6!2R2E)2P!U'HLISS/_> &6;B36T MG@=F9)5)/6!'88E7, =Y7]YQU;-;EI3D4 C""L1A.;&NAU=QH.--P$\"&]%I M(ZUDP=B#[MRF$\O1"0&%1&H&K%YKF *EFDBE\=AP6NV2&MAM/[-_-=J5E@46 M,&7T%TEE-K$N+93"$E=4SMCF&S1Z3(()H\(\T::)=2R45$*RO &K#')2U&_\ MU/C0 0S] P"W ;BO!7@-P'LMP&\ OG&FEF)\B+'$48Q. M3\[0"2(%^I&Q2BB$"&VIQ.D4[:01A3YPK4>($)I8Z4@3P-5C1QP_#D?.YS^#W)(O?B6S+?*\UWSO&'K6; M.=$-^.]FGX4UU&]KKKS7[4:!QXSG94W!,U'(Z\-FI+C=^J M\8^JZ>P.K:=/0TT0=-9U@]'%CH2CJ[RUO"^LN"4T:(4&+Y9ML%#S>,>%H!F\UH6=)[Z*S*6H7[,[AKF]B==2L2"$0A:7".><7BH;7MUO= MD:PTY_V"275[F&:F?@B ZP UOV1,/G?T%=+^8D3_ %!+ P04 " !-.:Q: MZ:08E]4# 9% &0 'AL+W=O9 A;G16GBAT$P\%/&A3<9Y>?NU&0D-R;A NX4T9LT9>KI$R1R M-_:H]WSBGJ_6QI[P)Z.,K6 .YB&[4SCR2Y28IR TEX(H6(Z]*;V:T:$MR&?\ MPV&G#XZ)I;*0\JL=W,1C+[ =00*1L1 ,?[8P@R2Q2-C'MP+4*^]I"P^/G]%_ MR\DCF073,)/)OSPVZ[$W]$@,2[9)S+W<_0$%H;[%BV2B\[]D5\P-/!)MM)%I M48P=I%SL?]EC(<1! >T=*0B+@O"E!=VBH)L3W7>6T[IFADU&2NZ(LK,1S1[D MVN35R(8+^QCG1N%5CG5F,I-IR@T^%Z,)$S&926&X6(&(.&CR@4SCF%N]64)N MQ'[56/7?78-A/-'O<_.>O"%)#A!CWR#W=E[^%'1R:=])^&1 M3O[4S=_DM4UA.\_*@7NZC)J4P82E,F./UCN#-0;,4R'2E M *P\Y/,MI M07YJ8.:&L$Z]TQB(8>V@U#6H+WN3M+W00?&SBV1)8C76W9-W- MT;MG+8?JJ7_^"PO)C8%4-PK2;5.0EL!J@O1*07K.9?"W%!_PQ;(1,5LDL(?= M9$N%NI",/>4K0T$$^"Z*FX38HU_FZ/:5NIT$'3KRMX?\G!VK_0"CL=RZ_8^2\YYF,!B6C@9L1Q'S+U0N=Z\0Z=:&V M!%:C?5'2OG@5YUZT*4A+8#5!AJ4@0^*B[M(FK$^!4KL,&I_=*7]0H7)84 M+D\T9Q,+)\:I+/9@-#B@08_1H$$5,H(S/4G^(_,,(K[D$)-[6&T29J1Z(M,L M4W*+J6.*:WG.4 =2JJ&=CG:W;:'5A3M(9_157%W""EN)80;O_XRWH)Z+IRX#_VY/?08#A4;Y,X-&=_]Q=G:S-STB M(J ]'4R(&TU!+:% M5A>EBH'4G0-/\$FK>;! &QS8Y/N/A7^P;V,WS6Z96G&A20)+K$%3H=74?A]J M/S RR[=R%M(8F>:':V Q*#L!KR^E-,\#NSM4[@9._@=02P,$% @ 33FL M6D68_T:C @ DP< !D !X;"]W;W)K&ULK57+ M;MLP$/P50BWZ %+KX4<*5Q:0. V:0PLC0=-#T0,MK2TB%*F0E)WTZ[ND%$%. M92<'^V"1U,YP9KE:QENI[G0.8,A#P86>>;DQY=3W=9I#0?5 EB#PS4JJ@AJ< MJK6O2P4T%,P$(1714%58_GP.5VYH7>T\(U M6^?&+OA)7-(UW(#Y62X4SOR6)6,%",VD( I6,^\LG,XG-MX%W#+8ZLZ86"=+ M*>_LY"J;>8$5!!Q28QDH/C8P!\XM$/9+"B%3?7KJL:TCVJ/C.U4#,@Q/2!1$XQ[X_##\ M(6 M/MJ%^YB1-BU1FY;(\0WW\#G7N>09*/V>?+VOF'DD/Z0!\OMLJ8W"ZOO39[)F M'?6SVB]RJDN:PLS#3TZ#VH"7O'L33H(O?9:/1+:3@&&;@.$A]FY=I)VZ*-NZ MT*XNZN,FM#*Y5.PO9'U)J7<:NYUL5]DD85#_8G_3-?R*P!TSH];,Z!AF%E01 MJ;#BJ<&U6\HK_! %ZS)/F/UKJ<=O<$@",)GKEZ*VK$T;BV-CV#IA#"MJ_Y3 M&?^7[.?'<2AB1_2D%3TYBFB\;;2A(F-BW:=\\J+R0Q&U&PO=V]R:W-H965T7Z'$+,5,,IZ!P.78 MNR974S(T!G;&GPQWLM$&0V7!^9/IW,5C+S >88*1,A!4_VSQ!I/$(&D__BY! MO6I-8]AL']!_M>0UF065>,.3SRQ6Z[$W\"#&)=TDZH'O?L.24-?@13R1]C_L MBKG]H0?11BJ>EL;:@Y1EQ2]]+@/1, A/&82E06C]+A:R7MY212/5U.-:\8;GBJ-UM2&ZY+N(YC9IHT@;NL MV'_SX=TM*LH2^1XN@&5PSY)$#\N1K[0[!M2/RJ6GQ=+AB:7;<,\SM9;P,8LQ M_K>]KVE47,(#EVGH!+RGH@5M\@'"(.S"X_P6WEV\![FF J4#OEV%JFWA.ZY0 MP1^YB8*$+_>8+E#\=8RW$\>\(O#RT[E9<>B MMT]Y:>C"D0V]%H)F*]0G2L%T#\UY,[JWP]<[*F+X\KN&A#N%J3S*KG,&=MV* M7=>Y!X^9P(BO,O95NRUM[BXLA:A)%9]-&^$?N#A&H%AB:)Z1"P@#2XJB0 M$&*Z=V5SOW*X[X8.0@*SA&;.3'9BO'*O!Y6'@S?.Y,$9V TK=D-G_#]M3-"! M+\L+"LHE8M!7+3 I-S2+\)C7!6ZWD;[]3I]TAKWC&4R"6@J"EU*BK:_Z>!,5 ML7TQ.]QXKPP@:4@7>>,$*1WXP03#FF!XIAPI@9M)$@8=$I#NB22I19"X5=#> M&Q_3/.%[1"@T<;81T5J']SLRYAS22&IM)&\MCN021N?=2DM%(4ROCA MD#4F4?[[P"J][?XO38(3"5(+(7%KUL/\T9T"3O/71JB6/=)_ZQ0XAVB26C6) M4[9^S!.I7*/Y1AJTVD'S[\2#B=0"2-P*^-HGTPNPAS=3^!UO)K]1.*4H5K8\ ME#I2FTP5-50U6I6@UT7A54\OZE==?*R8K@L27&K3H-77ATH4)6'143RW9=B" M*UW4V>9:E]$HS 3]?&PO=V]R:W-H965T:,!G;M6HX&8JDYR^!:$K5,4RH?Q\#%>NBTG*>%&[9(M%EP M1X.<+F *^C:_ECAS*Y28I9 I)C(B83YTSEJGDY9G$FS$#P9KM3$F1LI,B'LS MN8R'CF<8 8=(&PB*CQ5,@'.#A#Q^EZ!.M:=)W!P_H7^RXE',C"J8"/Z3Q3H9 M.CV'Q#"G2ZYOQ/H+E((Z!B\27-E?LBYC/8=$2Z5%6B8C@Y1EQ9,^E$9L)"!. M?8)?)OB[">T7$H(R(;!""V96UCG5=#208DVDB48T,[#>V&Q4PS)SC%,M\2W# M/#V::A'='X_1B)A,1(K5H:CU]YA,L63B)0 Z:,JZ.,/%V M>DX.#X[( 6$9^9Z(I:)9K :N1KYF5ST]=(+*^\#B!2_@7:0Y%X\ 9 IR MQ2)\)E0"J7'YC',1%<-OQSJJ&P+:,:U?&M?>AET4[LSY%FSY! M48UUX@O$T"*:NVTUZOH=+(+5IJA_@\)NJU\%;9'M5&0[>\G>H'PJHX3@1T#. M884W9X[WH"9W5Y#.0-8>U5[(UQY50V!;ZL-*??BF:CQLTKB&P+:,ZU;&=1NO M\0*QLU&^0;\7[M1X35#/"^MKO%>1[>TE^QDRD)3;$C^+\6^**2VI^8/>6^5[ M05][6 V!;>GO5_K[;ZK*^TT:UQ#8EG$M[[G_\!JO\Q)R\YX._+"_4^@U47Z_ M%>Q4NKO1.Z4@%[:E5$AEF>FBLZA6B[9U;-I6TWOMK&,[>V:;./<9INB%L6]8 ML$P1#G.$]$ZZ^/')HKTL)EKDMD.;"8W]GATFV)*#- 'X?BZ$?IJ8#:HF?_07 M4$L#!!0 ( $TYK%IIO_W%9@0 *D3 9 >&PO=V]R:W-H965TW53M[UGJ[^W!U M#Q%:I0:(F\1Q_/:7 *("9F:E W[=".2 M.(,I0WR3IH3MQI#0[<# QO[&EWBY$NJ&.>ROR1)F(+ZNITR.S$I+%*>0\9AF MB,%B8(SP]00'2B"?\2V&+3^Z1@IE3NF]&GR,!H:E/(($0J%4$/GW !-($J5) M^O&C5&I4-I7@\?5>^Q\YO(29$PX3FGR/([$:&#T#1; @FT1\H=N_H 1RE;Z0 M)CS_1=MRKF6@<,,%34MAZ4$:9\4_>2P#<21@NV<$[%+ K@MTSP@XI8"3@Q:> MY5@W1)!AG]$M8FJVU*8N\MCDTI(FSM0RS@233V,I)X8S0M7HU':_%"'J_B\5[&<_L(+(QY.Y'7(+K"EF?7>+06+^3Q*Q[_ M93P3M=V2I)W';_+87A#@.I'6YH5$O8JH]P89=EO\:=*KUV"UG1[&MNO78)L3 M&WEX A)4(,'+EF;/ <66(_.DU?&@Z8\=.%V,ZXYKS5^X2M@ZO-8M+=[WO'^1 M;X+1 S#9CU69A*8L#N$5A;$TW#N*@-_IXAJ]WKU+\8^Z&OP:?%V=+#5C?+PW M.[V@#JAUX%) ^P!HOPI06SA+W2>(N..Y=42M"YK&T5GD34UM)2]PFB MUW$:B#^C6\&'=@7K^Y6+LO3IXEI:K<$W2FLY[6PFGT(=>A*L;TJ>6K=G%MK2 M2N^$P:^_"_6^7+J AWX%ZQN6!NM$?HHP^6VZ(0GZ!UC:NH2MN'I#/MH!81SY M*"T^=@(4D1UO_5QZGB9WKZG;HNDT'(=V!^O[G2?#\>S%U]OQ2@9OSV!KPO$S MVB5\Z)>POF$:+9<,ED3([R\9BCCC<8B^D633GMRML2@,>$>)8-6SH#G%QJZ/ M??],,A^Z)*QOD\ZZ_^R5#)[V_DU;)?/H,"0%MLS/B#@*Z283Q;E(=;@L !D !X;"]W M;W)K&ULK99M;^)&$,>_RLBMJE:Z8'L=@TG!$N3N MVI,N)Q24W(M37RSV %9L+]U=X"+UPW=V38Q;C--&\()]\,[,[[^/,]H+^:36 MB!J^%WFIQLY:Z\V-ZZIDC057/;'!DKXLA2RXIJ93\4AL=9Z5.).@MD7!Y?,4<[$?.[[STG&?K=;:=+CQ:,-7.$?]L)E) M:KFUES0KL%29*$'B8Y\83:QZ/I-B#-*/)FZE8J=::X++2K,I<2_J:D9V.YUHD3U=3TI7"K2AHL16W MTW4%\VJA0"SA'I666:)ID#6 AS+3"B9F2C/]##^_1\VS7/U"9O?S!_AVA\4" MY1\C5Q.CB>0F!YYIQ#WO5\[U%W7 MZJZ[O,=?MF8ES29HK/P[*G:T)T@)+U.@TZXT5;)R!5-<965I:@N>\S)!^*MU MJBME5>S0QC87R"[VF3<,@F#D[EJ@PQHZ? OT;[0>AKF+*#PA&@0L"KQVH'X- MU'\+T&,UAUT\_1.>JV PN(["=J!!#31X"Q#==$O,7F,:G#*Q0=A)_M7<^H4UV*.D-JS88T$6,\)%G$AYY MOD68D2I[^/_GL3E>5FV:*K2HH2GJ#5F[(-\[/@?>A24=#U4W[R&P[S>(62\: MGB%N/&#^A8GK4_<*L'\*'/6B<-C\G:%G1WIV8?KF$7U% #L5T.^Q@.T16B5[5T&)CDZN%T)2JV>J:DF.49@!]7PJA7QHF M0)UNQW\#4$L#!!0 ( $TYK%J^S9^]%0, *P) 9 >&PO=V]R:W-H M965T!T@%.FW2.J&RKI]- MW<G^]\@ZV0;RH!T.0]2[D:.HG6Z[[K MJBB!C*J&6 /'+TLA,ZIQ*E>N6DN@L05EJ1MX7MO-*./.:OG(T$+E.&8>9 M)"K/,BK_C"$5VZ'C.[N%9[9*M%EP1X,U7<$<],MZ)G'F5EYBE@%73' B83ET M'OS^I&?LK<$O!ENU-R9&R4*(-S/Y%@\=SQ""%")M/%!\;6 ":6H<(8W?I4^G M^J4![H]WWK]8[:AE015,1/K*8IT,G:Y#8EC2/-7/8OL52CTMXR\2J;)/LBUM M/8=$N=(B*\'((&.\>-/W.K/8,[,J:*183RF$Q9FFN(R>T4-&6I^H3HE_F4W-Y\(C?$)/,,G;"*1VC]A:?BD6<@J1:R7[YSIA5W)V(+-9R6R>\VZ/78K'KDYD@6Q; MI"E"F]%]V.MVV@-WLT^_SJS3\YN5V0&Q5D6L=7;_I\ %IMG)"+2N&8$K.3L0 MVJZ$ML]&X-46.(COZ08/W I()+(,ZRI6G.B-8+U7&C,4,Q\S>F'RO6XWBE^T M]F+@^U[H^4'K.%HUEE[7[_C-=E@?L$ZEHW,U'7%1K>J4="Y64F-Y7DFW4M*] M*"?(&BOM3D59D4]&H'#9W<\"KQ$>__-]\Q.]RYB7&]US-C= MN_BP;JYL/Z"03,YU<054JT7+,<:6PU[-1^O8BCS8&]C]YZ;H8[# KQA7)(4E MNO0:'8R\+'J#8J+%VEZO"Z'QLK;#!-LID,8 OR^%T+N)^4'5H(W^ E!+ P04 M " !-.:Q:[ZV!)Z<" !C!P &0 'AL+W=O##H&UNR=/_[W9U\BK="/JL<0)-=P4LU=W*MJS/756D.!54C M44&)*RLA"ZIQ*M>NJB30S!H5W T\+W(+RDHGB>VWA4QB46O.2EA(HNJBH/+' M!7"QG3N^L_]PS]:Y-A_<)*[H&AY ?ZD6$F=NIY*Q DK%1$DDK.;.N7]V,3/[ M[8:O#+;J8$Q,)$LAGLWD.IL[G@$"#JDV"A1?&[@$SHT08GQO-9W.I3$\'._5 M/]G8,98E57 I^"/+=#YW9@[)8$5KKN_%]C.T\4R,7BJXLD^R;?9.Q@Y):Z5% MT1HC0<'*YDUW;1X.#,+@B$'0&@26NW%D*:^HIDDLQ99(LQO5S,"&:JT1CI6F M* ]:XBI#.YW<8=UOA%)D 9(\Y%0".2'G6<9,SB@GUV53>)/!MU>@*>/J7>QJ M=&T$W+1U<]&X"8ZX.:_7(^+[[TG@!2%Y35RBC"_5OGX7=#&&+I"@"R2P'L9' M/"PDVU -9,%I"GAJ-'FZA6()\EL?[:"6^1'.5(4Z8;[$BCU1*BJ!"$OLSD*<;W$JN-12JESI\ >IQ1ST>S.]= M;9)IL/>5$SSK@VQD)E;&M(1-XH?^:11-_=C=] !,.H#)/PH,)ZNZS"#;)TX- MEGA0[3^3%76LT0N5.'H!ZFE'/1W,<)=6+4A5RS3';K>O-L:2BJ+ +H M*7WN M0Y_^5?@@''N3Z6E_W6<=U6R0ZN,.9,J0I)(L!?+SH'OT431B?G" X8T\S_OS M]+D'/=-3+2H;!M="HU-V0YSO 5!F@VXOA)" M[R>F,W?W:O(+4$L#!!0 ( $TYK%I;UBQW+P, ,D, 9 >&PO=V]R M:W-H965TL"F)A05D+<%;43WK?"+$'0)YN0- @F/ Z!% V !"&VCM MF0WKDFHZGTJQ(])8(YL96&TL&J-AA4GC4DM\RQ"GYY_QI'P22I$;D&2940GD M+5GB84FK'(A8D_-"LY3EE5&;+"&I)-,,%+FZ3_(JA92LI>!D(7A9:6HS@Z K M*@M6;/997UV"IBQ7KY%?F14U=34&8-QPD\;9B]K9X!%G0W(M"IWAY@7NW(%? M]./]H(? 1>5:^8('^2Z"7L9K*D](Z+\A@1?$70[UPR\A:>%1CSMAF\W0\H6/ M\ V5K.^?D)A\U,#5CZXTU5Y$W5Z8F^=,E32!F8-7BP*Y!6?^\H4_\MYU2300 MV8%@42M8U,<^E&!OR#D75:&[M*H=B*T#YE+=SH,XC":1'TS=[;X.'8;^) I' M$[\U/(@Q;F.,>V-<:I'<$5$:]Q71@I253#*\^D@B.,>0E#7X?@U\!;(SW[T; M/#7? Y$=:#%JM1@]BP(9#2G80&0'@HU;P<;_NT#&?Y_[<.+[03P^*I .0R^> MG ;FYNTJD$D;XZ0WQMMB"TIC+"B?EBPQPW\NC5[JIV9Z(+(#%4Y;%4Z?16F< M#BG80&0'@OG>G][)^]_%T7BP?^C].!S[<7Q4'%V&01Q%\>BH.-R]9I&#W-@> M6N&!1P_JOK%=;?OT<]N=NG_,ZR8?NY\-P_^4'-8(]4[&N+NL^^9ZHD5I6\^5 MT-C(VF&&WQH@C0&^7PNA'R9F@_;K9?X;4$L#!!0 ( $TYK%K[(%H@^0( M *4) 9 >&PO=V]R:W-H965T$80 M9! KPX#U;PD#R#)#I&7\V7 ZA4L#++>W[+N@A.N0C3B3,TDNF$))+MX5\LNM =;[?V@DG"$10V%_B<4>$'CB)[!O\/K M%7+"(I6AY:N?X!L+OB1V=^O$(9(G5IG$'LM5SM6T7.:H+:.P[GE>QUV6(SBT M,D8O5CM"ZX70>J70FS0%>WI*(I' "H[IK*:Z\&J^]^'89AC\!W GFD813:.2 MZ182$'J_2H750G'Q?#*4G,%U*OJS<,%Q%@JPJ;F#L23#- W+B4:B6PG->TB->TSKF+[8'GV%[#2VUMC<4LO'@4QM86 1#%? M,)4_(,5H7FOT=:UAW^2]<5V#].S3Z[[0Y 6,?AZFA$F40:HIO5I+7PPB+PKR MCN)S^ZY.N-*OM&W.=!T%PACH^91SM>T8!T5E%OT%4$L#!!0 ( $TYK%I9 MM)H=>@, @( 9 >&PO=V]R:W-H965TV%(ZW M=AM395%D0:E4<3(8C.-22!W-I^%L;>=34SLE-:XM4%V6PGZ[167VLV@8O1S< MRVWA_$$\GU9BBP_H'JNUY5W2"F\?6 &;4FO>+Q^@7]??"=?=D(PH51 MO\K,%;/H;009YJ)6[M[L/^#!GY''2XVB\(7]078005J3,^5!F1F44C=_\7R( MPW]12 X*2>#=& HLE\*)^=2:/5@OS6A^$5P-VDQ.:O\H#\[RK60]-W_ +8?8 MP4?=/+"/U 7<9)GT2Z&^NSA?HA-2T1LX ZEA)97B8YK&CIEXO#@]6+UMK";_ M8/425D:[@N!.9YA]KQ^S!ZT;R8L;MTDGX$K8/EP.>Y ,DA$\/BSA_.P-')SK MP+]LPW09\"__)4SW6!GKI-["EYL-.#TK!N<$+S\M5C[,JDSN9U9Q@/TNG$(3.8&TH9!T8"S]: M4U?P290(7^Z>G>\"&Q:[TW49?#+Z9-R[Z9!UUXM"8G[WC&GMV\'G/)G7*LV^R" MJU"2\Y;WTA7@"DG^=%*9Y\#E36I$C4XUN$A2DKH;^]?O4V&4[>46 ) M-2%!REA&R4PX3XM84^'%(7\@EUKH5/*SR:.^P"NH:EL9K\]YASNAZB;Q. .# MG$[96UYA*BA3(]<9/SN4:<(Y83$GW5G)UZE,;*#T?UD@S'_MF/NINGN?XHW,Y+;W%9J H4YJP[Z$\YWV\R= M9N-,%7K]QCB>'&%9\*A&ZP7X/C?&O6R\@7;XS_\ 4$L#!!0 ( $TYK%IE M)QZ)G@8 *8D 9 >&PO=V]R:W-H965T#Z65Z[DY.+T6B0QZS.XE4$D54OERS M4#Q=#?!@>^*>+U?:G!A.+]=TR1Z8_K&^DW T+% "'K%8<1$CR197@U_QQ//W&\H9<@^>+4*5_T5,> M:PV0GR@MHCP9*HAXG/VGSSD1.PG8/I! \@2RG^ >2+#S!'L_P3F0X.0)3LI, MUDK*PXQJ.KV4X@E)$PUHYD-*9IH-[?/87/<'+>%;#GEZ^L"6- M70XU5&;PAWY>Q4U6!3E0A8UN1:Q7"GV* Q94\X?04=$6V;9U0UH!;ZD\1S8^ M0\0B;D,]L_^?[K248Q?83E>[864O-X6>'[\7<(1U\UB]3?3=QEV$XS MMID8+M2:^NQJ '>^8G+#!M.WOV#/^MC4>$]@%1J<@@:G#7UZSS8L3EBC0+), M+\TTD]5FZMH3Y3*\HTVLM\P^]8C!?YT)BV7F/U(,\F5G-?HZ*O46L]W^#9%@K5J(E1;;P/]F0\VB^K*6PTP4YS M8>.BL'%K8=^_?7$\@@(NX1&%UE(L)8T*XF'RNW]+H_7'&7J\9=&NOV!%9A8U*P,3GA##;IDX:>P"HT8*M\7EJ]31_)MBK+&7K-Z M\T*A6E'\&MS_EN*K9K M^L0V)>355?:%4J2EN%6^U*-Q5/&O1):G:B'G5@(B:EZ2'MIL=( MV!J_4L+M8W2];GVA51DIW17!)Y0PZ=56]856I:*T5:35JW21\/41J$?23!=I MF+[Q_L_NABB'N.,#VB^M$FFW2J!]VWFU]GM]A],76I61TI81YY3:[]6/]856 MI:+T8Z2WET?71Z >[6:ZZF^3]GU+0XAM6X/*%QLF7UZK_=9A M.E_PGM"JI)1FCHQ.J?U>75Q?:%4J2A='VE^0=;$N.51E;O9&DWTAUZ-<%Q]X MOTM*CT7:/=8=DTK$,0L_2!92S8+."N[U_55?:-65B-++V=8IUR)Z-7%]H56I M*$V2 "[%+DV6W.Z//U.LMSD[:U1Y M0_4H9W?]I5JH<4W5,Z77L(^N2J'F%2[$8S], E YCXNUZ#A?--I^J="2Q4S2 M,&V=!A&/N=*2FCT%6Z0S"-8,>-Y29U+"AU#\4(EDJ4%%5GI;@FN7PPG M7ZYOT1HZA9QL;C#WP4*$7$ [7$B8-/Y-;X;SN>D>DC!H!+$%)20@:730 8J$GF0\SH; MVX)WB3C29]-M.]S9C!$QN4PWM2A(2&*=+9479XN-,]?I=I&]\S?X8H8;SL.] M='&3[;2I?>/"-^D6EV$Y=+:#YY;*)>@+A6P!95CG(WA$R6Q33'8 XDVWB&PO.Z:"_?CX[A)?Z&.N'E2X1Q+[']]SC\R4Q]"N]Y/1N M1JD.%@47U2"<:5U^C*)J,J,%J2YD285!A-W&%+C+EVP0MI/+,'!T(YG10?AP]O[G7.KK=X&[ MGGPX.6D]G%_OVL\L M$_W),3TPD_M3B=%W6QY=IXVL4^L6U84T[.=2K.LI#IW!\)*"!H^$#\(1X6RL M&'CEI&!\ZG8P=;X# KJ]OVR- JGBBS;G:MP[6 O)LA8JHRJ M)DP[7)F&?4YSD*/8= 97+6+>(.2/4K]>6ZF(VP?JHS>*IJSA>TO M\D8 QM[&V4E9\N4GSJ:BH&[R!P<<]LG*+YA)Q9Y,-"B5B3%0%0:/5&DVV;3\ M4J2\IPN]*J=%CFONO$'-_S;/4RJH(GQ3M*G]8\[RBQ7'W=>2;)\JNX*]&NNW M^K&+O'H+(I.W(/)-U&3O^$7&Z?%KK/>$1RZR^VI/]KTBHWHGM+'=VMIL-=8 M-K6#\#MLCODZ:#">,ZZ9J'LSEF54/-MS&7I-QN:GW!:_&9_1G,RYOF_ 0;AN M?Z,9FQ=I,^H6$E&/6K>_PO3:2;.C-K&8R.B"9J.ZJZ9CVPQ,PT2M#W#816[L MX4'^C@O'S*R)Q;'[Y.: MPS_3-(WC),$R.AIY%8RPO"4)?/QLF#;PP.) I+_+-;[:>(7LKP-L3?=5"#93 MO!*QF>*Y!L2?-_!(4_]J8W' UL%K'8@OC\.U)3?)XYA53%MV!V,(VF*(5"+ M_AI-$B0["9S^]<'NDCA.4S\"F%]!'&,(W(TX@BD #1@2Q_8]N/,^BE;OJ6C] M_^;P-U!+ P04 " !-.:Q:EXJ[', 3 @ "P %]R96QS+RYR96QS MG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2 MW!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N M&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,E MC'%BM/XU@LD/['X 4$L#!!0 ( $TYK%K^@Q--000 &\B / >&PO M=V]R:V)O;VLN>&ULQ9I=<]LH%$#_"J.G[D/6UH?=-E-W)FVV6\^T64^5R>L. M%M0$G37[^ XA;5]IU](7JRA"1\=!'W -*[1Z7OUTK=D^^MD&:1[:S= M7TXFIME!2\V?:@_2'=DHW5+K=O5V8O8:*#,[ -N*23&=SB>"&K[G@]FF1A6T!&6FYY"W_ 6R133-B=NKQ ML]+\AY*6BKK12HA%EO<'[D!;WAP5UQ[REJY-*+%T_8TZD$4VG[H*-UP;&\X( M]5/'^ #NY'ZOL^H3%Q;T-;7PMU;=GLNMK\;=Q22ZC1"'PV\?Q$O]?\*H-AO> MP+5JNA:D[>.H07A :79\;S(B:0N+[' *N9*,_"6M"Q)9RKXJ=ZZ_4_?72];? MM76X40SU)7<'])(%\'20'Y5D( TPXK:,$IPY#D8^4$%E R2"+!#(8D3(?XL( MLD0@RU$@:X_C+HT@*P2R&A%R$,D9 CD;$[*,(.<(Y#PMY(H^D0=#5J##Y;ZS M7'/3"&4Z#1'B:P3Q=5K$I32<@2:WFC*7!,F5UE1N_<-H343X!B%\DY;PAEH7 M+:(VQ.Z ?.@,EV ,H=)W;L,CR+<(Y-NTD'77ME0_>I>(P1=*QV.D*NMAJ.6SE'1)#;-)\HUN:.B _(5J.\E1WB88O+$ MCOE*]3VXD88 4D/3:6XY#. PM>2)W5)W^[T(\:+BIYO#$"B,*&),3"YYA64,?=NG;NL0#LODMEIA<\L1V^0;,]8S0T([OP0] _?9*PP;T('7GF%[R MQ'ZIK6KN+UP6#!IL74WF:-B(N25/+)<;5^\798(!W:-(AY'#G)(GELI2-JH% MI\&2#8S8I4MOD M./^<9,2,4J0V"C89&#Z4F%Z*Q'HY-\XF%^2*L7@Z4&#&*1(;!\4I)$(8Y;'3TCES$F9J'JY2=!?7.SSO6D6)859J$J ML85.8CX+75(18V(6JEY\=2V*YO#9Q"Q4O>!2VR"._40SQL0L5+W\ZEM,&[_U MQ"PT2[T2=Q+S9Q^*,3$+S?IO'0X?.##8N(DTNW%_85QY0T6STL3_].] M : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V;ENPD 4A>%707X MAKN8+()4:=)&O(!%AD4LMCP3!=X^" IRK!1IHCF5-;9\_X_[)F_; M8]ILNS0Z'?;'-*\V.7?/(:3E)AZ:-&Z[>+Q<6;7]HL8=#*9 MAO[GC.IE]G/F:''NXE\FMJO5=AE?V^7G(1[S+X/#5]OOTB;&7(T63;^.>5Z% MT_Y^.H7K0<:7R=7H[6->]6\?4H7200I!6C[((,C*!SD$>?F@&H+J\D%3")J6 M#WJ H(?R08\0]%@^Z F"GLH'R01EG! D#; FT%J0:R'P6A!L(1!;D&PA,%L0 M;2%06Y!M(7!;$&XAD%N0;B&P6Q!O(=!;46\ET%M1;R706PBOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'K; M8+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O M1[V=0&]'O9U ;Q]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z%VCWC6! MWC7J7?^GWBF?]S'=>VYK?/Y_4ITO]\;[XZ_+V\G!2[CB'."'],LW4$L#!!0 M ( $TYK%HHM&@3PP$ (D> 3 6T-O;G1E;G1?5'EP97-=+GAM;,W9 MR6[",!0%T%]!V5;$>( . C9MMRV+_H";/" BB2W;4/C[.F&06M&HB$J]FT2) M[7=?;.EL,G[;6?*];576?I(L0[ /C/EL297VJ;%4QY&Y<94.\=$MF-792B^( MB<%@Q#)3!ZI#/S0UDNGXB>9Z78;>\S:^]H6I)XFCTB>]Q_W$)FN2:&O+(M,A MCK--G7]+Z1\2TKBRG>.7A?4W<4+"SB8T(S\''-:];LBY(J?>3+OPHJLXBVU+ MYL.N))]VESC3HYG/BXQRDZVKN"3UUI'._9(H5&6Z+WK3G1SB#M/^RJ_.;\MT M!<:9,V>LCR?FZ/*XXY$TJ_LV%B(7BNY//"7&TE=_'S6GG5/^R^RXO1_&K=KS M\*R]7;_'7\_X5/_"/@1('Q*D#P72QQ"DCQ%('[<@?=R!]'$/T@,! !X;"]T:&5M92]T M:&5M93$N>&UL4$L! A0#% @ 33FL6@F,.47Y!0 TA\ !@ M ("!) @ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ 33FL6I' "K@:!0 X10 !@ ("!>!< 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 33FL6C"GLU], M @ HP4 !@ ("!1BH 'AL+W=O+P >&PO=V]R:W-H965T&UL4$L! A0#% @ 33FL6CKMM2%8!P 5A, !D M ("!XC8 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ 33FL6B3A33,D!@ &1 !D ("!1$P 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 33FL M6GO0_2O1 @ 8@8 !D ("!U60 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 33FL6KT(DR9; P $P@ M !D ("!/74 'AL+W=O M>&PO=V]R:W-H965T&UL4$L! A0#% @ 33FL6I#A%+]/ P 2 @ !D M ("!:X< 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 33FL6LU>[IM)! G@H !D ("!LY, 'AL+W=O M8# # M"0 &0 @($SF >&PO=V]R:W-H965T&UL4$L! A0#% @ 33FL6BOA MYYY. @ G00 !D ("!%Z$ 'AL+W=O&PO=V]R:W-H965T6J !X;"]W;W)K&UL4$L! A0#% @ 33FL6C0\:#/&PO M=V]R:W-H965T&UL4$L! A0#% @ 33FL6F5O,M7$ P !( !D ("! M/+D 'AL+W=O64# "S"P &0 @($WO0 >&PO=V]R:W-H965T&UL4$L! A0#% M @ 33FL6@'_;B'A @ OP@ !D ("!,<4 'AL+W=O&UL4$L! A0#% @ 33FL6NFD&)?5 M P &10 !D ("!4,X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 33FL6EJA'9TU P \ L !D M ("!+]D 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 33FL6K[-G[T5 P K D !D ("!Y.0 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M33FL6OL@6B#Y @ I0D !D ("!=.X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 33FL6C,]<8%% P M[!0 T ( !*OP 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ 33FL6J&7ZI3) 0 H!X M !H ( !\00! 'AL+U]R96QS+W=O XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 127 226 1 true 50 0 false 6 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995455 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://www.tangotx.com/20250331/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation Nature of the Business and Basis of Presentation Notes 9 false false R10.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995475 - Disclosure - Collaboration Agreements Sheet http://www.tangotx.com/20250331/taxonomy/role/CollaborationAgreements Collaboration Agreements Notes 11 false false R12.htm 995485 - Disclosure - Fair Value Measurements Sheet http://www.tangotx.com/20250331/taxonomy/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 995495 - Disclosure - Marketable Securities Sheet http://www.tangotx.com/20250331/taxonomy/role/MarketableSecurities Marketable Securities Notes 13 false false R14.htm 995505 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.tangotx.com/20250331/taxonomy/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 14 false false R15.htm 995515 - Disclosure - Commitments and Contingencies Sheet http://www.tangotx.com/20250331/taxonomy/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 995525 - Disclosure - Redeemable Convertible Preferred Stock Sheet http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStock Redeemable Convertible Preferred Stock Notes 16 false false R17.htm 995535 - Disclosure - Stock-Based Compensation Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation Stock-Based Compensation Notes 17 false false R18.htm 995545 - Disclosure - Net Loss Per Share Sheet http://www.tangotx.com/20250331/taxonomy/role/NetLossPerShare Net Loss Per Share Notes 18 false false R19.htm 995555 - Disclosure - Income Taxes Sheet http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 995565 - Disclosure - Segment Information Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformation Segment Information Notes 20 false false R21.htm 995575 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 995595 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.tangotx.com/20250331/taxonomy/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.tangotx.com/20250331/taxonomy/role/FairValueMeasurements 22 false false R23.htm 995605 - Disclosure - Marketable Securities (Tables) Sheet http://www.tangotx.com/20250331/taxonomy/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.tangotx.com/20250331/taxonomy/role/MarketableSecurities 23 false false R24.htm 995615 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.tangotx.com/20250331/taxonomy/role/SupplementalBalanceSheetInformation 24 false false R25.htm 995625 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation 25 false false R26.htm 995635 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.tangotx.com/20250331/taxonomy/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.tangotx.com/20250331/taxonomy/role/NetLossPerShare 26 false false R27.htm 995645 - Disclosure - Segment Information (Tables) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformation 27 false false R28.htm 995655 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails Nature of the Business and Basis of Presentation - Additional Information (Details) Details 28 false false R29.htm 995675 - Disclosure - Collaboration Agreements - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails Collaboration Agreements - Additional Information (Details) Details 29 false false R30.htm 995685 - Disclosure - Collaboration Agreements - Additional Information (Details1) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1 Collaboration Agreements - Additional Information (Details1) Details 30 false false R31.htm 995695 - Disclosure - Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details) Details 31 false false R32.htm 995705 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 32 false false R33.htm 995715 - Disclosure - Marketable Securities - Summary of Debt Securities, Available For Sale (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails Marketable Securities - Summary of Debt Securities, Available For Sale (Details) Details 33 false false R34.htm 995725 - Disclosure - Marketable Securities - Summary of Fair Value and Gross Unrealized Losses on Securities (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails Marketable Securities - Summary of Fair Value and Gross Unrealized Losses on Securities (Details) Details 34 false false R35.htm 995735 - Disclosure - Marketable Securities - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails Marketable Securities - Additional Information (Details) Details 35 false false R36.htm 995745 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details) Details 36 false false R37.htm 995755 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails Supplemental Balance Sheet Information - Additional Information (Details) Details 37 false false R38.htm 995765 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details) Details 38 false false R39.htm 995775 - Disclosure - Supplemental Balance Sheet Information - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails Supplemental Balance Sheet Information - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) Details 39 false false R40.htm 995785 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 40 false false R41.htm 995795 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails Redeemable Convertible Preferred Stock - Additional Information (Details) Details 41 false false R42.htm 995805 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 42 false false R43.htm 995815 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) Details 43 false false R44.htm 995825 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails Stock-Based Compensation - Schedule of Stock Option Activity (Details) Details 44 false false R45.htm 995835 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) Details 45 false false R46.htm 995845 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) Details 46 false false R47.htm 995855 - Disclosure - Net Loss Per Share - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails Net Loss Per Share - Additional Information (Details) Details 47 false false R48.htm 995865 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 48 false false R49.htm 995875 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 49 false false R50.htm 995885 - Disclosure - Segment Information - Additional Information (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails Segment Information - Additional Information (Details) Details 50 false false R51.htm 995895 - Disclosure - Segment Information - Schedule of Segment Expense (Details) Sheet http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails Segment Information - Schedule of Segment Expense (Details) Details 51 false false All Reports Book All Reports tngx-20250331.htm tngx-20250331.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tngx-20250331.htm": { "nsprefix": "tngx", "nsuri": "http://www.tangotx.com/20250331", "dts": { "inline": { "local": [ "tngx-20250331.htm" ] }, "schema": { "local": [ "tngx-20250331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 197, "keyCustom": 29, "axisStandard": 19, "axisCustom": 0, "memberStandard": 22, "memberCustom": 28, "hidden": { "total": 13, "http://fasb.org/us-gaap/2024": 9, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 127, "entityCount": 1, "segmentCount": 50, "elementCount": 510, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 425, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } }, "R3": { "role": "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } }, "R4": { "role": "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } }, "R5": { "role": "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_4d00c2fb-940d-4c6d-8d16-8cf19dcb0890", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4d00c2fb-940d-4c6d-8d16-8cf19dcb0890", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.tangotx.com/20250331/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation", "longName": "995455 - Disclosure - Nature of the Business and Basis of Presentation", "shortName": "Nature of the Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.tangotx.com/20250331/taxonomy/role/CollaborationAgreements", "longName": "995475 - Disclosure - Collaboration Agreements", "shortName": "Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.tangotx.com/20250331/taxonomy/role/FairValueMeasurements", "longName": "995485 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.tangotx.com/20250331/taxonomy/role/MarketableSecurities", "longName": "995495 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.tangotx.com/20250331/taxonomy/role/SupplementalBalanceSheetInformation", "longName": "995505 - Disclosure - Supplemental Balance Sheet Information", "shortName": "Supplemental Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.tangotx.com/20250331/taxonomy/role/CommitmentsAndContingencies", "longName": "995515 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStock", "longName": "995525 - Disclosure - Redeemable Convertible Preferred Stock", "shortName": "Redeemable Convertible Preferred Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "tngx:RedeemableConvertiblePreferredStockDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "tngx:RedeemableConvertiblePreferredStockDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation", "longName": "995535 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.tangotx.com/20250331/taxonomy/role/NetLossPerShare", "longName": "995545 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxes", "longName": "995555 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformation", "longName": "995565 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995575 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.tangotx.com/20250331/taxonomy/role/FairValueMeasurementsTables", "longName": "995595 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.tangotx.com/20250331/taxonomy/role/MarketableSecuritiesTables", "longName": "995605 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables", "longName": "995615 - Disclosure - Supplemental Balance Sheet Information (Tables)", "shortName": "Supplemental Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables", "longName": "995625 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.tangotx.com/20250331/taxonomy/role/NetLossPerShareTables", "longName": "995635 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationTables", "longName": "995645 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails", "longName": "995655 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)", "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "tngx:CashCashEquivalentsAndMarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "tngx:CashCashEquivalentsAndMarketableSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "longName": "995675 - Disclosure - Collaboration Agreements - Additional Information (Details)", "shortName": "Collaboration Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_9d93be90-0b8f-48a9-9ef6-c3fe21304489", "name": "tngx:NumberOfLicensedProduct", "unitRef": "U_Program", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9d93be90-0b8f-48a9-9ef6-c3fe21304489", "name": "tngx:NumberOfLicensedProduct", "unitRef": "U_Program", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1", "longName": "995685 - Disclosure - Collaboration Agreements - Additional Information (Details1)", "shortName": "Collaboration Agreements - Additional Information (Details1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_50aa37d3-3f8c-4441-8c89-9fbb713014cf", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_50aa37d3-3f8c-4441-8c89-9fbb713014cf", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails", "longName": "995695 - Disclosure - Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_50c0e079-0775-450b-9f59-52321387f209", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_50c0e079-0775-450b-9f59-52321387f209", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "995705 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "tngx:FairValueAssetLevel1ToLevel2TransferAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "tngx:FairValueAssetLevel1ToLevel2TransferAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails", "longName": "995715 - Disclosure - Marketable Securities - Summary of Debt Securities, Available For Sale (Details)", "shortName": "Marketable Securities - Summary of Debt Securities, Available For Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails", "longName": "995725 - Disclosure - Marketable Securities - Summary of Fair Value and Gross Unrealized Losses on Securities (Details)", "shortName": "Marketable Securities - Summary of Fair Value and Gross Unrealized Losses on Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "longName": "995735 - Disclosure - Marketable Securities - Additional Information (Details)", "shortName": "Marketable Securities - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails", "longName": "995745 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "longName": "995755 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Details)", "shortName": "Supplemental Balance Sheet Information - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b6ea992a-00c9-4090-a3c3-1e1f3b4cf9d8", "name": "us-gaap:RestrictedCash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } }, "R38": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails", "longName": "995765 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "tngx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "tngx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails", "longName": "995775 - Disclosure - Supplemental Balance Sheet Information - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)", "shortName": "Supplemental Balance Sheet Information - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ad7bdb2e-c252-4419-8983-97ae09e8527b", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } }, "R40": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995785 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_ccf23f4b-27d0-4b6e-9039-919d0e1d53c4", "name": "tngx:NonRefundableUpfrontPaymentReceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ccf23f4b-27d0-4b6e-9039-919d0e1d53c4", "name": "tngx:NonRefundableUpfrontPaymentReceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails", "longName": "995795 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)", "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_8375de45-ea67-4080-be89-d01b88c0ae8b", "name": "us-gaap:TemporaryEquitySharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "longName": "995805 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "shortName": "Stock-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_cae5313b-fc9f-486e-bf7b-e650ece40e65", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cae5313b-fc9f-486e-bf7b-e650ece40e65", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails", "longName": "995815 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails", "longName": "995825 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)", "shortName": "Stock-Based Compensation - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_d5a8add7-56ba-4225-a8b4-4f560912f2ca", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } }, "R45": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "longName": "995835 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)", "shortName": "Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_00d492b8-6472-4881-82e7-e52888ceb8f5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_00d492b8-6472-4881-82e7-e52888ceb8f5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "longName": "995845 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "shortName": "Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": null }, "R47": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "longName": "995855 - Disclosure - Net Loss Per Share - Additional Information (Details)", "shortName": "Net Loss Per Share - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_618b2a45-66a5-45fc-9052-b2247130d186", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_618b2a45-66a5-45fc-9052-b2247130d186", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "995865 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails", "longName": "995875 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } }, "R50": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails", "longName": "995885 - Disclosure - Segment Information - Additional Information (Details)", "shortName": "Segment Information - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails", "longName": "995895 - Disclosure - Segment Information - Schedule of Segment Expense (Details)", "shortName": "Segment Information - Schedule of Segment Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d3790368-9954-4366-81f0-59d2a858e009", "name": "us-gaap:SegmentReportingOtherItemAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tngx-20250331.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate202309Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingStandardsUpdate202309Member", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2023-09 [Member]", "label": "Accounting Standards Update 2023-09 [Member]", "documentation": "Accounting Standards Update 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures." } } }, "auth_ref": [ "r385", "r386", "r387" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r34", "r726" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r869" ] }, "tngx_AccretionOnMarketableSecurities1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "AccretionOnMarketableSecurities1", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Accretion on marketable securities 1.", "label": "Accretion On Marketable Securities 1", "terseLabel": "Accretion on marketable securities" } } }, "auth_ref": [] }, "tngx_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities", "documentation": "Accrued expenses and other current liabilities.", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "tngx_AccruedResearchAndDevelopmentCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "AccruedResearchAndDevelopmentCostsCurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails": { "parentTag": "tngx_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development costs", "label": "Accrued Research And Development Costs Current", "documentation": "Accrued research and development costs current." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r27", "r115", "r532" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r12", "r13", "r50", "r121", "r528", "r571", "r575" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r6", "r13", "r424", "r427", "r478", "r566", "r567", "r848", "r849", "r850", "r857", "r858", "r859", "r860" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r781" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Additional Paid in Capital, Total", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "terseLabel": "Additional\u00a0paid-in\u00a0capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r45", "r726", "r987" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r586", "r857", "r858", "r859", "r860", "r932", "r988" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r794" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r794" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r794" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r794" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r103", "r104", "r105", "r106", "r107", "r108", "r143", "r144", "r145", "r146", "r156", "r209", "r210", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r290", "r291", "r295", "r383", "r384", "r385", "r386", "r387", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r457", "r458", "r466", "r467", "r468", "r473", "r474", "r475", "r476", "r477", "r478", "r513", "r514", "r515", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "tngx_AdjustmentsToAdditionalPaidInCapitalBusinessCombinationAndPipeFinancingIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "AdjustmentsToAdditionalPaidInCapitalBusinessCombinationAndPipeFinancingIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital business combination and pipe financing issuance costs.", "label": "Adjustments To Additional Paid In Capital Business Combination And Pipe Financing Issuance Costs", "terseLabel": "Business combination and PIPE financing, issuance costs", "negatedLabel": "Business combination and PIPE financing, issuance costs" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash from operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r827" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r753", "r763", "r773", "r805" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r756", "r766", "r776", "r808" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r828" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r794" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r801" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r757", "r767", "r777", "r801", "r809", "r813", "r821" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r819" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r366", "r372" ] }, "tngx_AmendedGileadAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "AmendedGileadAgreementMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Amended Gilead Agreement [Member]", "documentation": "Amended gilead agreement." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r166" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r413" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r70", "r79", "r117", "r137", "r170", "r179", "r198", "r202", "r246", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r414", "r416", "r459", "r524", "r625", "r695", "r696", "r726", "r744", "r901", "r902", "r943" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r111", "r122", "r137", "r246", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r414", "r416", "r459", "r726", "r901", "r902", "r943" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r443", "r444", "r716" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r219" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Loss", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r220" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r216", "r263", "r523" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Current", "totalLabel": "Debt Securities, Available-for-sale, Current, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r213", "r263" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r816" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r817" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r812" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r812" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r815" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r814" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r813" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r813" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r16", "r17", "r18" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r15", "r113", "r685" ] }, "tngx_CashCashEquivalentsAndMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "CashCashEquivalentsAndMarketableSecurities", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash cash equivalents and marketable securities", "label": "Cash Cash Equivalents and Marketable Securities", "documentation": "Cash Cash Equivalents and Marketable Securities" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents and marketable securities", "label": "Cash, Cash Equivalents, and Short-Term Investments", "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r847" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, cash equivalents and restricted cash", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r15", "r58", "r135" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r15", "r58", "r135" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r58" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of noncash investing and financing activity:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "tngx_CashPaidForLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "CashPaidForLeases", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for leases", "label": "Cash Paid For Leases", "documentation": "Cash paid for leases." } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accounting principle accounting standards update adopted [true or false]", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r97", "r98", "r108", "r142", "r209", "r247", "r248", "r249", "r254", "r255", "r290", "r295", "r385", "r396", "r397", "r405", "r406", "r408", "r419", "r420", "r431", "r432", "r457", "r458", "r467", "r473", "r474", "r513", "r514", "r564", "r565" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle accounting standards update adoption date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r97", "r98", "r108", "r209", "r247", "r248", "r249", "r254", "r255", "r256", "r290", "r295", "r385", "r396", "r397", "r405", "r406", "r407", "r408", "r409", "r418", "r419", "r420", "r421", "r431", "r432", "r433", "r436", "r457", "r458", "r467", "r473", "r474", "r513", "r514", "r564", "r565", "r833" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r792" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r789" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r787" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]", "verboseLabel": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r101", "r118", "r119", "r120", "r137", "r160", "r161", "r163", "r165", "r172", "r173", "r246", "r305", "r307", "r308", "r309", "r312", "r313", "r316", "r317", "r318", "r319", "r321", "r459", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r613", "r634", "r652", "r673", "r674", "r675", "r676", "r677", "r832", "r854", "r861" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r322" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Warrants to purchase shares of common stock", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r29" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r793" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r793" ] }, "tngx_CollaborationAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "CollaborationAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Collaboration Agreements [Abstract]", "documentation": "Collaboration Agreements ." } } }, "auth_ref": [] }, "tngx_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "CollaborationRevenueMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Collaboration Revenue [Member]", "documentation": "Collaboration Revenue Member" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CollaborationAgreements" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration Agreements", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r87", "r89", "r100" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r413" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 8)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r40", "r71", "r525", "r612" ] }, "tngx_CommitmentsAndContingenciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "CommitmentsAndContingenciesDetailsLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and Contingencies.", "label": "Commitments And Contingencies Details [Line Items]", "terseLabel": "Commitments and Contingencies (Details) [Line Items]" } } }, "auth_ref": [] }, "tngx_CommitmentsAndContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "CommitmentsAndContingenciesDetailsTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies Details [Table]", "documentation": "Commitments and Contingencies.", "label": "Commitments And Contingencies Details [Table]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r64", "r299", "r300", "r678", "r896", "r898" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of shares reserved for issuance", "terseLabel": "Share based payment arrangement, Shares reserved for future issuance", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r44" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r734", "r735", "r736", "r738", "r739", "r740", "r741", "r857", "r858", "r860", "r932", "r986", "r988" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Par or Stated Value Per Share", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r44" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares Authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r44", "r613" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Issued", "label": "Common Stock, Shares, Issued", "totalLabel": "Common Stock, Shares, Issued, Total", "verboseLabel": "Common Stock Shares", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r44" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock, Shares, Outstanding", "label": "Common Stock, Shares, Outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "verboseLabel": "Common shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r44", "r613", "r631", "r988", "r989" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; 108,107,890 and 107,729,343 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r44", "r526", "r726" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r798" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r797" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r799" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r796" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r14", "r124", "r126", "r132", "r519", "r538", "r539" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Computer Equipment [Member]", "terseLabel": "Computer equipment [Member]", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer Software [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r681", "r684", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895" ] }, "tngx_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Software [Member]", "documentation": "Computer Software Member" } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized, Cumulative\u00a0catch-up\u00a0adjustment", "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract", "verboseLabel": "Revenue recognized, cumulative catch-up adjustment", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r708" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Short-term deferred revenue", "verboseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r324", "r325", "r326" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Long-term deferred revenue", "verboseLabel": "Deferred revenue, net of current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r324", "r325", "r326" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with customer liability, revenue recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r327" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contractual Obligation", "totalLabel": "Contractual Obligation, Total", "terseLabel": "Contractual obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r856" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "tngx_CummulativeResearchExtensionFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "CummulativeResearchExtensionFee", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cummulative research extension fee", "label": "Cummulative Research Extension Fee", "documentation": "Cummulative research extension fee." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtAndEquitySecuritiesGainLossExcludingOtherThanTemporaryImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndEquitySecuritiesGainLossExcludingOtherThanTemporaryImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairments to marketable securities or reserves for credit losses", "label": "Debt and Equity Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss", "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities, excluding other-than-temporary impairment (OTTI)." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities, Accrued interest", "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss", "totalLabel": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total", "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r222", "r263", "r264", "r265" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r264" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities Greater than twelve months, Fair value", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r84", "r269", "r703" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Securities Greater than twelve months, Unrealized loss", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r84", "r269" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Securities Less than twelve months, Fair value", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r84", "r269", "r703" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Securities Less than twelve months, Unrealized loss", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r84", "r269" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table Text Block]", "verboseLabel": "Summary of Debt Securities, Available-for-sale", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Securities, Total Fair value", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Debt securities considered to be an unrealized loss position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r82", "r267", "r703" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Securities, Total Unrealized loss", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r83", "r268" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair value and Gross Unrealized Losses on Securities", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r81", "r703", "r887" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Current, Total", "label": "Deferred Revenue, Current", "terseLabel": "Short-term deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r845" ] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Noncurrent, Total", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Long-term deferred revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r846" ] }, "us-gaap_DeferredTaxAssetDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Asset [Domain]", "documentation": "Identification of the deferred tax asset for which a valuation reserve exists." } } }, "auth_ref": [ "r931" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "totalLabel": "Depreciation, Total", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r26" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r336", "r339", "r367", "r368", "r370", "r714" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "tngx_DiscoveryDirectProgramExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "DiscoveryDirectProgramExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Discovery Direct Program Expenses - R&D [Member]", "documentation": "Discovery direct program expenses - R&D.", "terseLabel": "Discovery direct program expenses - R&D [Member]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r748" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r780" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r791" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share - basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r133", "r147", "r148", "r149", "r150", "r151", "r152", "r158", "r160", "r163", "r164", "r165", "r169", "r403", "r412", "r440", "r441", "r520", "r540", "r687" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per common share - diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r133", "r147", "r148", "r149", "r150", "r151", "r152", "r160", "r163", "r164", "r165", "r169", "r403", "r412", "r440", "r441", "r520", "r540", "r687" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r157", "r166", "r167", "r168" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Effective income tax rate", "totalLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r377", "r715" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal statutory rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r138", "r377", "r388", "r715" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails": { "parentTag": "tngx_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Payroll and employee-related costs", "label": "Employee-related Liabilities, Current", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r36" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrecognized stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r369" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average amortization period", "verboseLabel": "Share-based compensation expense, Period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r369" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Stock options to purchase common stock [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r746" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r746" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r831" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r746" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r830" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r746" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r746" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r746" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r746" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r785" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r826" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r826" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r826" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equipment [Member]", "label": "Equipment [Member]", "terseLabel": "Laboratory Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r105", "r127", "r128", "r129", "r139", "r140", "r141", "r144", "r151", "r153", "r155", "r171", "r251", "r257", "r291", "r323", "r383", "r384", "r399", "r400", "r401", "r404", "r411", "r412", "r422", "r424", "r425", "r426", "r427", "r429", "r439", "r460", "r461", "r462", "r463", "r464", "r465", "r467", "r469", "r478", "r536", "r566", "r567", "r568", "r586", "r652" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r795" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r753", "r763", "r773", "r805" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r750", "r760", "r770", "r802" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r801" ] }, "tngx_FacilitiesAndOtherRelatedExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "FacilitiesAndOtherRelatedExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Facilities and Other Related Expenses - R&D [Member]", "documentation": "Facilities and other related expenses - R&D.", "terseLabel": "Facilities and other related expenses - R&D [Member]" } } }, "auth_ref": [] }, "tngx_FairValueAssetLevel1ToLevel2TransferAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "FairValueAssetLevel1ToLevel2TransferAmount", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value assets transfer from Level 1 to Level 2", "label": "Fair Value Asset Level1 To Level2 Transfer Amount", "documentation": "Fair value asset level1 to level2 transfer amount." } } }, "auth_ref": [] }, "tngx_FairValueAssetLevel2ToLevel1TransferAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "FairValueAssetLevel2ToLevel1TransferAmount", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value assets transfer from Level 2 to Level 1", "label": "Fair Value Asset Level2 To Level1 Transfer Amount", "documentation": "Fair value asset level2 to level1 transfer amount." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r443", "r444", "r451", "r716" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r443", "r444", "r451", "r716" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r716", "r934", "r935", "r940" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r314", "r329", "r330", "r331", "r332", "r333", "r334", "r442", "r444", "r445", "r446", "r447", "r450", "r451", "r453", "r482", "r483", "r484", "r705", "r706", "r710", "r711", "r712", "r716", "r719" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r443", "r444", "r445", "r447", "r716", "r937", "r941" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r314", "r329", "r334", "r444", "r451", "r482", "r710", "r711", "r712", "r716" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r314", "r329", "r334", "r444", "r445", "r451", "r483", "r705", "r706", "r710", "r711", "r712", "r716" ] }, "tngx_FairValueLiabilitiesLevel1ToLevel2TransferAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "FairValueLiabilitiesLevel1ToLevel2TransferAmounts", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value liabilities transfer from Level 1 to Level 2", "label": "Fair Value Liabilities Level1 To Level2 Transfer Amounts", "documentation": "Fair value liabilities level1 to level2 transfer amounts." } } }, "auth_ref": [] }, "tngx_FairValueLiabilitiesLevel2ToLevel1TransferAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "FairValueLiabilitiesLevel2ToLevel1TransferAmounts", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value liabilities transfer from Level 2 to Level 1", "label": "Fair Value Liabilities Level2 To Level1 Transfer Amounts", "documentation": "Fair value liabilities level2 to level1 transfer amounts." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r443", "r444", "r445", "r447", "r716", "r937", "r941" ] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r69" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r314", "r329", "r330", "r331", "r332", "r333", "r334", "r442", "r444", "r445", "r446", "r447", "r450", "r451", "r453", "r482", "r483", "r484", "r705", "r706", "r710", "r711", "r712", "r716", "r719" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value Measurements Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r716", "r934", "r935", "r936", "r937", "r938", "r941" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r258", "r259", "r260", "r261", "r262", "r266", "r270", "r271", "r315", "r320", "r430", "r454", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r537", "r703", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r727", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r882", "r883", "r884", "r885", "r933", "r936", "r937", "r938", "r939", "r941" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r512", "r516", "r681" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r681" ] }, "tngx_ForecastingTaxableLossPositionDeferredTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ForecastingTaxableLossPositionDeferredTaxAssetsMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Forecasting taxable loss position deferred tax assets member.", "label": "Forecasting Taxable Loss Position Deferred Tax Assets [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r757", "r767", "r777", "r809" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r757", "r767", "r777", "r809" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r757", "r767", "r777", "r809" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r757", "r767", "r777", "r809" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r757", "r767", "r777", "r809" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r790" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r53", "r636" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and Administrative [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r53" ] }, "tngx_GileadAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "GileadAgreementMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Gilead Agreement [Member]", "documentation": "Gilead Agreement ." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r51", "r73", "r78", "r521", "r534", "r689", "r695", "r863", "r865", "r866", "r867", "r868" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r292", "r294", "r296", "r448", "r449", "r452", "r561", "r563", "r637", "r681", "r718", "r957" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r294", "r296", "r448", "r449", "r452", "r561", "r563", "r637", "r681", "r718", "r957" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r138", "r375", "r377", "r378", "r379", "r380", "r381", "r382", "r389", "r391", "r394", "r395", "r585", "r715" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "negatedLabel": "Provision for income taxes", "verboseLabel": "Tax provision or benefit", "terseLabel": "Provision for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r85", "r99", "r154", "r155", "r170", "r187", "r202", "r376", "r377", "r390", "r541", "r715" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "IncreaseDecreaseInAccruedExpensesAndOtherLiabilities", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Increase (Decrease) In Accrued Expenses And Other Liabilities", "documentation": "Increase (decrease) in accrued expenses and other liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r682" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "tngx_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) In Operating Lease Liabilities", "documentation": "Increase (decrease) in operating lease liabilities." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other long-term assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r851" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r757", "r767", "r777", "r801", "r809", "r813", "r821" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r819" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r749", "r825" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r749", "r825" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r749", "r825" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Income (Expense), Net, Total", "label": "Interest Income (Expense), Operating", "terseLabel": "Interest income", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": [ "r517", "r865" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r598", "r599", "r600", "r601", "r602", "r655", "r658", "r660", "r664", "r665", "r666", "r668", "r669", "r670", "r671", "r672", "r736" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r598", "r599", "r600", "r601", "r602", "r655", "r658", "r660", "r664", "r665", "r666", "r668", "r669", "r670", "r671", "r672", "r736" ] }, "us-gaap_InvestmentTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeExtensibleEnumeration", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Type [Extensible Enumeration]", "documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company." } } }, "auth_ref": [ "r598", "r601", "r656", "r658", "r659", "r660", "r661", "r665", "r667", "r668" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "totalLabel": "Marketable debt securities", "verboseLabel": "Marketable debt securities", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r934", "r935", "r939" ] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/MarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r75", "r102", "r212", "r214", "r455", "r456", "r952" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r63", "r472" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r10", "r35", "r36", "r37", "r38", "r39", "r40", "r41", "r137", "r246", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r415", "r416", "r417", "r459", "r611", "r688", "r744", "r901", "r943", "r944" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r49", "r72", "r530", "r726", "r855", "r886", "r942" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r37", "r112", "r137", "r246", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r415", "r416", "r417", "r459", "r726", "r901", "r943", "r944" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "tngx_LicenseRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "LicenseRevenueMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "License Revenue [Member]", "documentation": "License Revenue Member" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "tngx_MarketableDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "MarketableDebtSecuritiesMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Debt Securities [Member]", "documentation": "Marketable Debt Securities .", "terseLabel": "Marketable Debt Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "totalLabel": "Marketable Securities, Current, Total", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r844" ] }, "us-gaap_MarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table]", "documentation": "Disclosure of information about investment in marketable security." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Marketable Security, Unrealized Gain (Loss)", "totalLabel": "Marketable Securities, Unrealized Gain (Loss), Total", "terseLabel": "Unrealized loss on marketable securities", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r54" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r335", "r373", "r447", "r510", "r560", "r562", "r576", "r603", "r604", "r657", "r659", "r662", "r663", "r667", "r679", "r680", "r702", "r707", "r713", "r719", "r720", "r724", "r725", "r729", "r903", "r945", "r946", "r947", "r948", "r949", "r950" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r793" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r793" ] }, "tngx_MedivirAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "MedivirAgreementMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Medivir agreement.", "label": "Medivir Agreement [Member]", "terseLabel": "Medivir Agreement [Member]" } } }, "auth_ref": [] }, "tngx_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "MilestonePayments", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "auth_ref": [] }, "tngx_MilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "MilestonePaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments receivable", "label": "Milestone Payments Receivable", "documentation": "Milestone payments receivable." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r335", "r373", "r447", "r510", "r560", "r562", "r576", "r603", "r604", "r657", "r659", "r662", "r663", "r667", "r679", "r680", "r702", "r707", "r713", "r719", "r720", "r724", "r729", "r903", "r945", "r946", "r947", "r948", "r949", "r950" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r812" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds, at Carrying Value", "terseLabel": "Cash equivalents, Money market funds", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r820" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r794" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r134" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r134" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r58", "r59", "r60" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited2": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r52", "r60", "r74", "r110", "r123", "r125", "r129", "r137", "r143", "r147", "r148", "r149", "r150", "r151", "r154", "r155", "r162", "r246", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r403", "r412", "r441", "r459", "r535", "r633", "r650", "r651", "r742", "r901" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r793" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r757", "r767", "r777", "r801", "r809" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r784" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r783" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r801" ] }, "tngx_NonRefundableUpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "NonRefundableUpfrontPaymentReceived", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-refundable\u00a0upfront payment received", "label": "Non Refundable Upfront Payment Received", "documentation": "Non-refundable upfront payment received." } } }, "auth_ref": [] }, "tngx_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "NonRule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non Rule 10B51 Arr Modified Flag", "documentation": "Non-Rule 10b5-1 Arrangement Modified Flag.", "terseLabel": "Non-Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r820" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r820" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r55" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income:" } } }, "auth_ref": [] }, "tngx_NonrefundableUpfrontPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "NonrefundableUpfrontPaymentsReceived", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Nonrefundable Upfront Payments Received", "terseLabel": "Non-refundable upfront payment received", "documentation": "Non-refundable upfront payments received" } } }, "auth_ref": [] }, "tngx_NumberOfLicensedProduct": { "xbrltype": "integerItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "NumberOfLicensedProduct", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Licensed Product", "documentation": "Number Of Licensed Product.", "terseLabel": "Number of licensed product" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r696", "r864" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r78", "r689", "r863", "r865", "r866", "r867", "r868" ] }, "tngx_OperatingLeaseLiabilitiesFromObtainingRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "OperatingLeaseLiabilitiesFromObtainingRightOfUseAssets", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease Liabilities from Obtaining Right-of-Use Assets", "documentation": "Operating lease liabilities from obtaining right-of-use assets.", "terseLabel": "Operating lease liabilities from obtaining right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r471" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r471" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease\u00a0right-of-use\u00a0asset", "terseLabel": "Operating lease\u00a0right-of-use\u00a0assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r470" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash operating lease expense", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r852" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of the Business and Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r32", "r68", "r577", "r578" ] }, "tngx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "documentation": "Organization consolidation and presentation Of financial statements." } } }, "auth_ref": [] }, "tngx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "documentation": "Organization consolidation and presentation of financial statements." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails": { "parentTag": "tngx_AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r36" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "totalLabel": "Other Assets, Noncurrent, Total", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r116" ] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax", "totalLabel": "Other Comprehensive Income (Loss), Tax, Total", "terseLabel": "Other comprehensive loss", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r2", "r127", "r131", "r376", "r392", "r393", "r460", "r463", "r465", "r518", "r536" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Other Noncash Income (Expense)", "totalLabel": "Other Noncash Income (Expense), Total", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r60" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "terseLabel": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r56" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r793" ] }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairments to marketable securities or reserves for credit losses", "totalLabel": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale", "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI)." } } }, "auth_ref": [ "r80" ] }, "tngx_OtherThanTemporaryImpairmentLossDebtSecuritiesReservesCreditLossesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesReservesCreditLossesAvailableForSale", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairments to marketable securities or reserves for credit losses", "label": "Other Than Temporary Impairment Loss Debt Securities Reserves Credit losses Available For Sale", "documentation": "Other than temporary impairment loss debt securities reserves credit losses available for sale." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r755", "r765", "r775", "r807" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r758", "r768", "r778", "r810" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r758", "r768", "r778", "r810" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r782" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "verboseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable securities", "label": "Payments to Acquire Marketable Securities", "totalLabel": "Payments to Acquire Marketable Securities, Total", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r870" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r57" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r792" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r792" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r784" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r801" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r794" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r783" ] }, "tngx_PercentageOfOwnershipInterestInEquityInvestment": { "xbrltype": "percentItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "PercentageOfOwnershipInterestInEquityInvestment", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage in common stock", "label": "Percentage of Ownership Interest in Equity Investment", "documentation": "Percentage of ownership interest in equity investment." } } }, "auth_ref": [] }, "tngx_Personnel-RelatedExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "Personnel-RelatedExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Personnel-related expenses - R&D [Member]", "label": "Personnel-Related Expenses - R&D [Member]", "documentation": "Personnel-related expenses - R&D." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r785" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r829" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r784" ] }, "tngx_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Pre-funded warrants.", "label": "Pre-funded Warrants [Member]", "terseLabel": "Pre-funded Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r847" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "tngx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds From Issuance of Common Stock and Pre-funded Warrants, Net", "documentation": "Proceeds from issuance of common stock and pre-funded warrants, net.", "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants" } } }, "auth_ref": [] }, "tngx_ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsAndPurchaseOfSharesUnderEmployeeStockPurchasePlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsAndPurchaseOfSharesUnderEmployeeStockPurchasePlans", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under employee stock purchase plans.", "label": "Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under Employee stock purchase plans", "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options and purchase of shares under ESPP" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and maturities of marketable securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r205", "r511", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r683", "r709", "r728", "r729", "r730", "r732", "r733", "r899", "r900", "r904", "r956", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r205", "r511", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r683", "r709", "r728", "r729", "r730", "r732", "r733", "r899", "r900", "r904", "r956", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5", "r472" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment, Gross", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r63", "r114", "r533" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r472" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r472", "r522", "r533", "r726" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r5", "r91", "r96", "r531" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule of Property, Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r63", "r472" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r782" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r782" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r328", "r335", "r362", "r363", "r364", "r373", "r447", "r485", "r494", "r510", "r560", "r562", "r576", "r603", "r604", "r657", "r659", "r662", "r663", "r667", "r679", "r680", "r702", "r707", "r713", "r719", "r720", "r724", "r725", "r729", "r736", "r897", "r903", "r937", "r946", "r947", "r948", "r949", "r950" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r328", "r335", "r362", "r363", "r364", "r373", "r447", "r485", "r494", "r510", "r560", "r562", "r576", "r603", "r604", "r657", "r659", "r662", "r663", "r667", "r679", "r680", "r702", "r707", "r713", "r719", "r720", "r724", "r725", "r729", "r736", "r897", "r903", "r937", "r946", "r947", "r948", "r949", "r950" ] }, "tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements", "label": "Recently Issued Accounting Pronouncements [Policy Text Block]", "documentation": "Disclosure of accounting policy for recently issued accounting pronouncements." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r750", "r760", "r770", "r802" ] }, "tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "RedeemableConvertiblePreferredStockDisclosureTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStock" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable Convertible Preferred Stock", "label": "Redeemable Convertible Preferred Stock Disclosure [Text Block]", "documentation": "Redeemable convertible preferred stock disclosure." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r374", "r681", "r695", "r951" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "tngx_ResearchExtensionFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ResearchExtensionFee", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research Extension Fee", "documentation": "Research Extension Fee .", "terseLabel": "Research extension fee" } } }, "auth_ref": [] }, "tngx_ResearchExtensionFeeVariableConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ResearchExtensionFeeVariableConsideration", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research extension fees, variable consideration", "documentation": "Research extension fee variable consideration.", "label": "Research Extension Fee Variable Consideration" } } }, "auth_ref": [] }, "tngx_ResearchTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ResearchTerm", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research Term", "documentation": "Research term.", "terseLabel": "Research term" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r751", "r761", "r771", "r803" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r752", "r762", "r772", "r804" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r759", "r769", "r779", "r811" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Cash", "totalLabel": "Restricted Cash, Total", "verboseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r842", "r853", "r953", "r955" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Axis]", "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage." } } }, "auth_ref": [ "r33" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r113" ] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r15", "r86", "r135" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Short-term restricted cash", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r842", "r853" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash, net of current portion", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r86", "r843", "r853" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards [Member]", "verboseLabel": "Unvested restricted common stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r19" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSU [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r46", "r65", "r529", "r570", "r575", "r584", "r614", "r726" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r105", "r139", "r140", "r141", "r144", "r151", "r153", "r155", "r251", "r257", "r291", "r383", "r384", "r399", "r400", "r401", "r404", "r411", "r412", "r422", "r425", "r426", "r429", "r439", "r467", "r469", "r566", "r568", "r586", "r988" ] }, "tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Revaluation of Right-of-use Asset and Lease Liability Upon Lease Modification", "documentation": "Revaluation of right-of-use asset and lease liability upon lease modification.", "terseLabel": "Revaluation of right-of-use asset and lease liability upon lease remeasurement" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction price allocated to performance obligation", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r94" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue remaining performance obligations expected remaining contractual term", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r95" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r95" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenue", "label": "Revenues", "totalLabel": "Total collaboration revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r76", "r77", "r130", "r137", "r170", "r180", "r181", "r196", "r202", "r205", "r207", "r208", "r246", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r459", "r521", "r695", "r901" ] }, "tngx_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "Rule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10B51 Arr Modified Flag", "documentation": "Rule 10b5-1 Arrangement Modified Flag.", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r820" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r820" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares sold", "verboseLabel": "Number of units issued in transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Accrued Expenses And Other Current Liabilities Current [Table Text Block]", "documentation": "Schedule of accrued expenses and other current liabilities current.", "verboseLabel": "Schedule of Accrued Expenses and Other Current Liabilities Current" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r413" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r862" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r31" ] }, "tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of estimated useful lives of the Company's property and equipment.", "label": "Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]", "terseLabel": "Summary of estimated useful lives of property and equipment" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5", "r472" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Expense", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r337", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r66" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Unit Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r745" ] }, "tngx_SecurityDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SecurityDepositsMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Security Deposits [Member]", "documentation": "Security deposits." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r747" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r76", "r77", "r78", "r79", "r170", "r175", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r208", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r289", "r297", "r298", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r691", "r695", "r696", "r704", "r731", "r956", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting." } } }, "auth_ref": [ "r178", "r694", "r701" ] }, "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description", "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource." } } }, "auth_ref": [ "r195", "r691", "r698" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r79", "r170", "r174", "r175", "r176", "r177", "r179", "r191", "r193", "r194", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r208", "r690", "r692", "r693", "r695", "r697", "r699", "r700" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Other Segment Item, Amount", "terseLabel": "Other segment expenses", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": [ "r170", "r193", "r194", "r202", "r695" ] }, "tngx_SeriesBOnePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SeriesBOnePreferredStockMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Series B One Preferred Stock [Member]", "documentation": "Series B One\u00a0Preferred Stock.", "terseLabel": "Series B-1 Preferred Stock [Member]" } } }, "auth_ref": [] }, "tngx_SesameAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SesameAgreementMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sesame Agreement", "label": "Sesame Agreement [Member]", "documentation": "Sesame Agreement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Disclosure [Abstract]", "label": "Share-Based Payment Arrangement, Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Stock Units, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r356" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r356" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Stock Units, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r354" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r354" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Stock Units, Unvested and outstanding Ending balance", "periodStartLabel": "Number of Stock Units, Unvested and outstanding Beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r351", "r352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested and outstanding Ending balance", "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested and outstanding Beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r351", "r352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Stock Units, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Stock Units, Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r355" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r355" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r337", "r338", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "verboseLabel": "Number of shares Options exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r345" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares Cancelled", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r349" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Number of shares Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r347" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate Intrinsic Value, Options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodStartLabel": "Number of shares, Options outstanding Beginning balance", "periodEndLabel": "Number of shares, Options outstanding Ending balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r343", "r344" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price, Options outstanding Ending balance", "periodStartLabel": "Weighted Average Exercise Price, Options outstanding Beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r343", "r344" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r348" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price Cancelled", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r349" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Exercise Price Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r347" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate Intrinsic Value Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r30" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Contractual Term Options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r30" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Contractual Term, Options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r67" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodStartLabel": "Balance at the beginning (in Shares)", "periodEndLabel": "Balance at the ending (in Shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "tngx_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SignificantAccountingPoliciesLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "tngx_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SignificantAccountingPoliciesTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Table]", "label": "Significant Accounting Policies [Table]", "documentation": "Significant accounting policies." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r61", "r136" ] }, "tngx_SpecifiedClinicalMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SpecifiedClinicalMilestonesMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Specified clinical milestones.", "label": "Specified Clinical Milestones [Member]", "terseLabel": "Specified Clinical Milestones [Member]" } } }, "auth_ref": [] }, "tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Specified regulatory and sales milestones for genetic context.", "label": "Specified Regulatory And Sales Milestones For Genetic Context [Member]", "terseLabel": "Specified Regulatory And Sales Milestones For Genetic Context [Member]" } } }, "auth_ref": [] }, "tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SpecifiedRegulatoryApprovalAndSalesMilestonesMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Specified regulatory approval and sales milestones.", "label": "Specified Regulatory Approval And Sales Milestones [Member]", "terseLabel": "Specified Regulatory Approval And Sales Milestones [Member]" } } }, "auth_ref": [] }, "tngx_SponsoredALicenceProgramfeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "SponsoredALicenceProgramfeeAmount", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "License fee amount", "label": "Sponsored A Licence Program,Fee Amount", "documentation": "Sponsored a license program, fee amount." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r76", "r77", "r78", "r79", "r109", "r170", "r175", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r208", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r289", "r293", "r297", "r298", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r691", "r695", "r696", "r704", "r731", "r956", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r101", "r118", "r119", "r120", "r137", "r160", "r161", "r163", "r165", "r172", "r173", "r246", "r305", "r307", "r308", "r309", "r312", "r313", "r316", "r317", "r318", "r319", "r321", "r459", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r613", "r634", "r652", "r673", "r674", "r675", "r676", "r677", "r832", "r854", "r861" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r44", "r47", "r48", "r105", "r127", "r128", "r129", "r139", "r140", "r141", "r144", "r151", "r153", "r155", "r171", "r251", "r257", "r291", "r323", "r383", "r384", "r399", "r400", "r401", "r404", "r411", "r412", "r422", "r424", "r425", "r426", "r427", "r429", "r439", "r460", "r461", "r462", "r463", "r464", "r465", "r467", "r469", "r478", "r536", "r566", "r567", "r568", "r586", "r652" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r139", "r140", "r141", "r171", "r469", "r511", "r579", "r597", "r605", "r606", "r607", "r608", "r609", "r610", "r613", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r626", "r627", "r628", "r629", "r630", "r632", "r635", "r636", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r652", "r737" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r139", "r140", "r141", "r171", "r211", "r469", "r511", "r579", "r597", "r605", "r606", "r607", "r608", "r609", "r610", "r613", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r626", "r627", "r628", "r629", "r630", "r632", "r635", "r636", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r652", "r737" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r754", "r764", "r774", "r806" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "tngx_StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsNet": { "xbrltype": "sharesItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "StockIssuedDuringPeriodSharesCommonStockAndPreFundedWarrantsNet", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares common stock and pre funded warrants net.", "label": "Stock Issued During Period Shares Common Stock And Pre Funded Warrants Net", "terseLabel": "Issuance of common stock from private placement financing, net (in Shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under stock plans, (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r7", "r43", "r44", "r65" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "At-the-market offerings, net of issuance costs (in shares)", "terseLabel": "Common stock, shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r43", "r44", "r65", "r580", "r652", "r674" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share based payment arrangement,Options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options, (in Shares)", "negatedLabel": "Number of shares Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r7", "r43", "r44", "r65", "r348" ] }, "tngx_StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsNet", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value common stock and pre funded warrants net.", "label": "Stock Issued During Period Value Common Stock And Pre Funded Warrants Net", "terseLabel": "Issuance of common stock from private placement financing, net" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under stock plans", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r7", "r43", "r44", "r65" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "At-the-market offerings, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r43", "r44", "r65", "r586", "r652", "r674", "r743" ] }, "tngx_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "StockOptionsMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options [Member]", "label": "Stock Options [Member]", "documentation": "Stock options." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at the beginning", "periodEndLabel": "Balance at the ending", "label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r44", "r47", "r48", "r62", "r615", "r631", "r653", "r654", "r726", "r744", "r855", "r886", "r942", "r988" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/SupplementalBalanceSheetInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Balance Sheet Information", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r841" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "tngx_TNG260DirectProgramExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TNG260DirectProgramExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "TNG260 Direct Program Expenses - R&D [Member]", "documentation": "TNG260 direct program expenses - R&D.", "terseLabel": "TNG260 direct program expenses - R&D [Member]" } } }, "auth_ref": [] }, "tngx_TNG348DirectProgramExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TNG348DirectProgramExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TNG348 direct program expenses - R&D [Member]", "label": "TNG348 Direct Program Expenses- R&D [Member]", "documentation": "TNG348 direct program expenses- R&D." } } }, "auth_ref": [] }, "tngx_TNG456DirectProgramExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TNG456DirectProgramExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "TNG456 Direct Program Expenses - R&D [Member]", "documentation": "TNG456 direct program expenses - R&D.", "terseLabel": "TNG456 direct program expenses - R&D [Member]" } } }, "auth_ref": [] }, "tngx_TNG462DirectProgramExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TNG462DirectProgramExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "TNG462 Direct Program Expenses - R&D [Member]", "documentation": "TNG462 direct program expenses - R&D.", "terseLabel": "TNG462 direct program expenses - R&D [Member]" } } }, "auth_ref": [] }, "tngx_TNG908DirectProgramExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TNG908DirectProgramExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "label": "TNG908 Direct Program Expenses - R&D [Member]", "documentation": "TNG908 direct program expenses - R&D .", "terseLabel": "TNG908 direct program expenses - R&D [Member]" } } }, "auth_ref": [] }, "tngx_TNG961DirectProgramExpenses-RDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TNG961DirectProgramExpenses-RDMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TNG961 direct program expenses - R&D [Member]", "label": "TNG961 Direct Program Expenses - R&D [Member]", "documentation": "TNG961 Direct Program Expenses - R&D [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r800" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Taxes Payable, Current, Total", "label": "Taxes Payable, Current", "terseLabel": "Income tax payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35", "r36" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodStartLabel": "Balance at the beginning", "periodEndLabel": "Balance at the ending", "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r305", "r307", "r308", "r309", "r312", "r313", "r371", "r527" ] }, "us-gaap_TemporaryEquityDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Temporary Equity Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable convertible preferred stock Par or Stated Value Per Share", "terseLabel": "Temporary Equity, Par or Stated Value Per Share", "label": "Temporary Equity, Par or Stated Value Per Share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r11", "r28" ] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable convertible preferred stock shares authorized", "terseLabel": "Temporary Equity, Shares Authorized", "label": "Temporary Equity, Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r42" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Redeemable convertible preferred stock, issued", "terseLabel": "Temporary Equity, Shares Issued", "verboseLabel": "Redeemable Convertible Preferred Stock Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r42" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.tangotx.com/20250331/taxonomy/role/RedeemableConvertiblePreferredStockAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Redeemable convertible preferred stock, outstanding", "terseLabel": "Temporary Equity, Shares Outstanding", "periodStartLabel": "Balance at the beginning (in Shares)", "periodEndLabel": "Balance at the ending (in Shares)", "verboseLabel": "Redeemable Convertible Preferred Stock Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r42" ] }, "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Par Value", "terseLabel": "Temporary equity, par value", "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r11", "r28" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r792" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r799" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r819" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r821" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r315", "r320", "r430", "r454", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r537", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r727", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r882", "r883", "r884", "r885", "r933", "r936", "r937", "r938", "r939", "r941" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r822" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r823" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r823" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r821" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r821" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r824" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r822" ] }, "tngx_TwoThousandAndEighteenGileadAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TwoThousandAndEighteenGileadAgreementMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand And Eighteen Gilead Agreement [Member]", "documentation": "Two Thousand And Eighteen Gilead Agreement .", "terseLabel": "2018 Gilead Agreement [Member]" } } }, "auth_ref": [] }, "tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Employee Stock Purchase Plan [Member]", "label": "Two Thousand and Twenty One Employee Stock Purchase Plan [Member]", "documentation": "Two thousand and twenty one employee stock purchase plan." } } }, "auth_ref": [] }, "tngx_TwoThousandAndTwentyOnePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TwoThousandAndTwentyOnePlanMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Plan [Member]", "documentation": "Two thousand and twenty one plan.", "label": "Two Thousand And Twenty One Plan [Member]" } } }, "auth_ref": [] }, "tngx_TwoThousandTwentyThreeInducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "TwoThousandTwentyThreeInducementPlanMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Inducement Plan [Member]", "label": "Two Thousand Twenty Three Inducement Plan [Member]", "documentation": "Two Thousand Twenty Three Inducement Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r103", "r104", "r105", "r106", "r107", "r108", "r143", "r144", "r145", "r146", "r156", "r209", "r210", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r290", "r291", "r295", "r383", "r384", "r385", "r386", "r387", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r457", "r458", "r466", "r467", "r468", "r473", "r474", "r475", "r476", "r477", "r478", "r513", "r514", "r515", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r413" ] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Bonds [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r686", "r710", "r954" ] }, "us-gaap_USGovernmentSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentSecuritiesAtCarryingValue", "crdr": "debit", "calculation": { "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "US Government Securities, at Carrying Value", "terseLabel": "Cash equivalents, U.S. Treasury bills", "documentation": "Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnARecurringBasisDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails", "http://www.tangotx.com/20250331/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfFairValueAndGrossUnrealizedLossesOnSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury Bills [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r686", "r710", "r712", "r716", "r954" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r818" ] }, "tngx_UpfrontPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tangotx.com/20250331", "localname": "UpfrontPayment", "crdr": "credit", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Upfront payment.", "label": "Upfront Payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r20", "r21", "r22", "r88", "r90", "r92", "r93" ] }, "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceByDeferredTaxAssetAxis", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance by Deferred Tax Asset [Axis]", "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences." } } }, "auth_ref": [ "r931" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r788" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average common stock outstanding - diluted", "terseLabel": "Weighted average number of common shares outstanding - diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r159", "r165" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.tangotx.com/20250331/taxonomy/role/DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails", "http://www.tangotx.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average common stock outstanding - basic", "terseLabel": "Weighted average number of common shares outstanding - basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r158", "r165" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r786" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-8A" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2A" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r832": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 67 0000950170-25-068549-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-25-068549-xbrl.zip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�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end XML 68 tngx-20250331_htm.xml IDEA: XBRL DOCUMENT 0001819133 tngx:TNG462DirectProgramExpenses-RDMember 2024-01-01 2024-03-31 0001819133 tngx:SecurityDepositsMember 2024-03-31 0001819133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0001819133 2025-03-31 0001819133 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2025-03-31 0001819133 tngx:TNG456DirectProgramExpenses-RDMember 2025-01-01 2025-03-31 0001819133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001819133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-31 0001819133 us-gaap:CommonStockMember 2025-03-31 0001819133 us-gaap:ConstructionInProgressMember 2024-12-31 0001819133 tngx:FacilitiesAndOtherRelatedExpenses-RDMember 2025-01-01 2025-03-31 0001819133 tngx:SpecifiedRegulatoryApprovalAndSalesMilestonesMember tngx:MedivirAgreementMember 2020-03-31 0001819133 tngx:ComputerSoftwareMember 2024-12-31 0001819133 tngx:TwoThousandAndEighteenGileadAgreementMember 2018-10-01 2018-10-31 0001819133 tngx:AmendedGileadAgreementMember 2025-01-01 2025-03-31 0001819133 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001819133 srt:MaximumMember 2024-01-01 2024-03-31 0001819133 tngx:FacilitiesAndOtherRelatedExpenses-RDMember 2024-01-01 2024-03-31 0001819133 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0001819133 tngx:AmendedGileadAgreementMember 2021-09-30 0001819133 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001819133 tngx:TwoThousandAndTwentyOnePlanMember 2025-03-31 0001819133 2024-03-31 0001819133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001819133 tngx:Personnel-RelatedExpenses-RDMember 2024-01-01 2024-03-31 0001819133 tngx:PreFundedWarrantsMember 2023-08-11 0001819133 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001819133 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-31 0001819133 tngx:SecurityDepositsMember 2025-03-31 0001819133 tngx:AmendedGileadAgreementMember 2020-12-31 0001819133 tngx:TNG348DirectProgramExpenses-RDMember 2024-01-01 2024-03-31 0001819133 tngx:TNG260DirectProgramExpenses-RDMember 2024-01-01 2024-03-31 0001819133 tngx:TwoThousandAndEighteenGileadAgreementMember 2025-01-01 2025-03-31 0001819133 us-gaap:RetainedEarningsMember 2023-12-31 0001819133 tngx:SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember tngx:MedivirAgreementMember 2020-03-31 0001819133 tngx:CollaborationRevenueMember tngx:GileadAgreementMember 2025-01-01 2025-03-31 0001819133 tngx:TNG908DirectProgramExpenses-RDMember 2025-01-01 2025-03-31 0001819133 tngx:StockOptionsMember 2025-03-31 0001819133 tngx:AmendedGileadAgreementMember 2020-08-31 0001819133 tngx:SesameAgreementMember 2024-06-30 0001819133 tngx:TNG908DirectProgramExpenses-RDMember 2024-01-01 2024-03-31 0001819133 tngx:CollaborationRevenueMember 2024-01-01 2024-03-31 0001819133 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001819133 tngx:AmendedGileadAgreementMember 2020-08-01 2020-08-31 0001819133 2025-01-01 2025-03-31 0001819133 2024-12-31 0001819133 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001819133 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001819133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001819133 us-gaap:ComputerEquipmentMember 2024-12-31 0001819133 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001819133 tngx:CollaborationRevenueMember tngx:GileadAgreementMember 2024-01-01 2024-03-31 0001819133 us-gaap:RetainedEarningsMember 2024-03-31 0001819133 us-gaap:RetainedEarningsMember 2024-12-31 0001819133 tngx:MarketableDebtSecuritiesMember 2025-01-01 2025-03-31 0001819133 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-12-31 0001819133 us-gaap:USTreasurySecuritiesMember 2024-12-31 0001819133 2025-05-05 0001819133 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001819133 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-12-31 0001819133 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0001819133 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001819133 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001819133 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001819133 tngx:GileadAgreementMember 2025-03-31 0001819133 us-gaap:EquipmentMember 2024-12-31 0001819133 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001819133 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001819133 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2025-03-31 0001819133 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001819133 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001819133 tngx:ComputerSoftwareMember 2025-03-31 0001819133 tngx:TNG348DirectProgramExpenses-RDMember 2025-01-01 2025-03-31 0001819133 us-gaap:EquipmentMember 2025-03-31 0001819133 us-gaap:RetainedEarningsMember 2025-03-31 0001819133 tngx:ForecastingTaxableLossPositionDeferredTaxAssetsMember 2025-01-01 2025-03-31 0001819133 us-gaap:FurnitureAndFixturesMember 2025-03-31 0001819133 tngx:GileadAgreementMember 2024-12-31 0001819133 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0001819133 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001819133 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001819133 tngx:TNG961DirectProgramExpenses-RDMember 2025-01-01 2025-03-31 0001819133 tngx:StockOptionsMember 2025-01-01 2025-03-31 0001819133 tngx:DiscoveryDirectProgramExpenses-RDMember 2025-01-01 2025-03-31 0001819133 us-gaap:CommonStockMember 2024-03-31 0001819133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001819133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001819133 tngx:MedivirAgreementMember 2020-03-31 0001819133 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-12-31 0001819133 tngx:TNG462DirectProgramExpenses-RDMember 2025-01-01 2025-03-31 0001819133 tngx:MarketableDebtSecuritiesMember 2025-03-31 0001819133 tngx:TNG961DirectProgramExpenses-RDMember 2024-01-01 2024-03-31 0001819133 tngx:SpecifiedClinicalMilestonesMember tngx:MedivirAgreementMember 2020-03-31 0001819133 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001819133 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001819133 tngx:DiscoveryDirectProgramExpenses-RDMember 2024-01-01 2024-03-31 0001819133 us-gaap:ComputerEquipmentMember 2025-03-31 0001819133 us-gaap:USTreasurySecuritiesMember 2025-03-31 0001819133 us-gaap:ConstructionInProgressMember 2025-03-31 0001819133 srt:MaximumMember 2025-01-01 2025-03-31 0001819133 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0001819133 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001819133 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001819133 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001819133 tngx:TNG260DirectProgramExpenses-RDMember 2025-01-01 2025-03-31 0001819133 2023-12-31 0001819133 tngx:Personnel-RelatedExpenses-RDMember 2025-01-01 2025-03-31 0001819133 tngx:TwoThousandTwentyThreeInducementPlanMember 2025-03-31 0001819133 2025-04-01 2025-03-31 0001819133 us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001819133 2024-01-01 2024-03-31 0001819133 2024-01-01 2024-12-31 0001819133 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001819133 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-31 0001819133 us-gaap:PrivatePlacementMember 2023-08-11 2023-08-11 0001819133 us-gaap:CommonStockMember 2024-12-31 0001819133 tngx:SeriesBOnePreferredStockMember tngx:AmendedGileadAgreementMember 2020-08-31 0001819133 us-gaap:GeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001819133 tngx:TNG456DirectProgramExpenses-RDMember 2024-01-01 2024-03-31 0001819133 tngx:MarketableDebtSecuritiesMember 2024-01-01 2024-12-31 0001819133 tngx:CollaborationRevenueMember 2025-01-01 2025-03-31 0001819133 tngx:TwoThousandAndEighteenGileadAgreementMember 2018-01-01 2018-12-31 0001819133 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001819133 us-gaap:CommonStockMember 2023-12-31 0001819133 tngx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember 2025-01-01 2025-03-31 0001819133 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-03-31 0001819133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 tngx:Program pure shares tngx:Segment iso4217:USD shares iso4217:USD Q1 0001819133 false --12-31 http://www.tangotx.com/20250331#MarketableDebtSecuritiesMember http://www.tangotx.com/20250331#MarketableDebtSecuritiesMember http://fasb.org/us-gaap/2024#MarketableSecuritiesCurrent http://fasb.org/us-gaap/2024#MarketableSecuritiesCurrent http://fasb.org/srt/2024#ChiefExecutiveOfficerMember 10-Q true 2025-03-31 2025 false 001-39485 TANGO THERAPEUTICS, INC. DE 85-1195036 201 Brookline Ave. Suite 901 Boston MA 02215 857 320-4900 Common stock, par value $0.001 per share TNGX NASDAQ Yes Yes Large Accelerated Filer false false false 108394190 58432000 69530000 158292000 188387000 428000 0 7778000 8426000 224930000 266343000 7539000 8102000 39697000 39476000 2139000 2567000 1000 4000 274306000 316492000 3239000 1601000 10374000 16497000 2824000 2454000 19480000 17618000 35917000 38170000 34122000 34039000 37511000 44766000 107550000 116975000 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 200000000 200000000 108107890 108107890 107729343 107729343 108000 108000 707888000 700631000 194000 336000 -541434000 -501558000 166756000 199517000 274306000 316492000 5392000 6471000 36442000 38065000 11480000 10661000 47922000 48726000 -42530000 -42255000 1614000 2197000 1074000 2184000 2688000 4381000 -39842000 -37874000 34000 40000 -39876000 -37914000 -0.36 -0.36 -0.35 -0.35 110301256 110301256 108171463 108171463 -39876000 -37914000 -142000 -443000 -40018000 -38357000 107729343 108000 700631000 336000 -501558000 199517000 378547 2000 2000 7255000 7255000 -142000 -142000 -39876000 -39876000 108107890 108000 707888000 194000 -541434000 166756000 102202759 102000 624076000 186000 -371256000 253108000 526826 1000 1258000 1259000 4001200 4000 41719000 41723000 6719000 6719000 -443000 -443000 -37914000 -37914000 106730785 107000 673772000 -257000 -409170000 264452000 -39876000 -37914000 622000 625000 1012000 925000 7255000 6719000 -638000 -1371000 56000 10000 -649000 -360000 -1000 -35000 1630000 1042000 -6124000 -1609000 -780000 -188000 -5392000 -6471000 -41697000 -37857000 51000 195000 77812000 109255000 47164000 120263000 30597000 -11203000 41723000 2000 1259000 2000 42982000 -11098000 -6078000 72097000 69808000 60999000 63730000 1935000 1351000 8000 71000 1308000 75000 497000 <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of the Business and Basis of Presentation </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tango Therapeutics, Inc. is a precision oncology company committed to the discovery and development of novel drugs in defined patient populations with high unmet medical need.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tango Therapeutics, Inc. (together with its consolidated subsidiaries, Tango or the Company), formerly known as BCTG Acquisition Corp. (BCTG), was incorporated in Delaware on May 21, 2020. BCTG was a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated financial statements reflect the operations of Tango and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the opinion of management, all adjustments necessary for a fair statement of the financial information, which are of a normal and recurring nature, have been made for the interim periods reported. Results of operations for the three months ended March 31, 2025 and 2024 are not necessarily indicative of the results for the year ending December 31, 2025, any other interim periods, or any future year or period. The unaudited condensed consolidated financial statements for the three months ended March 31, 2025 and 2024 have been prepared on the same basis as and should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on February 27, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expects that its existing cash, cash equivalents and marketable securities as of March 31, 2025 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">216.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance date of these financial statements with an expected cash runway into the first quarter of 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since inception, the Company has incurred significant operating losses and expects to continue to generate operating losses and negative cash flows from operations for the foreseeable future. The Company will need to finance its operations through public or private securities offerings, debt financings or other sources, which may include licensing, collaborations or other strategic transactions or arrangements. If the Company is unable to obtain funding, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</span></p> 216700000 <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no significant changes from the significant accounting policies disclosed in Note 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024.</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its consolidated financial statements and disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">." The standard is intended to enhance the existing income tax disclosures to provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The standard is effective for annual periods beginning after December 15, 2024. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">" The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.</span></p></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosures. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on its consolidated financial statements and disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">." The standard is intended to enhance the existing income tax disclosures to provide information to better assess how an entity’s operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. The standard is effective for annual periods beginning after December 15, 2024. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">" The standard is intended to require more detailed disclosures about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is evaluating the potential impact of this adoption on the consolidated financial statements and related disclosures.</span></p> <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration Agreements </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2018, the Company entered into a Research Collaboration and License Agreement (the 2018 Gilead Agreement) with Gilead Sciences, Inc. (Gilead). Pursuant to the terms of the 2018 Gilead Agreement, the Company received an initial upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">five</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> validated programs (Gilead Program License).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2020, the Company and Gilead entered into an Amended Research Collaboration and License Agreement (the Gilead Agreement), which superseded and replaced the 2018 Gilead Agreement. The Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the 2018 Gilead Agreement. Under the Gilead Agreement:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company received upfront, non-refundable consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from Gilead upon execution of the Gilead Agreement in 2020; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement has a research term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gilead expanded its option to license up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> programs for which Gilead may obtain exclusive, worldwide licenses to develop and commercialize therapies, subject to applicable license fees; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to exercising its option to license a program, Gilead may “extend” such program, in which case Gilead will pay research option-extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gilead has the option to “reserve” a target during which Gilead may: (i) license the target, (ii) “extend” the target, or (iii) decline the target, during the designated reserve target period. If, during the reserve target period Tango elects to work on the reserved target, Tango will retain full rights to the target program and Gilead receives a right of first negotiation in connection with any future partnering or licensing of such target by Tango, if any; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For up to five programs licensed by Gilead, the Company has the option to co-develop and co-promote the lead product in the U.S., subject to certain exceptions, and is eligible to receive tiered royalties in the first decile on ex-U.S. sales. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">410.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per program in license, research option-extension, and clinical, regulatory, and commercial milesto</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nes and royalties on future sales of commercialized products, if any.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2020, Gilead also made an equity investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million into the Company as a participant in the Company’s Series B-1 preferred stock offering. At the time of the original investment, as of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 balance sheet date, and based on current ownership of common stock, Gilead is not considered to be a related party to the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for the Gilead Collaboration</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Gilead Agreement is accounted for under ASC 606. The Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering committee during the research term. For research option-extension fees, the Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the on-going research plan. Consideration pertaining to each of the research option-extensions is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule.</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research option-extension consideration are added to the transaction price under the Gilead Agreement. License fees are recognized as revenue immediately as the Company has no continued involvement in the advancement of the program, Gilead can benefit from the license on its own, and the license is separately identifiable from the research services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gilead Revenue Recognized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">199.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The total transaction price was comprised of the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment pursuant to the 2018 Gilead Agreement, the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront payment pursuant to the Gilead Agre</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ement, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million payment pursuant to the research option-extension fee in December 2020 and in September 2021. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, of collaboration revenue associated with the Gilead agreements based on performance completed during each period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reevaluates the transaction price and the total estimated costs expected to be incurred to satisfy the performance obligations at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the Company is responsible for, are resolved or other changes in circumstances occur. As of March 31, 2025 and December 31, 2024, the Company had short-term deferred revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">17.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n, respectively, and long-term deferred revenue of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, related to the Gilead collaboration. The remaining long-term deferred revenue is expected to be recognized proportionally to the completed obligations over an expected remaining contractual term of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company’s condensed consolidated balance sheets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs incurred pursuant to the Gilead Agreement and the 2018 Gilead Agreement are recorded as research and development expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> 50000000 5 125000000 P7Y 15 410000000 20000000 199000000 50000000 125000000 24000000 24000000 5400000 6500000 19500000 17600000 37500000 44800000 P2Y4M24D <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company’s financial assets measured at fair value on a recurring basis:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Market Value Measurements<br/>as of March 31, 2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,801</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,801</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_c2bedc2c-85d1-45c5-bb68-202c7351a9c6;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></span></span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,386</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,386</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,906</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,906</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,801</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,292</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,093</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Market Value Measurements<br/>as of December 31, 2024</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,915</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,915</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,112</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,112</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_7be35b2f-ba41-4bf9-99d6-b0047f5006d3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></span></span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,374</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,374</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,013</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,013</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,915</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198,499</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,414</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between fair value levels during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company’s financial assets measured at fair value on a recurring basis:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Market Value Measurements<br/>as of March 31, 2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,801</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,801</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_c2bedc2c-85d1-45c5-bb68-202c7351a9c6;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></span></span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,386</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,386</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,906</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,906</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,801</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,292</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,093</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Market Value Measurements<br/>as of December 31, 2024</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,915</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,915</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,112</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,112</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_7be35b2f-ba41-4bf9-99d6-b0047f5006d3;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></span></span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,374</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,374</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,013</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,013</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,915</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198,499</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213,414</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table> 14801000 14801000 147386000 147386000 10906000 10906000 14801000 158292000 173093000 14915000 14915000 10112000 10112000 176374000 176374000 12013000 12013000 14915000 198499000 213414000 0 0 0 0 <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable Securities</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company values its marketable securities using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company’s marketable debt securities, classified as available-for-sale:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.137%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements<br/>as of March 31, 2025</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities:</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,194</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">218</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,386</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,904</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,906</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,098</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,292</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.137%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements<br/>as of December 31, 2024</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities:</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,049</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,374</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,002</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,013</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,051</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">375</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,387</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate fa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ir value of marketable debt securities with a contractual maturity date of greater than one year was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> summarizes the fair value and gross unrealized losses aggregated by category and the length of time that individual securities have been in an unrealized loss position:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:28.426%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than twelve months</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Greater than twelve months</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,897</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,897</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,957</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,957</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,854</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,854</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:26.085%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than twelve months</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Greater than twelve months</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,016</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,016</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,016</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,016</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company holds investment grade marketable securities considered to be in an unrealized loss position. Although these marketable securities are held at an unrealized loss position at March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company does not intend to sell the marketable securities prior to the value of the securities being recovered and the Company has concluded that it is more likely than not that the marketable securities cost basis values will be recovered prior to sale of the securities and that there are no conditions or events that might require the Company to sell the securities before recovery of the cost basis occurs. Further, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t record any impairments to marketable se</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">curities or reserves for credit losses related to its marketable debt securities during the periods then ended. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5b8c7907-8450-48de-a2ae-a7e961c91ace;"><span style="-sec-ix-hidden:F_9300b676-7918-4a35-b1b7-8e147b3c422a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> securities i</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nclude $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million i</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n accrued interest at March 31, 2025 and December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company’s marketable debt securities, classified as available-for-sale:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.137%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements<br/>as of March 31, 2025</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair<br/>Value</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities:</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,194</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">218</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,386</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,904</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,906</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,098</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,292</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.137%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.421%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.044%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements<br/>as of December 31, 2024</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Loss</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable debt securities:</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,049</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">364</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,374</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,002</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,013</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,051</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">375</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,387</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> 147194000 218000 26000 147386000 10904000 3000 1000 10906000 158098000 221000 27000 158292000 176049000 364000 39000 176374000 12002000 11000 0 12013000 188051000 375000 39000 188387000 7200000 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> summarizes the fair value and gross unrealized losses aggregated by category and the length of time that individual securities have been in an unrealized loss position:</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:28.426%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.402000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than twelve months</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Greater than twelve months</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,897</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,897</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency bonds</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,957</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,957</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,854</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,854</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> </table><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:26.085%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.58%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.742%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than twelve months</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Greater than twelve months</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized loss</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury bills</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,016</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,016</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,016</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,016</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> </table> 53897000 26000 53897000 26000 2957000 1000 2957000 1000 56854000 27000 56854000 27000 46016000 39000 46016000 39000 46016000 39000 46016000 39000 0 0 900000 1400000 <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental Balance Sheet Information </span></div></div><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.04%;box-sizing:content-box;"></td> <td style="width:2.7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.779999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.779999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,936</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,936</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,437</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,437</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,945</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,945</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,870</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,870</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,524</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,465</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,985</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,363</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,539</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,102</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expen</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">se was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million fo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">r the three months ended March 31, 2025 and 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and employee-related costs</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,951</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,216</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,811</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,978</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,735</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,374</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,497</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025 and 2024, the Company maintained a restricted cash balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, all of which was related to a security deposit associated with the Company’s facility lease. The cash will remain restricted in accordance with the lease agreement absent the event of a lease termination or modification. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the condensed consolidated statements of cash flows are as follows: </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.799%;box-sizing:content-box;"></td> <td style="width:1.112%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.455000000000002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.223%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.412%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,432</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,163</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,567</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,567</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,999</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,730</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.04%;box-sizing:content-box;"></td> <td style="width:2.7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.779999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.7%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.779999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,936</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,936</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,437</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,437</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer software</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,945</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,945</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,870</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,870</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction in progress</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">152</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,524</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,465</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,985</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,363</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,539</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,102</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> 8936000 8936000 2437000 2437000 125000 125000 1945000 1945000 2870000 2870000 211000 152000 16524000 16465000 8985000 8363000 7539000 8102000 600000 600000 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payroll and employee-related costs</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,180</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,951</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,216</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,811</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,978</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,735</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,374</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,497</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table> 3180000 8951000 5216000 5811000 1978000 1735000 10374000 16497000 2600000 2600000 <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the condensed consolidated statements of cash flows are as follows: </span> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.799%;box-sizing:content-box;"></td> <td style="width:1.112%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.455000000000002%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.223%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:22.412%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2024</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,432</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,163</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,567</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,567</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,999</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,730</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table> 58432000 61163000 2567000 2567000 60999000 63730000 <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sesame Therapeutics, Inc.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, the Company and Sesame Therapeutics, Inc. (Sesame) entered into a license agreement pursuant to which the Company granted Sesame a non-exclusive license to certain know-how associated with preclinical research (the Sesame Agreement). Pursuant to the Sesame Agreement, the Company received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront, non-refundable payment in June 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Sesame Agreement, the Company is eligible to receive up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in potential future clinical, regulatory, and commercial milestone event payments. The Company is also eligible to receive low single-digit tiered royalties on net sales of any product covered by a licensed patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluated the Sesame Agreement under ASC 606. The Company identified the following promises under the agreement: (1) the non-exclusive license and (2) the initial know-how transfer, and determined that the promises were immaterial as the upfront license payment at contract inception was an inconsequential payment amount. The initial upfront license payment was recorded as license revenue on the consolidated statements of operations and comprehensive loss during the period ended June 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All potential future milestone payments are considered to be variable consideration and have been excluded from the transaction price. Revenue for all potential clinical and regulatory milestone achievements will be recognized when the related milestones are achieved or when it becomes probable that a significant reversal in the amount of revenue recognized relating to the milestone event will not occur. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. Additionally, revenue related to potential sales milestones and royalties from the sales of the licensed products will be recognized when the related sales occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to common relationships amongst members of management and the boards of directors, the transaction above with Sesame is a related party transaction.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Medivir AB</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2020, the Company entered into a license agreement (the Medivir Agreement) with Medivir AB (Medivir), pursuant to which the Company obtained an exclusive license to all patents, know-how and other intellectual property associated with certain USP1 assets. Pursuant to the Medivir Agreement, the Company made an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Medivir Agreement, the Company is obligated to pay Medivir in connection with development, regulatory and commercial activities. The Company has agreed to make certain milestone payments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate for the first licensed product that achieves specified clinical milestones, plus $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the first licensed product that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate if that first licensed product achieves specified clinical milestones, plus $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development, regulatory and sales milestones in either of the first two specified genetic contexts. The Company has the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir’s patents or if payments are due to a third party for a license under such third party’s intellectual property rights. The Company is also obligated to pay Medivir a low single-digit royalty on net sales of any product covered by a licensed patent. The Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront fees and subsequent milestone amounts paid pursuant to the Medivir Agreement were recorded to research and development expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:5.2%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company made the decision to discontinue further development of TNG348, the basis of the USP1 program, due to liver toxicity experienced by patients in the dose escalation portion of the Phase1/2 clinical trial. As a result, the Company does not expect any on-going material obligations under the Medivir Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Collaboration and Supply Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the Company and Revolution Medicines, Inc. (RevMed) entered into a Clinical Trial Collaboration and Supply Agreement. The agreement provides that RevMed will supply daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, at no cost to the Company for use in trials that will include TNG462 and each of these RAS(ON) inhibitors. The Company will be the sponsor of any combination trials and bear associated costs. Each company will retain commercial rights to its respective compounds, and the agreement is mutually non-exclusive. Due to common relationships amongst members of management and the boards of directors, this transaction is a related party transaction.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Funding Commitments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the Company had ongoing preclinical and clinical studies. The Company enters into contracts in the normal course of business with contract research organizations in connection with the preparation and operation of clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other preclinical and clinical services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Guarantees</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, construction companies, contract research organizations, clinical trial sites, and other parties. Under these provisions, the Company generally indemnifies, defends and holds harmless the indemnified party for losses suffered or incurred by the indemnified party under the terms of the contract, including as a result of the Company’s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of March 31, 2025, and no material legal proceedings are currently pending or threatened. Because of uncertainties related to claims, proceedings and litigation, assessments of potential liabilities are based on the Company's best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse effect on the operating results of the Company. Costs associated with involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were to be unable to prevail in any such proceedings, the consolidated financial position, results of operations, and future cash flows of the Company may be materially impacted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> 100000 25900000 400000 1400000 25000000 700000 5000000 <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company’s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of preferred stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The number of shares of preferred stock authorized to be issued is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and December 31, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The shares of preferred stock are currently undesignated and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares are issued or outstanding</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p> 0.001 10000000 0 0 <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-Based Compensation </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2017, the Company’s stockholders approved the 2017 Stock Option and Grant Plan (the 2017 Plan), under which stock options and restricted stock awards were granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances under the 2017 Plan were subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors at the time of issuance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon effectiveness of the 2021 Stock Option and Incentive Plan (the 2021 Plan) in August 2021, the remaining shares available under the 2017 Plan ceased to be available for issuance and no future issuances will be made under the 2017 Plan. The shares of common stock underlying outstanding awards under the 2017 Plan that are forfeited, cancelled, reacquired by the Company prior to vesting, expire or are otherwise terminated (other than by exercise) will be added to the shares of common stock available for issuance under the 2021 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2021, the Company's board of directors and stockholders approved the 2021 Plan, under which stock options, restricted stock units (RSUs) and other equity-based awards or any combination of these may be granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances are subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors at the time of issuance. As of March 31, 2025, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,471,496</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future issuance under the 2021 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2023, the Company's board of directors approved the 2023 Inducement Plan (the Inducement Plan), under which the Company reserved shares of common stock, to be used exclusively for grants of non-qualified stock options, restricted stock units and other equity-based awards, or any combination of these to individuals who were not previously employees or directors of the Company. As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,041,015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future issuance under the Inducement Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,986</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,806</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,269</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,913</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,255</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,719</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.167%;box-sizing:content-box;"></td> <td style="width:1.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.039%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.729999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.203999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.173%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>shares</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Contractual<br/>Term</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options outstanding as of December 31, 2024</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,615,023</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.41</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.43</span></span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,157,177</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,467,208</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.89</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,062</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,912</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.35</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options outstanding as of March 31, 2025</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,811,257</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.57</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.61</span></span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable as of March 31, 2025</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,934,117</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.72</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.58</span></span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, total unrecognized compensation expens</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e related to stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Activity</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.349%;box-sizing:content-box;"></td> <td style="width:1.358%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.561%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.796%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.933999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Units</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value Per Share</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested and outstanding as of December 31, 2024</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,209,333</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.92</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732,830</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.89</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377,485</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.86</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,523</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.22</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested and outstanding as of March 31, 2025</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,537,155</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.11</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, total unrecognized compens</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ation expense related to RSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2021 Employee Stock Purchase Plan (the 2021 ESPP) was adopted and approved by the Company’s board of directors and by the Company’s stockholders and beca</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">me effective in August 2021. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were issued under the 2021 ESPP during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p> 7471496 2041015 <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying condensed consolidated statements of operations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.993%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.883000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,986</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,806</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,269</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,913</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,255</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,719</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> 3986000 3806000 3269000 2913000 7255000 6719000 <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:39.167%;box-sizing:content-box;"></td> <td style="width:1.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.039%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.729999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.203999999999999%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.422%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.173%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>shares</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Contractual<br/>Term</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in years)</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options outstanding as of December 31, 2024</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,615,023</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.41</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.43</span></span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,157,177</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,467,208</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.89</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,062</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cancelled</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,912</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.35</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options outstanding as of March 31, 2025</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,811,257</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.57</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.61</span></span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercisable as of March 31, 2025</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,934,117</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.72</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.58</span></span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">—</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table> 19615023 7.41 P7Y5M4D 2157177 4467208 2.89 1062 1.65 269912 6.35 23811257 6.57 P7Y7M9D 0 12934117 6.72 P6Y6M29D 0 45100000 P2Y8M12D <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the RSU activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.349%;box-sizing:content-box;"></td> <td style="width:1.358%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.561%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.796%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.933999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Stock Units</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average<br/>Grant Date Fair Value Per Share</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested and outstanding as of December 31, 2024</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,209,333</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.92</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">732,830</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.89</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377,485</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.86</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,523</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.22</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested and outstanding as of March 31, 2025</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,537,155</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.11</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table> 1209333 8.92 732830 2.89 377485 8.86 27523 6.22 1537155 6.11 8300000 P2Y2M12D 0 <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.127%;box-sizing:content-box;"></td> <td style="width:1.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.617%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.617%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except share and per<br/>share data)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,876</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,914</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common stock outstanding – basic and diluted</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,301,256</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,171,463</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share – basic and diluted</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.36</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.35</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, the Company completed a private placement, in which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,196,671</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were sold together with pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,340,579</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share. The pre-funded warrants were classified as a component of permanent equity in the Company's condensed consolidated balance sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate basic and diluted net loss per common share because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company’s potential dilutive securities, which include common stock options and unvested restricted common stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.738%;box-sizing:content-box;"></td> <td style="width:1.146%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.482%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.146%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.488%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,811,257</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,589,225</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted common stock</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,537,155</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,254,456</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,348,412</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,843,681</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.127%;box-sizing:content-box;"></td> <td style="width:1.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.617%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.617%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except share and per<br/>share data)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,876</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,914</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common stock outstanding – basic and diluted</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,301,256</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">108,171,463</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per common share – basic and diluted</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.36</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.35</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> </table> -39876000 -37914000 110301256 110301256 108171463 108171463 -0.36 -0.36 -0.35 -0.35 13196671 2340579 0.0001 <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </span> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:87.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:60.738%;box-sizing:content-box;"></td> <td style="width:1.146%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.482%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.146%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:15.488%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,811,257</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,589,225</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested restricted common stock</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,537,155</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,254,456</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,348,412</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,843,681</span></p></td> <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> </table> 23811257 20589225 1537155 1254456 25348412 21843681 <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company’s effective income tax rate wa</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and -</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024, respectively. The income tax provision was less than </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for both the three months ended March 31, 2025 and 2024, respectively. Consistent with the prior year, for 2025 the Company assessed the requirement to capitalize and amortize research and experimentation expenditures for US tax purposes, which remains effective as of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company is forecasting a taxable loss position in 2025 for which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> tax benefit is recorded due to the valuation allowance maintained against the Company’s deferred tax assets.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The effective income tax rate for the three months ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> differed from the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% federal statutory rate primarily due to the valuation allowance maintained against the Company’s deferred tax assets.</span></p> -0.001 -0.001 100000 100000 0 0.21 0.21 <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company operates in the U.S. and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment that is managed on a consolidated basis. The Company’s revenues are primarily generated through its license and collaboration agreement with Gilead. The accounting policies, as described in the summary of significant accounting policies, is applicable across all Company operations. The Company’s chief executive officer (</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6bdf481a-d025-4424-a491-c7c4d4755165;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), as the chief operating decision maker (CODM), manages and allocates resources to the operations of our company on a consolidated basis. Managing and allocating resources on a total company basis enables the CODM to assess the overall level of resources available and how to best deploy these resources across departments and research and development programs that are in-line with our long-term company-wide strategic goals. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with this decision-making process, the Company’s CODM uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results and allocating resources.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM assesses performance and decides how to allocate resources based on segment net income (loss). This measure is used to monitor budget versus actual results to assess performance of the segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company’s segment expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.72%;box-sizing:content-box;"></td> <td style="width:2.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:20.759999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.56%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:20.759999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Oncology Segment</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,392</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,471</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less R&amp;D expenses:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG462 direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,461</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,086</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG456 direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,324</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG260 direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,730</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,236</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG961 direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,221</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG908 direct program expenses*</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,712</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,258</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG348 direct program expenses**</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       Discovery direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,679</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,511</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       Personnel-related expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,850</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,798</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       Facilities and other related expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,465</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,876</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less G&amp;A and other expenses:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       Other segment expenses (a)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,826</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,320</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment net loss</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,876</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,914</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> </table><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">**</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. The CODM reviews cash, cash equivalents and marketable securities as a measure of segment assets. As of March 31, 2025, the Company’s cash, cash equivalents and marketable securities were $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">216.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. All long-lived assets of the Company reside in the U.S.</span></p> 1 Consistent with this decision-making process, the Company’s CODM uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results and allocating resources. <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the Company’s segment expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months ended March 31, 2025 and 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.72%;box-sizing:content-box;"></td> <td style="width:2.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:20.759999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.56%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:20.759999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Oncology Segment</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended March 31,</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,392</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,471</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less R&amp;D expenses:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG462 direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,461</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,086</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG456 direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,324</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG260 direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,730</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,236</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG961 direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,221</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG908 direct program expenses*</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,712</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,258</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       TNG348 direct program expenses**</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,300</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       Discovery direct program expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,679</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,511</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       Personnel-related expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,850</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,798</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       Facilities and other related expenses</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,465</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,876</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less G&amp;A and other expenses:</span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">       Other segment expenses (a)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,826</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,320</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Segment net loss</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,876</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td> <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,914</span></p></td> <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td> </tr> </table><p style="margin-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">**</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.</span></p> 5392000 6471000 5461000 5086000 1324000 0 1730000 2236000 2221000 0 1712000 4258000 0 3300000 4679000 5511000 13850000 12798000 5465000 4876000 8826000 6320000 -39876000 -37914000 216700000 false false false false false false In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs. In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs. Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.